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Towards optimising HIV-1 derived lentiviral vectors through structure 
informed genome modifications 
 
Lentiviral vectors are being successfully used as therapeutic agents in a series of clinical 
applications of gene therapy, genome editing and cancer immunotherapy. 3rd generation 
HIV-1 derived lentiviral vectors are produced from 4 independent plasmids.  Here, I focus on 
the transfer vector that contains the therapeutic gene and the cis-acting elements that drive 
its expression including the packaging signal (psi).  Lentiviral vector particles carry two 
copies of transfer vector RNA that become linked via a process known as dimerisation. I 
focused on improving the infectivity of vectors by targeting their dimerisation and packaging 
properties based on the hypothesis that WT HIV-1 regulates genome encapsidation tightly 
by recognising dimeric RNA. The genomic RNA (gRNA) leader region is thought to act as a 
switch between the monomeric conformation that is associated with translation and the 
dimeric conformation linked with packaging. I therefore attempted to identify the structures 
that are important for packaging and optimise those at the expense of structures that are 
used by the virus for translational control. To do so, I created mutants in the 5’UTR that 
target regions that play important roles in the process of dimerisation including the 
Dimerisation Stem Loop (DSL), the U5-AUG duplex formed by sequences located at the 
beginning of the U5 region and nucleotides surrounding the start of the gag gene, and the 
polyA stem loop, a region suppressed in the 5’LTR, but known to regulate polyadenylation in 
the 3’LTR. The introduction of these mutations aimed to create vectors whose RNA is more 
likely to adopt the dimeric conformation and therefore be packaged. To evaluate this, I 
developed a novel competitive RT-qPCR assay to measure the relative packaging efficiencies 
(RPE) of transfer vectors in a competitive co-transfection environment. Biochemical 
characterisation showed an overall negative effect of the introduced mutations on viral 
infectivity. Northern Blots confirmed that the propensity of mutated vector RNA to dimerise 
has increased in the mutants as hypothesised. Here, I report the effect of the dimerisation-
stabilising mutations on infectious and physical titres of lentiviral vectors, as well as on their 
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packaging efficiency measured with our novel competitive qPCR assay. Our data suggest 
that enhancing dimerisation does not automatically lead to better packaging of vector RNA. 
Despite the improvement of vector RNA dimerisation efficiency and in some cases RPE, the 
effect of introduced mutations on the ability of the designed transfer vectors to successfully 
transduce 293T cells was negative, reflecting the multifunctionality of the HIV-1 leader 
regions and the significance of RNA flexibility. Finally, I explored by Selective 2′-Hydroxyl 
Acylation Analysed by Primer Extension (SHAPE) the structure of psi in our vector RNAs, in 
particular studying the influence of regions adjacent to psi on dimerisation and packaging. 
SHAPE identifies the RNA backbone flexibility, which is an indication of whether nucleotides 
are base-paired or not. Our single nucleotide level structural analysis revealed that the 
presence of gag sequences stabilise the psi element of the dimeric RNA, suggesting their 
role in supporting a stable RNA conformation that can be packaged and offering a potential 
explanation for their requirement in the transfer vector plasmid for maintenance of 
infectious titres. These findings will give us better insights into the biology of lentiviral 
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HIV............................................................................................Human immunodeficiency virus  
HLA.....................................................................................................Human leukocyte antigen  
hnRNPs...................................................................heterogeneous nuclear ribonucleoproteins  
 HR.............................................................................................................................High Range  
HSPCs.........................................................................Hematopoietic Stem and Progenitor cells  
IN..................................................................................................................................Integrase 
INS.............................................................................................................Instability sequences  
LDI......................................................................................................Long-distance interaction 
LDLR..............................................................................low-density lipoprotein receptor family  
lncRNAs.....................................................................................................long noncoding RNAs  
LPL..................................................................................................................Lipoprotein lipase  
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LR...............................................................................................................................Low Range  
LTR............................................................................................................Long Terminal Repeat 
LVs...................................................................................................................Lentiviral vectors  
MA....................................................................................................................................Matrix  
MCS............................................................................................................Multiple cloning site 
MGB...........................................................................................................Minor groove binder  
MIQE Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
guidelines 
MLV.........................................................................................................Murine leukemia virus 
MoMLV...................................................................................Moloney murine leukaemia virus  
mRNA.................................................................................................................messenger RNA  
MTOC......................................................................................Microtubule organization center  
NC........................................................Negative control or Nucleocapsid (context dependent) 
NEAT1......................................................................Nuclear paraspeckle assembly transcript 1  
NFQ....................................................................................................Nonfluorescent quencher  
NICE...............................................................National Institute for Health and Care Excellence  
NMR........................................................................Nuclear magnetic resonance spectroscopy 
ORF............................................................................................................Open Reading Frame 
OTC.................................................................................................Ornithine transcarbmaylase  
PBS................................................................................................................Primer binding site 
or Phosphate-Buffered Saline (context dependent)   
PIC..........................................................................................................Preintegration complex  
PR..................................................................................................................................Protease 
psi......................................................................................................................Packaging signal  
Rb......................................................................................................................Refolding buffer  
RCL..........................................................................................Replication competent lentivirus 
RF.....................................................................................................................Restriction factor 
RPA.............................................................................................Ribonuclease protection assay  
RPE................................................................................................Relative packaging efficiency  
RRE..........................................................................................................Rev Response Element  
RT.............................................................................................................Reverse Transcriptase  
RTC.............................................................................................Reverse transcription complex  
SCID...................................................................................Severe combined immunodeficiency  
SD............................................................................................................................Splice donor  
SDM...................................................................................................Site directed mutagenesis 
SHAPE........................................Selective 2′-Hydroxyl Acylation Analysed by Primer Extension  
SELEX.............................................Systematic evolution of ligands by exponential enrichment 
SIN......................................................................................................................Self inactivating  
SL1-4.....................................................................................................................Stem Loop 1-4 
SU.................................................................................................................glycoprotein gp120 
TBE...................................................................................................................Tris-borate-EDTA  
TBS...............................................................................................................Tris-Buffered Saline  
TM.......................................................................................Transmembrane glycoprotein gp41  
TRiP............................................................Transgene Repression In vector Production system 
TSS...........................................................................................................Transcription start site  
TU...................................................................................................................transduction units 
UCOEs...........................................................Ubiquitously acting chromatin opening elements  
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VLPs................................................................................................................Virus like particles  
VSVg..............................................................................Vesicular Stomatitis Virus glycoprotein  
WAS...................................................................................................Wiskott-Aldrich syndrome  


















2.1. HIV-1 biology 
2.1.1. The HIV-1 genome 
 
Figure 1. HIV-1 genome organisation 
(LTR: Long Terminal Repeat, PR: Protease, RT:  Reverse Transcriptase, IN: Integrase, env: 
envelope). 
  
The Human immunodeficiency virus (HIV) is a Lentivirus that belongs to Orthoretrovirinae, a 
subfamily of viruses belonging to Retroviridae. HIV is classified into types 1 and 2 (HIV-1, 
HIV-2) according to differences in genetic characteristics and viral protein products1. HIV-1 
carries its genetic information on a 9.7 kb RNA that codes for the structural, enzymatic, 
accessory and regulatory proteins required for viral replication. As shown in Figure 1, the 
Open Reading Frames (ORFs) are flanked between two Long Terminal Repeats (LTRs), which 
contain regulatory cis-acting elements. These elements are important for various steps of 
the viral life cycle including transcription, packaging and polyadenylation2. The Gag ORF is 
responsible for the expression of Matrix (MA), Capsid (CA), Nucleocapsid (NC) and p6 
structural proteins.  These constitute the core of the virion.  The Pol ORF codes for the 
enzymatic proteins Protease (PR), Reverse Transcriptase (RT), Integrase (IN) and RNase H. 
Due to the presence of a stem loop between the gag and pol ORFs that causes ribosomal 
frameshifting, Gag/Pol is synthesised as a polyprotein. It is then cleaved into the 
aforementioned products by the self-activated protease. The env ORF codes for the 
envelope glycoproteins which are produced by processing of the gp160 precursor to the 
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external gp120 glycoprotein (SU) and the transmembrane glycoprotein gp41 (TM)3 4.The 
accessory proteins Vpu, Vpr, Vif and Nef are important for the virulence of the pathogen, 
whereas the regulatory proteins Tat and Rev are responsible for transcription initiation and 
export of full length and singly spliced RNAs to the cytoplasm respectively. These various 
products are produced from their respective RNAs spliced from the gRNA5.   
2.1.2. Overview of the gRNA journey 
 
Upon transcription of the integrated proviral DNA, the full length 9.7 kb unspliced transcript, 
which contains the Rev Response Element (RRE), is transported from the nucleus to the 
cytoplasm in a Rev-dependent manner6. The gRNA is an active player in the production of an 
infectious virion. The transport from the transcriptional site to the virion involves the 
adoption of several RNA structures that display the relevant cis-acting elements for each 
process the virus needs to perform7 8. It has a dual role: as a template for translation of gag 
and gag/pol, and as the gRNA for the newly assembled virions. A conformational switch in 
the cis-acting elements of the 5’UTRs of the gRNA controls the balance between the 
monomeric RNA, characterised by a structural conformation that contains an exposed gag 
start codon (AUG) for translation, and the dimerisation competent RNA, which is 
preferentially packaged, from the same template9. The presence of cis-acting elements in 
the 5’UTR of the full-length transcript promotes the dimerisation and packaging of the gRNA 
dimer in the newly formed virions, and the specific binding of the NC domain of the Gag 
polyprotein on the gRNA promotes its trafficking from the cytoplasm to the membrane site 
of budding10. Furthermore, the viral RNA molecules act as a scaffold for their own capture 
by the NC in the context of Gag, and in a later stage, act as a nucleation site for the assembly 
of newly formed viral particles11 12.  The final, late stage contribution of the gRNA for virion 
production is at the budding site, where the interaction between gRNA, Gag and the ESCRT 
machinery are necessary for the completion of the budding process. Although, the exact 
mechanism is unclear, mutations in the 5’UTR cis-acting elements of the gRNA affect 
maturation, highlighting the importance of the interaction between gRNA and Gag at this 
stage13 14. In the next sections I will be looking at these different steps of the gRNA journey 





2.1.3. Gag/gRNA interaction and packaging 
 
As mentioned above, the Gag/gRNA interaction plays an important role in coordinating and 
facilitating the transport of the gRNA molecule from the export site to the budding site. 
However, where and when the interaction between these two determinants occurs in the 
cell remains controversial. Live cell co-imaging showed accumulation of HIV-1 gRNA at the 
nuclear envelope but detection of Gag protein in the cytoplasm and not at the nuclear rim. 
This observation suggests initiation of the Gag/gRNA interaction in the cytoplasm15. A 
different study reported the pericentriolar microtubule organization center (MTOC) as the 
primary site of HIV-1 Gag/gRNA interaction16, while an imaging study detected higher order 
Gag-RNA complexes at the plasma membrane and smaller oligomeric complexes in the 
cytoplasm17. Use of total internal reflection fluorescence microscopy demonstrated that 
stabilisation of the RNA dimer on the plasma membrane requires Gag protein10.  
Crosslinking-immunoprecipitation (CLIP) sequencing experiments suggest a two-step 
genome packaging process that starts with interactions between monomeric Gag and the ψ 
element, followed by interactions between multimeric Gag and the A-rich viral mRNA18.  
Even though it still remains unclear where exactly the initial HIV-1 Gag/gRNA takes place, 
  Figure 2. Overview of the assembly pathway of an HIV-1 virion286. 
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the aforementioned studies suggest formation of ribonucleoprotein particles prior to 
plasma membrane localisation. 
The presence of sequences important for efficient gRNA packaging were first described 
when deletion of 19 bp between the SD in the 5’LTR and the gag ORF resulted in reduced 
HIV-1 replication and gRNA encapsidation in human T-lymphocytes19. Although the 
packaging defect was profound, it was not complete, suggesting some redundancy in the 
system. gRNAs get successfully packaged in a specific way despite the fact that they only 
represent approximately 1% of the cellular 5’-capped, polyadenylated mRNAs20. The 
specificity of this interaction is mainly driven by the presence of two highly conserved zinc 
finger motifs that lie in the NC domain of Gag21. The HIV-1 NC is highly basic and contains 
two zinc fingers,with the zinc-chelating cysteine and histidine residues arranged as C-X2-C-
X4-H-X4-C. These fingers and basic residues are very important for the interaction between 
NC and gRNA sequences. This electrostatic interaction is considered almost independent of 
the nucleotide sequence of the gRNA and mainly dependent of the zinc finger nucleic acid-
binding specificity22 23. The NC domain of Gag selects the gRNA during assembly while the 
cleaved NC coats the dimeric RNA within the mature viral paricle. The ability of NC to 
catalyse the rearrangement of nucleic acids into the most thermodynamically stable 
structures makes it an important DNA synthesis cofactor24. More specifically, the NC 
domain, in the context of Gag, catalyses the unwinding of tRNA Lys,3 and its annealing to the 
PBS25.  
On the gRNA level the selection is  governed by the ψ (psi) packaging element that lies in the 
5’UTR and is located downstream of the splice donor, such that the full length transcripts 
can preferentially get encapsidated26 27. Certain mutations in the NC domain gave a similar 
defective phenotype to deletions of the RNA packaging signal, highlighting the mutual 
importance of these two key players in RNA packaging28. Because of the high affinity of Gag 
to the ψ element on gRNA, it has been hypothesised that ψ-containing RNAs have a 
thermodynamic advantage over the cellular RNAs since their binding to Gag and subsequent 




2.1.4. Importance of RNA structure  
 
The central dogma of molecular biology states that "the coded genetic information hard-
wired into DNA is transcribed into individual transportable cassettes, composed of 
messenger RNA (mRNA); each mRNA cassette contains the program for synthesis of a 
particular protein (or small number of proteins)30."  
To understand the processes that govern the present-day living cells deeper, one needs to 
consider their evolution. Today, we understand the requirement of complex machineries 
that convert genetic information, stored in DNA, to function, performed by proteins through 
an RNA intermediate. However, it is still unclear how this machinery arose. One of the 
popular hypotheses, originally suggested by Alex Rich in 1962 and known as the RNA world, 
suggests that RNA was once able to both store genetic information (as it still does for some 
viruses, including HIV-1) and catalyze chemical reactions31. RNA still catalyzes several 
fundamental reactions in modern-day cells and plays a central role in gene regulation32. RNA 
performs key biological functions via folding into diverse structures directed by its 
nucleotide sequence.  
RNA acts both as a coding and noncoding molecule and as shown in Figure.3 can adopt 
complicated secondary structures that are in part responsible for its diverse functionality. 
Comparisons of many RNA structures have revealed certain frequently appearing conserved 
motifs shown in Figure 333. RNA structure plays important regulatory roles not just for 
specialized classes of RNAs such as riboswitches, small RNAs, and enzymatic RNAs ribozymes 
but essentially for all classes of RNA, including mRNAs and long noncoding RNAs (lncRNAs). 
Under the light of this recent realisation, RNA structure can be now seen as another layer of 
the genetic code whose understanding may enable us to study the evolution and function of 
biological systems34. Advancement of high-throughput sequencing methods has improved 
our understanding of transcriptome modifications and their ability to impact RNA secondary 
structure to alter processes like splicing, translation and RNA stability35. Notably, even the 
addition of small groups can affect the ability of bases to pair, to stack against neighbouring 
bases, to adopt one conformation over another, to favour one folded structure over another 
and to interact with proteins35. 
25 
 
    
 
From an evolutionary perspective, the conservation and diversity of the RNA structurome, 
defined as transcriptome wide structure profile, between species remains to be understood. 
Deng et al., generated rice (Oryza sativa) in vivo structure-seq libraries to compare the 
conservation and divergence of in vivo RNA structurome between rice and previously 
published structures of Arabidopsis36, and assess the evolutionary adaptation of RNA 
structure. This study found that in vivo RNA secondary structure conservation does not 
correlate with sequence conservation between rice and Arabidopsis, but that conservation 
and divergence in both sequence and RNA secondary structure are highly relevant with 
specific biological processes37. This suggests that evolutionary pressure does not only affect 
sequence but also RNA structure to regulate gene expression37.  
2.1.5. Techniques used to study RNA structure 
 
Precise folding into a complicated structure is a prerequisite for correct RNA function. 
Moreover, many RNAs require specific local structural flexibility to transition from one 
Figure 3. Common structural motifs of RNA34. 
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conformation to another38. Involvement of the RNA secondary structure is fundamental for 
cell processes like RNA synthesis, metabolism and pathway regulation, has caused an 
explosion in the need and interest to develop robust technologies to investigate RNA 
structure.  Previous efforts employed techniques including nuclear magnetic resonance 
spectroscopy (NMR), X-ray crystallography, and cryo-electron microscopy (cryo-EM) that are 
restricted by small length, low abundance and poor yield limitations39. 
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Traditional chemical and enzymatic reagents47 and backbone-based cleavage48 can be useful 
for mapping RNA secondary structure, but suffer from two important disadvantages 
including 1) use of reagents that cannot discriminate between single-stranded and base-
paired regions accurately enough and 2) use of reagents that typically react with only a 
subset of the four RNA nucleotides or backbone sites, requiring multiple reagents that in 
turn make data analysis difficult. Selective 2′-Hydroxyl Acylation analysed by Primer 
Extension, or SHAPE, takes advantage of reagents that preferentially bind and modify the 
backbone of RNA in structurally flexible regions of unpaired nucleotides49. SHAPE chemistry 
exploits hydroxyl-selective electrophiles used for 2‘-hydroxyl acylation leading to the 
formation of 2’-O-adducts. Since every nucleotide has a 2’-OH group in their ribose 
backbone the use of this chemistry should provide structural information for every 
nucleotide of the RNA sequence. SHAPE can give single nucleotide level structural 
information for all nucleotides and hence determine the structure of any RNA under diverse, 
relevant states50 51 52 53. Paired nucleotides remain unreactive whereas conformationally 
flexible nucleotides form 2’-O-adducts. These specific sites of modification can be 
determined by annealing a labelled primer to the RNA sequence of interest and then by 
extending to the nearest site of modification with a reverse transcription reaction. The 
position and degree of modification can be determined by reading the corresponding length 
and amount of cDNA labelled fragments. A negative control lacking the modifying reagent 
reaction is run in parallel. Mapping the measured reactivity to the RNA sequence is achieved 
by including two dideoxy sequencing ladders. In hSHAPE, each component of a SHAPE 
experiment uses the same primer sequence that is labelled with a different color-coded 
fluorophore. The resulting cDNAs are combined and resolved in a single capillary on a 
capillary electrophoresis sequencing instrument54. SHAPEFinder software is used to measure 
single nucleotide reactivity by calculating the difference of reactivity between the modifying 
reagent reaction and the modifying reagent lacking reaction, while aligning each reactivity 






2.1.6. Structural packaging signals in the HIV-1 leader 
 
The 5’-leader is the most conserved region of the HIV genome56; it contains the cis-acting 
elements that regulate a variety of processes including transcriptional activation, reverse 
transcription, splicing, dimerisation, packaging and translation of HIV-12 57. Various groups 
have published on the structure of the packaging signal and on the HIV-1 leader as a whole, 
using different technical approaches including nuclear magnetic resonance and probing 
approaches (reviewed in8 57 58 59 60 61 62). The intrinsic flexibility and instability of the RNA 
molecule, combined with technical limitations, can explain the differences in the plethora of 
these published structures.   Indeed, it has been clarified that the HIV-1 leader is not a static 
structure, but can adopt several stable conformations59. However, there is common 








The region shown in Figure 4 consists of the TAR loop, which is the binding site for the Tat 
protein leading to transcriptional activation63, the polyA loop, which is suppressed in the 
5’UTR64, the primer binding site (PBS) loop bound by the tRNA Lys,3  primer for reverse 
transcription65, followed by 4 stem-loops that are of significant importance to packaging. 
Stem Loop 1 (SL1) includes a conserved 6-base palindrome Dimerisation Initiation Site (DIS), 
which takes part in a loop-loop interaction with a complementary palindromic sequence 
from a second gRNA molecule to mediate dimerisation of the viral genomic RNA. SL2 
contains the major splice donor and SL3 contains the most important packaging 




determinants, discussed below. Finally, SL4, which is formed at the beginning of the gag 
ORF, is associated with the translational conformation of the RNA66 67 8. More recently, 
evidence suggests the presence and importance of another structural element in the 5’-
leader known as the U5-AUG duplex. The interaction between the 5’ U5 and the residues 
around the beginning of the gag ORF promotes the dimerisation structure61 and may 
influence the process of translation by blocking the accessibility of the Gag start codon7. As 
alluded to above, packaging of the gRNA depends on structural motifs in the RNA rather 
than sequence recognition68.  
2.1.7. Structure of the HIV-1 RNA genome 
 
The WT HIV-1 RNA sequence has evolved to be able to present critical replication signals in 
the context of a complex leader structure while the small intervening single-stranded 
segments passively contribute to proper RNA folding. Nearly any mutation in this RNA 
segment affects the leader RNA structure highlighting the importance of the selected WT 
HIV-1 sequence69. The HIV-1 leader is proposed to adopt two conformations that differ in 
their ability to dimerise. Originally, Abbink et al., have predicted a long-distance interaction 
(LDI) conformation in which the DIS nucleotides are paired to the polyA sequences 
restricting dimerisation. The branched multiple hairpin (BMH) conformation induced with 
NC binding is characterised by exposure of its DIS hairpin and its subsequent ability to form 
dimers58. More recently, Lu et al., proposed an alternative LDI conformation in which the 
DIS is occluded due to its intramolecular interaction with the lower U5 sequences. NC 
binding induces a shift to the BMH conformation that in this model finds the DIS free to 
interact with the DIS of another RNA molecule while the lower U5 sequences pair 
intramolecularly with the gag AUG61. 
The aforementioned findings on the RNA structural switch are derived from in vitro analysis 
of the HIV-1 leader RNA. However, inside virions HIV-1 gRNA exists as a 5’ capped, 3’ 
polyadenylated, non-covalent dimer that is annealed to a host tRNA Lys,3 molecule70. The 
architecture and the secondary structure of the entire HIV-1 gRNA extracted from virions 
were proposed based on the SHAPE technique and a thermodynamic structure prediction 
algorithm71.  Their findings suggest that regions with low SHAPE reactivities and hence 
involved in base pairing interactions, are associated with regulatory functions. Watts et al., 
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identified that peptide loops that link independently folded protein domains are encoded by 
highly structured RNA indicating that RNA structure encodes protein structure at a second 
level beyond the amino acid sequence71. 
Since then, this model has been updated; initially by employing the improved SHAPE-MaP 
technology72. However, even the updated structural version suffers from lack of long-
distance interactions and non-canonical base pairs. More recently, Sükösd et al., presented 
the first global RNA secondary structure model for the HIV-1 genome without such distance 
constraints73. Their model is the outcome of both a phylogenetic and a SHAPE data-driven 
approach. Their study showed that most of the HIV-1 genome appears to be relatively 
unstructured73. Such results support the hypothesis, brought forward by Knoepfel and 
Berkhout, that HIV-1 does not belong to the group of viruses with a global genome-wide 
RNA structure (GORS)74, the presence of which has been shown to correlate with persistent 
viral infection, potentially by facilitating escape from innate responses75. No major virus 
replication defects were detected when RNA structure destabilising mutations where 
introduced, suggesting that the hairpin structures studied were not important for HIV-1 
replication74. 
 Lastly, comparison of HIV-1 and SIV genomic RNA structures showed that the RNA 
secondary structure is evolving at a much faster rate than its sequence. Structured regions 
seem to be enriched in guanosines, while unpaired regions have higher adenosine content, 
and functionally important structures have stronger base pairing than non conserved 
structures. Secondary structures of functional elements are stabilised by higher guanosine 
content. That allows regions of structure to persist throughout evolutionary pressure while 
still allowing structures to evolve76.  
2.1.8. HIV-1 dimerisation 
 
Retroviruses package two copies of gRNA into each of their virions. The packaging of their 
genetic information in a dimeric form allows for recombination events to occur during 
reverse transcription, increasing the diversity of the viral sequences77. Also, packaging of a 
dimeric RNA can allow for the provision of functions of the viral RNA where one copy is 
damaged78. Thus, this strategy positively affects the replication and evolution of 
retroviruses, by promoting the generation of viruses that can evade immune recognition 
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and also build resistance to antiretroviral treatments. The dimeric nature of retroviral RNA 
was first suggested when measurement of buoyant density was double to what was 
expected from a single gRNA copy79, while gRNA heat treatment led to the expected 
buoyant density of monomeric RNA80. RNA dimerisation has been studied by employing 
both in vivo and in vitro approaches. The in vivo approach involves RNA isolation from 
produced virions in tissue culture subsequently analysed by native Northern Blotting. 
Retroviral RNA analysed under non-denaturing conditions was detected as a single band 
whose migration pattern changes upon heat denaturation, presumably due to the shift of 
the dimeric RNA to its monomeric state upon denaturation81. The other method involves 
synthesis of short segments of viral RNA in vitro, and then studying the ability of these 
fragments to form dimers. The exact location where dimerisation takes place in the cell has 
been a mystery for a long time, but it was recently shown that dimerisation occurs in the 
plasma membrane before packaging10 and requires the presence of Gag10 and intact 
complementary sequences in the DIS region82. Both the DIS and the U5-AUG structures are 
phylogenetically conserved among retroviruses suggesting the importance of their 
functions83. 
SL1, a highly conserved hairpin from nt 236 to nt 282 (based on HXB2 strain) appears to be 
the most important motif for dimerisation of HIV-1 gRNA84. Both its deletion85 and antisense 
nucleotide targeting86 prevent RNA dimerisation in vitro, making SL1 widely accepted as the 
dimerisation initiation site (DIS). It contains two internal bulges and an atypical loop of nine 
nucleotides, six of which form a palindrome. The palindromic nature of DIS allows it to form 
canonical Watson-Crick base pairs with the counterpart palindrome of another gRNA 
molecule; an interaction known as a kissing loop87. Purine residues flanking this palindromic 
sequence were also shown to be important for this initial interaction88. Not all palindromic 
sequences are equally efficient, with most known HIV-1 strains containing a DIS of either 
GCGCGC or GUGCAC sequences89. The length of the palindromic sequence also seems to be 
specific with any numerical alterations quickly reverting to 6 nucleotides90. Even with the 6 
nucleotide restriction, the DIS could be of 64 (64) potential sequences, however competition 
experiments showed that only a few other palindromes could successfully substitute the 
two WT DIS sequences mentioned above, with most mutant viruses characterised by 
decreased infectivity91. It is unclear why the nature of DIS is so restrictive, as it has been 
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demonstrated to be dispensable for efficient viral replication despite its central role in RNA 
dimerisation92. Interestingly, when DIS viral mutants were placed in long term culture the 
compensatory mutations found were located within the gag sequences enhancing the 
cleaving ability of Gag93 94 . This observation suggests that DIS is not required for replication 
but for enhancement of gRNA dimerisation that could facilitate its recognition by Gag.  
2.1.9. HIV-1 RNA packaging 
 
Identification of a minimal HIV-1 packaging signal has been proven to be a challenging task 
for a number of reasons. First, the 5´-leader contains elements that might be unrelated to 
packaging but are essential for viral replication. Hence, mutagenesis studies designed to test 
effects on packaging can adversely affect other functions95. Another complication relates to 
the fact that when packaging studies are conducted using transfection experiments, cellular 
concentration of mutant vector RNAs can be too high and thus mask potential packaging 
defects. Additionally, HIV-1 RNA packaging is dependent on correct Rev-mediated RNA 
localisation, so that even RNAs that contain intact packaging signals might be inefficiently 
packaged if the Rev-RRE pathway is distrurbed96. Lastly, as alluded to in section 2.1.6, efforts 
to determine the secondary structure of the HIV-1 5´-leader have given rise to multiple 
structural proposals and mechanistic predictions complicating the study of packaging 
structure-function relationship.  
A specific region in the MLV genome has been identified as sufficient for RNA packaging 
because insertion of this sequence in a heterologous RNA leads to its packaging into viral 
particles. At this time, the necessary and sufficient HIV-1 packaging signal had not been 
defined97 98. The first studies aiming at identifying sequences comprising the HIV-1 RNA 
packaging signal found that deletion of RNA sequences between the major splice donor (SD) 
and the gag coding region, defined as the ψ element, decreased the levels of genomic RNA 
packaged into virions19 99. It was hypothesised that this region could be responsible for 
selective packaging of gRNA since these sequences are located downstream of the major 5' 
SD and can be found only in the full length gRNA. Subsequent studies revealed that RNA 
sequences upstream of the 5' SD site also affect RNA packaging100. Meanwhile, several 
groups reported on the specific NC binding affinity and its requirement for retroviral RNA 
encapsidation99 101 102.  
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Genome deletions were performed to trim down the sequences required for packaging of 
the HIV-1 gRNA. A minimal 159 nt RNA sequence that includes SL1–SL3 through the U5-AUG 
stem, but lacks TAR, PolyA and the upper PBS hairpin structure was shown to dimerise and 
bind NC in vitro103. In addition, a 144 nt RNA sequence that contained the PBS hairpin, SL1, 
SL3 and SL4 proved to be sufficient to mediate intramolecular dimerisation when inserted 
into an ectopic position in the HIV-1 genome104. 
These findings combined with structural data described above, led to the establishment of a 
model for the HIV-1 ψ site made of four independent stem-loops named SL1-SL4105 106. All 
stem loops of the 5’UTR are acknowledged to contribute towards gRNA packaging and other 
essential parts of the viral life cycle. For example the central role of SL1 in the initiation of 
dimerisation was discussed in detail in section 2.1.8. The existence of such overlapping 
functions for this RNA structure raises the possibility that these two functions, dimerisation 
and packaging, might be linked. The existence of such a link in HIV-1 is discussed in the next 
section. 
2.1.10. The relationship between RNA dimerisation and packaging 
 
HIV-1 uses cis-acting elements of the gRNA and trans-acting elements in Gag to achieve 
specific packaging of the viral genome107. In an attempt to investigate the relationship 
between dimerisation and packaging, early in vivo studies assessed the infectivity efficiency 
of HIV-1 proviruses containing psi mutations in SL1 and SL3 that affect in vitro Gag binding, 
RNA dimerisation, or both. The outcome of this mutational analysis showed that deletion of 
SL1 alone, or SL3 plus adjacent flanking sequences, decreased gRNA packaging, while 
deletion of SL1 and SL3 simultaneously caused an even further reduction. Complete deletion 
of SL1 led to increased packaging of monomeric RNA, confirming once more the significance 
of SL1 for in vivo HIV-1 RNA dimerisation. However, these mutant genomes still managed to 
get encapsidated, suggesting that dimerisation is not a prerequisite for packaging but that it 
rather serves an independent function in the retroviral life cycle108. In an attempt to 
separate the dimerisation and packaging functions Sakuragi et al., created mutant 
constructs that contained duplications of approximately 1000 bp, including sequences in the 
encapsidation signal, in the dimerisation initiation site (DIS) and in the dimer linkage 
sequences (DLS), (E/DLS region). Duplication of the E/DLS region led to the packaging of 
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monomeric RNA in virus particles, which were likely generated by intramolecular 
interactions between the two E/DLS regions on the same RNA molecule109. 
 In a different study DIS deletions were combined with various combinations of previously 
identified compensatory point mutations, including the ΔLoop (lacking the loop region of 
SL1) and ΔDIS (lacking the complete SL1) mutants that were characterised by defects in 
replication, RNA dimerisation, and packaging. Surprisingly, all functions, apart from 
dimerisation, were restored by compensatory point mutations in gag110. A more recent 
report exploiting advanced technology of labelled constructs that contained two packaging 
signals confirmed the formation of intramolecular dimers that can get packaged12. 
Therefore, the authors of this study concluded that RNA packaging is promoted and 
regulated by the formation and recognition of this dimeric RNA.  
The region required for RNA packaging and RNA dimerisation overlaps in HIV-1 with several 
studies suggesting that the RNA fragments containing the highly conserved 5’UTR extended 
to gag can dimerise in vitro111 112. The link between dimerisation and packaging is a subject 
of ongoing debate113 114 115 106 116 117. gRNA can be packaged as a monomer, or as a weak 
dimer that appears as monomeric on gels, but dimerisation defective mutant viruses 
generally do not replicate as well as WT viruses. It is possible that in the absence of DIS 
other sequences that affect dimerisation may lead to formation of a weaker than WT dimer 
that, however, allows gRNA to be adequately packaged117. To conclude, packaging of 
monomeric gRNA is possible, but dimerisation is likely to be a prerequisite for the efficient 
production of infectious HIV-1 viral particles118. 
2.1.11. Packaging vs Translation: Maintaining the Balance 
 
While dimerisation positively regulates packaging, translation of the genome is in opposition 
to its encapsidation, as alluded to above.  Once the full-length RNA is exported to the 
cytoplasm it has two potential fates, it could either become the viral genomic RNA, serve as 
a template for translation or it could do both sequentially. In contrast to MLV that has two 
separate pools of RNA, one for translation and the other one for packaging119 120, HIV-1 
gRNA has the potential to serve both purposes121 and can be packaged with or without 
being translated first122. Cotranslational packaging poses a potential competition issue for 
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RNA between Gag and the ribosome, implying the requirement for a mechanism that would 




Figure 5. Conformational changes of the HIV-1 leader featuring a) a monomeric RNA 
structure, b) a dimeric RNA structure and c) a dimer interaction. Adapted from source:9. 
 
Evidence from NMR and RNA probing experiments suggest that the HIV-1 leader is able to 
adopt different conformations in order to regulate the processes of translation and 
packaging7 8 61. As shown in the model in Figure 5, in the unspliced monomeric viral RNA, 
the DIS loop interacts with the U5 region in a way that leaves the AUG start codon of gag 
accessible to ribosomal translation. Once sufficient levels of Gag are produced, NC can bind 
to RNA, promoting it to adopt the BMH conformation and thus, promoting dimerisation and 
packaging59 58. A conformational switch that leaves the DIS exposed while occluding the gag 
start codon, makes the same RNA template dimerisation competent9. This dimeric 
conformation is also characterized by the formation of another structural motif, the U5-AUG 
duplex. Mutations that strengthen the U5-AUG base pairing resulted in elevated levels of 
dimerisation61 7. Also, gel electrophoresis revealed that the strengthened U5-AUG mutant 
migrates faster than WT, potentially reflecting a more compact structure7. These results 
suggest that the formation of the U5-AUG duplex promotes dimerisation, and thus 
packaging, while potentially inhibiting translation of the Gag protein due to occlusion of the 
gag start codon. More recently, a study suggests the involvement of full length HIV-1 RNA in 
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regulating translation and packaging through an epitranscriptomic switch. Demethylation of 
two conserved adenosine residues present within the 5′-UTR was required for the 
encapsidation of gRNA into viral particles, while their methylation was associated with 
increased Gag production and reduced gRNA encapsidation123. Collectively, all data suggest 
that the gRNA plays an active role in its trafficking from the nucleus to the budding site and 
acts as a switch to control the processes of translation and packaging. Yet another possibility 
is that the RNAs are “marked” by host factors that sort the unspliced RNAs either for 
packaging or translation shortly after transcription. Identification of such marking factors 
was achieved by pulldown experiments on cell lysates using the HIV-1 5’ UTR sequences as a 
bait and mass spectrometry to spot the interacting host proteins124. Domain analysis of 
factors identified to interact with the HIV-1 RNA 5′ UTRs included nucleotide binding factors, 
DNA/RNA helicases, double-stranded RNA binding proteins, heterogeneous nuclear 
ribonucleoproteins (hnRNPs), splicing factors, ribosomal proteins, scaffold proteins and 
proteins involved in the DNA damage response. In addition to host factors, cellular RNAs 
such as long non-coding RNAs (lncRNAs) may also play a role in determining the fate of viral 
RNAs124. Nuclear paraspeckle assembly transcript 1 (NEAT1) lncRNA is one of several 
lncRNAs whose expression is changed by HIV-1 infection and was characterised to have a 
role in regulating HIV-1 replication by contributing to the integrity of the nuclear 
paraspeckle substructure125. Such observations highlight the involvement of host proteins 
and noncoding RNAs in marking and sorting retroviral unspliced RNA for packaging or 
translation126. Lastly, a more recent study challenges the dogma of a single HIV-1 RNA 
transcript serving both as a translation template and as the gRNA127. This study revealed the 
existence of multiple HIV-1 RNA transcripts of slightly different lengths due to 
heterogeneous transcriptional start site usage in infected cells. RNAs that begin with a single 
capped guanosine seem to be preferentially selected for packaging, whereas those that 
begin with two or three capped guanosines are enriched on polysomes and used for 
translation. Such results suggest that transcript length drastically affects its structure, 
function and fate and can thus serve as a regulating mechanism that directs the function 




2.1.12. Established methods for RNA packaging measurement 
 
The effect of RNA packaging on HIV-1 retroviral replication has led to the development of 
several methods to assess encapsidation of gRNA. Northern Blot analysis, ribonuclease 
protection assay (RPA) and quantitative reverse transcriptase-coupled polymerase chain 
reaction as well as the most recent sequencing technologies are different approaches for 
assessing RNA packaging128. The choice of the most appropriate method to quantify RNA in 
cells and virions should be based on several factors like sensitivity, accuracy, relative 
quantification, RNA size determination and probe flexibility. Northern Blot is the only 
technique that can be used to visualise RNA size and address dimerisation efficiency. The 
main advantage of the RPA over the Northern Blot is its higher sensitivity. However RT-qPCR 
is the technique of the highest sensitivity and accuracy. FISH, a method for in vivo RNA 
visualisation can provide information on quantity, localisation and dynamics of viral RNA. 
Finally, if afforded, deep sequencing of viral RNA can be used for representation of multiple 
target molecules in the sample. Advantages and limitations of these techniques are briefly 
summarised in table 2. To address how efficiently RNA is encapsidated into virions one can 
measure RNA packaging efficiency and RNA packaging ability. Packaging efficiency is defined 
as the absolute amount of RNA per virus and can be measured with quantitative methods. 
Precise viral production calculation is achieved by the combination of ELISA (enzyme-linked 
immunosorbent assay) for Gag and measurement of RT activity. RNA packaging ability is 










Table 2. Overview of methods to measure RNA packaging129. 
 
2.2. Lentiviral vectors for gene therapy 
2.2.1. History of gene therapy  
 
Gene therapy employs the introduction of therapeutic genes to either treat or prevent a 
disease. The concept of gene therapy, also commonly described as ‘using DNA as a drug’, 
was first explored during the 1960s and has been possible only after the identification of 
In 
Vitro 
Technique Advantages Disadvantages 
Northern Blot Information about the 
length and integrity of 
target RNA 
Labour intensive, variable 
transfer efficiency, 





Improved sensitivity and 
reproducibility 
Specificity based on probe 




RT-qPCR Highest sensitivity and 
accuracy, high throughput, 
safe   
Laborious, requirement of 
multiple controls for 
reliable detection, difficult 
to remove plasmid DNA  
FISH Visualisation of RNA on a 
single virus/cell level, high 
specificity, detection of 
protein-RNA interactions, 
information  on RNA 
localisation  
Fixation and 
permeabilisation of cells 







relative expression of 
multiple RNAs at the same 
time 





DNA as the molecule that carries the genetic information. This section presents a brief 
history of the evolution of gene therapy and the discoveries that led to its inception.  
Griffith’s experiment in 1928 showed that the virulence of Streptococcus pneumoniae 
bacteria can change with the presence of a transforming principle129. The exact nature of 
this transforming principle was later identified by the observations of Avery, McLeod and 
McCarty and by Hersey and Chase. The Avery-McLeod-McCarty experiment in 1944 
suggested for the first time that DNA and not proteins carry the genetic information and 
cause bacterial transformation130. In 1952, Hersey and Chase’s experiments on viruses that 
infect bacteria, bacteriophages, supported Avery’s, McLeod’s and McCarty’s conclusion. 
They used different radioactive isotopes to label proteins and DNA and observed that the 
DNA and not the proteins of T2 bacteriophages can enter the bacterial wall of E.coli bacterial 
cells
131. The final confirmation of the suitability of DNA to serve as genetic material came 
from the important work performed by Franklin, Watson and Crick, that elucidated the DNA 
tertiary structure in a form of a double helix132.  
The 1960s saw the birth of the ‘Central dogma’ of molecular biology, which describes the 
flow of information from DNA to proteins via an RNA intermediate. Between 1960-1980 
scientific advancements, including the development of genetically marked cell lines133, the 
clarification of mechanisms of cell transformation by SV40 and papoviruses, infection by 
RNA tumour viruses134,  the production of the first recombinant DNA molecule135 as well as 
the use of calcium phosphate for cell transformation136  led to the first human gene therapy 
study.  Despite calcium phosphate transfection being too inefficient to be used in clinical 
applications, Martin Cline at UCLA reported successful introduction of the human globin 
gene into murine bone marrow cells and partial repopulation of the marrow of recipient 
mice with these genetically modified bone marrow cells137. These surprising results 
encouraged Cline and his colleagues to embark on an epochal gene therapy clinical in 1980. 
Bone marrow cells from beta-thalassaemia patients in Italy and Israel were transfected ex 
vivo with plasmids encoding the human beta-globin gene and were then re-infused into 
patients. Cline had proceeded to this trial without having obtained permission from UCLA’s 
Institutional Review Board. Even though the results of his study showed no adverse effects, 
his failure to seek and secure appropriate approval attracted severe criticism from the 
scientific, public policy and ethics committees138. While this incident was disheartening for 
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the scientific community the controversy around it led to the establishment of the National 
Institutes of Health Gene Therapy Subcommittee for the regulation of genetic applications 
in humans in the United States in 1984. The Cline experiment also highlighted the need for 
more efficient gene delivery tools drawing much attention on the engineering of viral 
vectors. 
Sir Peter Medawar once described viruses as ‘‘bad news wrapped up in protein’’. However, 
advancements in the manipulation of DNA and molecular biology of viruses have enabled 
scientists to convert pathogens to therapeutic vehicles. Such advancements have led to 
blossoming of their use for disease treatment and more recently the commercialisation of 
several products. Glybera® was the first gene therapy product ever to receive approval from 
the European Medicines Agency (EMA). UniQure biopharma was given the green light by 
EMA to use Glybera®, an adeno-associated virus serotype 1 (AAV1)-based product, to treat 
patients with lipoprotein lipase (LPL) deficiency under exceptional circumstances in 2012139. 
However, five years after becoming the first gene therapy product to win approval in 
Europe, its limited usage in the EU market and its extreme cost, at an average of $1 million 
per treatment, have led to Glybera®’s  withdrawal. Upon publication of supportive results on 
the gene therapy treatment of 10 children with severe combined immunodeficiency (SCID) 
due to the lack of adenosine deaminase (ADA)140, an alliance between San Raffaele, Molmed 
and GSK was formed in 2010 which resulted in the launch of Strimvelis in 2016. Strimvelis is 
the first ex-vivo gene therapy to gain EMA approval and its use is indicated for the 
treatment of ADA-SCID patients for whom no suitable human leukocyte antigen (HLA)-
matched related stem cell donor is available. Strimvelis product contains autologous CD34+ 
cells transduced with a retroviral vector that encodes the human ADA cDNA sequence from 
human CD34+ cells. In 2018 GSK announced the sale of rare diseases drugs including 
Strimvelis, despite its approval by the National Institute for Health and Care Excellence 
(NICE)141. The success of gene therapy for the treatment of monogenic rare diseases and the 
need for personalised cancer treatments has given rise to a different gene therapy 
application. The University of Pennsylvania and Novartis first formed an alliance on 2012 
that enabled the translation of Carl June’s work on Chimeric Antigen Receptors (CARs)142 
from bench to bedside. KYMRIAH, a CD19-directed genetically modified autologous T cell 
immunotherapy, was the first FDA approved CAR-T therapy. T-cells are transduced with a 
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lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) used for the 
treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic 
leukemia (ALL)143.  
Gene therapy has the potential to become an important broad approach for disease 
treatment. As described in this section, gene therapy has entered clinical reality with 
authorisations for the treatment of inherited diseases and cancers both in Europe and the 
U.S. Rational vector design has been the focus of many research groups and is shown to be 
essential for the successful development of gene therapy. The next chapter outlines the 
different categories of viral vectors and their basic properties.  
2.2.2. Viral vectors as gene delivery tools  
 
The 1990s saw the rise of gene therapy as an approach to cure the majority of human 
diseases. This exciting potential was impeded with the death of the 18 year old patient Jesse 
Gelsinger who participated in a gene therapy pilot study for the treatment of the non life 
threatening condition ornithine transcarbmaylase (OTC) deficiency. Infusion of human 
adenovirus type 5 coding for the OTC cDNA caused systemic inflammatory response 
syndrome and multiple organ system failure that led to the death of this young patient 
within 98 h post treatment144. Moreover, the initial success achieved in the treatment of 
children with SCID was replaced with severe scepticism when two different groups reported 
LMO2 proto-oncogene triggered development of leukemia in some patients145 146. The 
integration pattern and the enhancer activity of the vector used in this study led to 
transcriptional dysregulation of nearby genes like LMO2, and were thus found to be 
accountable for the observed insertional oncogenesis. These two setbacks associated with 
inexperience in the design of clinical trials and in the assessment of viral vectors’ safety 
profile inevitably resulted in decrease of funding and conduct of gene therapy clinical trials.  
Luckily, it also led to a new round of viral vector engineering for improved safety and gene 
delivery which brought us the resurgence of gene therapy. The spectrum of viral vectors is 
broad and includes both DNA and RNA viruses, with either single stranded or double 
stranded genomes, developed for transient or permanent expression147. This wide selection 
allows for the appropriate choice of viral vector type depending on the application for which 
they are required. As this thesis focuses on viral vector design, the use of non-viral vectors 
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will not be discussed any further; instead a brief overview of the most popular viral vectors 
for gene therapy is presented below.  
 
Figure 6. Representation of vectors used in clinical trials. Adapted from source:149. 
 
Human Adenovirus serotype 5-derived vectors are presently the most commonly used gene 
delivery vehicle in clinical trials. Its genome is dsDNA with an insert capacity of 8-36 kb148, 
offering transient gene expression in a variety of host cells149. The first generation of 
adenoviral vectors was causing strong immune responses as adenoviruses can naturally 
infect a variety of human tissues. That led to the most recent third generation design that 
contains big deletions showing higher genome capacity, reduced immunogenicity and 
extended expression periods150. 
Retroviruses are the next most frequently used type of viral vector in clinical applications 
due to the availability of stable cell lines for large scale production. Retroviruses are ssRNA 
enveloped viruses with genome sizes that vary between 7 and 11 kb148 and which unlike 
that of adenovirus gets integrated in the DNA of the host, achieving sustainable 
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expression151. Unlike lentiviruses, retroviruses cannot pass through the nucleopore and as a 
consequence they can only infect mitotically active cells and are likely to integrate in cell 
cycle associated genes. More specifically, retroviruses like gammaretroviruses tend to 
integrate near transcription start sites due to their interaction with BET proteins152, a trait 
which has been associated with insertional deregulation of gene expression153, while 
lentiviruses tend to integrate throughout the bodies of actively transcribed genes due to 
interaction with the LEDGF/p75  protein154 155.  
Adeno-Associated virus (AAV) is a popular choice for in vivo gene therapy and was the first 
type of viral vector to be commercially licensed. AAV vectors have a small ssDNA genome 
with a packaging capacity of only 4 kb that similar to retroviral vectors, provides sustainable 
long-term gene expression through chromosomal integration156. Engineered dual vectors 
have been developed to address this insert capacity limitation associated with the use of 
AAV vectors157. Even though AAV is generally considered a vector with a safe profile 
characterised with low pathogenicity and toxicity, multiple AAV serotypes, including AAV2, 
3, 5, 6 and 8 have been developed to prevent potential immune responses triggered by 
repeated administrations158.  
As shown in Figure 6, other viral vectors frequently used in gene therapy clinical applications 
include lentiviruses, vaccinia virus, poxviruses and herpes simplex viruses. The next section 
discusses lentiviral vectors, the topic of this PhD project, in further detail.  
2.2.3. Evolution of lentiviral vector design 
2.2.3.1. First generation lentiviral vectors 
 
The majority of lentiviral vectors are derived from HIV-1, which is pathogenic. Lack of cure 
for the disease it is causing, acquired immune deficiency syndrome (AIDS), posed significant 
considerations for its use as a gene transfer vehicle. Initially, the main focus was the 
preparation of an HIV-1 derived vector characterised by a decreased likelihood of RCL 
(replication competent lentivirus) generation. Additionally, HIV-1 envelope glycoprotein 
gives access only to CD4+ cells that contain the correct co-receptors, CXCR4 and/or CCR5, 
which would limit the potential therapeutic use of the vector system to a very small number 
of cell types159. HIV-1 was converted into a replication deficient vector by separating its 
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genome into three independent plasmids, while broad tropism was achieved by VSVg 
pseudotyping160. As shown in Figure 7.A, the first-generation lentiviral vector system 
consisted of these three independent elements: i) the packaging construct coding for the 
enzymatic, structural, regulatory and accessory proteins, ii) an envelope construct, while the 
HIV-1 envelope gene was deleted or mutated and iii) the transfer vector genome construct, 
carrying the minimum cis-acting elements (LTRs, ψ and RRE for transcription, encapsidation 
and RNA transport), and the therapeutic transgene under an internal promoter. Splitting the 
genome into 3 separate plasmids means that multiple independent recombination events 
would have to take place for replication competent lentiviruses to be generated. 
Additionally, substitution of HIV-1 env for the VSV glycoprotein gene further minimised the 
risk of recombination by reducing the homologous sequences161. 
2.2.3.2. Second generation lentiviral vectors 
 
In second generation vectors, multiply attenuated LV systems were achieved by removing 
accessory proteins.  With five out of nine genes present in the parental virus deleted, the LV 
remained fully functional and able to transduce non dividing cells in vivo and in vitro162. 
These packaging constructs express Gag, Pol, Tat and Rev only (Figure 7.B)163. 
2.2.3.3. Third generation lentiviral vectors 
 
In an attempt to further improve the safety of the lentiviral system, the U3 promoter of the 
5’LTR was replaced with strong viral promoters, including those derived from  
Cytomegalovirus  or Rous Sarcoma Virus, to remove the requirement for Tat protein whose 
role lies at the transcription level163 164. Additionally, the rev open reading frame was moved 
to an independent fourth plasmid. Thus, third generation lentiviral vector systems contain 
only three out of nine HIV-1 genes and consist of four separate plasmids. Similar to previous 
systems, there is i) a packaging plasmid, which is now only expressing the Gag/Pol proteins, 
ii) an envelope construct typically coding for VSVg iii) an independent plasmid expressing 
the Rev protein and iv) a transfer vector construct that drives the expression of the 





Figure 7. Schematic presentation of the evolution of lentiviral vector design. 
 
[A] First generation lentiviral vector system consisting of a transfer vector, envelope and 
packaging construct. [B] For the second generation lentiviral vector system all accessory 
proteins are removed with the rest of the constructs remaining intact as presented in the 
first generation system. [C] Third generation lentiviral vector system consisting of four 
plasmids including a Tat-independent SIN transfer vector, an envelope construct, a Rev-
expressing and a Gag-expressing construct. (A detailed explanation of transfer vector 
elements, including cPPT, IP and WPRE, is presented in section 2.2.7 below.) 
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2.2.4. Properties of lentiviral vectors 
 
Moloney murine leukaemia virus (MoMLV) was the first gammaretrovirus to be used for the 
preparation of therapeutic vectors165. The construction of a mutant MoMLV that was 
defective in the packaging of gRNA into virions was an important step towards the 
development of retroviral vectors165. Until now, MoMLV-derived vectors have been the 
most frequently used retroviral vectors. Following the advancements in the retroviral vector 
design, the first lentiviral vector gene delivery systems based on HIV-1 were developed by 
the early 1990s166. The inability of retroviral vectors to transduce non-dividing cells151 
combined with the safer lentiviral vector integration profile167 have increased the interest 
for the development of clinical grade lentiviral vectors for gene therapy applications.  
Lentiviruses are a subclass of retroviruses characterised by a relative complex genome 
coding for a number of accessory proteins in addition to the canonical retroviral Gag/Pol 
and Env products. Retroviral particles are on average 100 nm in diameter and consist of 1% 
RNA, 60−70% protein, 30−40% lipid, the latter derived from the membrane of the producer 
cell and 2−4% carbohydrate, mainly from glycosylation of the envelope protein. This family 
of viruses is characterised by their ability to reverse transcribe and stably integrate their 
genetic information into the host genome hence when used as vectors, achieving sustained 
gene delivery and expression. Lentiviral vector replication includes receptor-mediated entry, 
capsid uncoating, reverse transcription, trafficking to the nucleus and integration into the 
host cell genome; common properties of the retroviral life cycle151.    
Various properties of HIV-1 have been exploited or modified on different stages of its life 
cycle to convert it to an attractive vector for clinical applications. Lentivirus mediated 
transduction starts with the interaction of the envelope protein with receptors on the target 
host cells. One mechanism for altering or expanding cellular tropism is through the 
formation of phenotypically mixed particles, a process known as pseudotyping, that can 
occur during viral assembly in cells infected with two or more viruses168. Several studies 
showed that WT HIV-1 produced in cells infected with xenotropic murine leukemia virus 
(MLV)169, amphotropic MLV170 or herpes simplex virus171 can give rise to phenotypically 
mixed virions with an expanded host range, suggesting that HIV-1 biology allows 
pseudotyping. These early observations were confirmed and extended in 1996 when three 
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independent groups showed that VSVg pseudotyped HIV-1 virions can be successfully 
produced172 173 174. These pseudotyped vectors had the advantages of targeting a plethora 
of cells as VSVg appeared to interact with a ubiquitous cellular “receptor” on cells. The 
receptor for VSV has long been thought to be a ubiquitous membrane lipid, 
phosphatidylserine175 until Finkelshtein et al., identified the low-density lipoprotein receptor 
family (LDLR) as the VSV receptors on the membranes of cells176. After the processes of 
entry and uncoating, the gRNA is reverse transcribed while forming the nucleus for the 
reverse transcription complex (RTC). The newly synthesised cDNA is associated with several 
cellular and viral proteins in the preintegration complex (PIC)177. The ability of LVs to 
transduce non-replicating cells has been of great importance for the development of 
clinically useful gene therapy vectors. Since the PIC is too big to cross the nuclear pores, HIV 
must have found alternative ways to interact with the nuclear import machinery to infect 
non dividing cells. The exact mechanism remains controversial, but the most recent studies 
by Emerman et al., suggest the viral capsid to be the key determinant of HIV-1 infection of 
non-dividing cells.  
Based on the properties described above, LVs have been proven to be an easy and useful 
system for stable expression of transgenes both for clinical and basic research 
applications178. Lentiviruses, unlike Adenoviruses achieve sustainable gene expression via 
stable integration in the host genome and, unlike gammaretroviruses, lentiviruses have the 
ability to infect both dividing and non-dividing cells, making them attractive tools to 
transduce cells regardless of their mitotic state179. HIV-1 derived vectors allow for 
pseudotyping with a plethora of envelopes, with VSVg being the most widespread one, 
offering broad tissue tropism. VSVg pseudotyping offers high vector particle stability, 
allowing for concentration by ultracentrifugation180. Notably, LV components show low 
immunogenicity in humans compared to that of other viral gene transfer vectors158 
181.Lastly, most recent studies suggest a potentially safer integration site preference for 
lentiviral vectors compared to other retroviral vectors. Gammaretroviral vectors have a 
tendency to integrate near the transcription start site (TSS) of genes, a property associated 
with clonal expansion and carcinogenesis, whereas LVs show a preference to integration 
inside actively transcribed genes167.  
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However, vectors that integrate their genome in the genetic material of the host always 
carry the possibility of transforming mutation182; although the introduction of Self 
Inactivating (SIN) LVs aims to eliminate the likelihood of such events, see below183. Despite 
being an easy system for manipulation and production, high vector doses and prolonged ex 
vivo culture conditions are required to achieve high transduction efficiencies of clinically 
relevant cellular targets as exemplified in recent attempts to use LVs in clinical trials184. 
Currently, lentiviral vector production is inefficient and expensive185. Therefore, 
advancement of the production system and increase of titres could significantly improve 
patient access to life changing gene therapy treatments. In the following paragraphs, I detail 
how vector design and safety has evolved and improved through successive generations as a 
prelude to our current approach targeting packaging efficiency. 
2.2.5. Clinical use of lentiviral vectors 
 
The first clinical trial using lentiviral vectors took place in 2003 and aimed to treat the 
acquired immunodeficiency syndrome. The vector used was a Tat and Rev dependent HIV-1 
derived lentiviral vector that expressed an HIV env antisense RNA in CD4+ T cells186. In 2006 
and 2007, two additional clinical trials employing lentiviral vectors were designed for the 
treatment of β-thalassemia, caused by reduced production of β-globin in erythroid cell187 
and Adrenoleukodystrophy (ALD), a brain disorder caused by myelin destruction188. The first 
attempt to treat β-thalassemia with a gene therapy approach used the LentiGlobin vector,a 
self-inactivating vector that contained large elements of the β-globin locus control region as 
well as chromatin insulators187. The first clinical trial using a non-HIV-1 based lentiviral 
vector started in 2007 in France. An equine infectious anaemia virus (EIAV) based lentiviral 
vector called ProSavin was designed to express the three key dopamine biosynthetic 
enzymes (tyrosine hydroxylase, aromatic L-amino acid decarboxylase and GTP 
cyclohydrolase 1) by Oxford Biomedica for the treatment of Parkinson ’s disease189. Ever 
since, multiple clinical therapies using lentiviral vectors have been announced and many 
more are to be expected. Currently, LVs are involved in 9.5% of all the gene therapy clinical 
trials worldwide and in 19% of those for monogenic diseases190. As shown in table 3, 
inherited immunodeficiencies are important targets for gene therapy191. Of special interest 
was the development of a lentiviral vector for Wiskott-Aldrich syndrome (WAS) whose 
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transfer vector construct contained a promoter fragment derived from the WAS protein 
(WASP) gene to drive the expression of WASP cDNA192. 
 














Wiskott-Aldrich syndrome 1/2 NCT01347346 
1/2 NCT01347242 
1/2 NCT02333760 
X-SCID 1/2 NCT01306019 
1/2 NCT01512888 
ADA-SCID 1/2 NCT02999984 
1/2 NCT01380990 









Table 3. Ongoing clinical trials using lentiviral vectors.Source:194. 
2.2.6. SIN (Self Inactivating) LVs 
 
Following safety advancements in Murine Leukaemia Vectors (MLV), the SIN (Self 
Inactivating) LV was constructed. Initially, this was achieved by a 133bp deletion in the U3 
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region of the 3’LTR183. Later in the same year, a different group described the production of 
a SIN LV by deleting 400bp of the 3’LTR193. Upon reverse transcription, this deletion is 
transferred to the 5’LTR, leading to the transcriptional inactivation and immobility of the 
transfer vector, while maintaining the viral titres at a similar level. SIN vectors inactivate the 
5’LTR and allow the internal promoters to work without upstream competition. As 
importantly, SIN vectors inactivate the 3’LTR and thus reduce the risk of it acting as a 
promoter that could potentially activate downstream cellular genes in the cell genome. 
Although retroviral infection can be associated with proto-oncogene activation, this has 
never been observed with HIV-1; a trait important for the clinical use of HIV-1 based vectors 
in gene therapy194. However, an expanded cell clone which contained an integrated vector 
in the proto-oncogene HMGA2 was noticed in a recent β thalassemia clinical trial195. The use 
of SIN vectors offers the advantage of reducing the likelihood of any potential insertional 
activation of cellular oncogenes and also helps reduce the possibility of RCL production.  
 
                  
 
Figure 8. Schematic representation of non-SIN and SIN vector. 
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2.2.7. Transfer Vector design The current system used in clinical gene therapy 
applications is a 3rd generation SIN LV system with a heavily modified transfer vector to 
achieve maximum efficiency and safety (Figure 9). The strong CMV promoter replaces the 
U3 promoter/enhancer region of the 5’LTR164. The cis-acting sequences from the R region up 
to the end of the 5’LTR are indispensable and are maintained intact. The SL3 stem loop with 
a 360 bp fragment of gag and other upstream sequences serve as the minimum core 
packaging signal19. Following the beginning of the gag ORF, there is a copy of the RRE 
required for successful transport of the unspliced transcript from the nucleus to the 
cytoplasm. There are multiple papers describing the efforts to make this system Rev/RRE 
independent in an attempt to reduce the amount of HIV-1 derived sequences; in one of 
them, the RRE element is substituted with alternative RNA export elements, primarily the 
constitutive transport element (CTE) from different Simian retroviruses. Despite the 
presence of data suggesting that the concatemerization of CTE elements could efficiently 
replace the Rev/RRE system196, the HIV-1 derived lentiviral transfer vector established for 
reliable high titre production continues to be a Rev dependent one. The central polypurine 
tract (cPPT) is important for the initiation of plus strand synthesis during reverse 
transcription and leads to increased transduction efficiency via stimulation of nuclear 
import197. Additionally, in vector systems that included the cPPT, a correlation between the 
dosage of the vector and transgene expression was noticed, which is in contrast with the 
plateau effect observed when using conventional non-cPPT including vectors198. Studies 
have demonstrated that alteration of the vector’s enhancer/promoter elements has a more 
significant effect on biosafety, with regards to transformation and expansion of transduced 
cells, than the retroviral insertion pattern per se199. Thus, traditionally, gene therapy 
approaches make use of weak internal promoters. The latest cis-acting modification that 
was introduced for improved expression is the WPRE (woodchuck hepatitis virus post 
transcriptional regulatory element) sequence that increases the level of transgene 
expression significantly, by increasing the amount of both nuclear and cytosolic WPRE-
containing unspliced transcripts. Based on the observations that HBV PRE (HPRE) and an 
intron were functionally equivalent, it was initially thought that WPRE enhanced gene 
expression via promoting nuclear export200. Further studies showed that its post 
transcriptional effects do not result from increased RNA export, or an increased 
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transcription rate, or a longer RNA half-life, but rather from improved RNA processing201. 
Although the exact mechanism of the WPRE remains unknown, it is thought to act by driving 
efficient 3’ processing of RNA during the early synthesis stage202. Despite the great 
advantage of including WPRE in the vector design, concerns arose due to the presence of an 
ORF within this element that codes for a truncated peptide derived from the WHV X gene 
that is associated with liver oncogenesis203. The safety of this element has been improved 
with the introduction of mutations that abrogate the WHV X expression while still 
maintaining high transgene expression202. 
Despite decades of study and iterative improvements in vector design, LV transduction 









2.2.8. Provisional lentiviral vector design modifications 
 
Introduction of the Chicken β-Globin Locus HS4 Insulator Element (cHS4) was used to 
address the safety issues regarding vector insertional mutagenesis. The full 1.2 kb insulator 
element negatively affected vector titre and transgene expression, whereas a 0.25 kb core, 
part of the insulator, managed to rescue vector titres by improving reverse transcription. 
Introduction of this core element was also shown to act as a barrier by reducing variability 
of expression due to position effects and by blocking enhancer activity204.  However, even 
though a single cHS4 insulator 0.25 kb core was found to be effective in lentiviral vectors204,  
its inclusion in the extended β-globin locus control region of a β-globin lentiviral vector205 
  Figure 9. Components of a typical 3rd generation lentiviral transfer vector. 
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did not manage to prevent cell expansion when used for the treatment of human β-
thalassaemia195. Similarly, the enhancerless novel human HNRPA2B1-CBX3 UCOE (A2UCOE) 
was assessed for its ability to overcome insertion-site position effects. A2UCOE belongs to 
the category of ubiquitously acting chromatin opening elements (UCOEs). UCOEs are genetic 
regulatory elements known for their ability to confer resistance to transcriptional silencing 
and thus achieving stable, reproducible, high levels of gene expression206. Results suggested 
that the A2UCOE reaches therapeutically relevant levels of gene expression in the absence 
of enhancer sequences adding an extra layer of safety to clinical vector use207.  Another 
approach that addressed the safety concerns associated with lentiviral integration led to the 
development of novel lentiviral vectors (LTR1) designed to prevent transfer of HIV-1 
packaging sequences to patient cells. LTR1 vectors reverse transcribe their genomes with a 
single strand transfer instead of the usual two, resulting in integrated proviruses that lack 
packaging sequences. LTR1 vectors are suggested to offer remobilisation resistance, 
reduced frequency of splicing into human genes and higher transgene expression208.  
The instability sequences present in the coding region of gag/pol and the codon bias of the 
HIV-1 genome, which unlike the human one, is AU-rich, are considered accountable for the 
Rev dependence of the lentiviral system209. To address poor Gag/Pol protein expression 
Kotsopoulou et al., created a codon optimised Rev-independent construct210. Codon 
optimisation is an approach used to substitute rare codons by frequent codons according to 
the genomic codon usage in a host organism and thus improve protein expression211. 
Additionally, the use of this codon optimised Rev independent construct offers improved 
safety by minimising the homology between the partial gag included in the transfer vector 
and the beginning of the gag ORF of the packaging construct. A similar codon optimisation 
approach was followed years later to address safety concerns associated with the 
production of replication competent lentiviruses. It was shown that Rev-Independent 
gag/pol eliminates psi-gag recombination, hence its inclusion in the lentiviral system offers 
a safety advantage for clinical use212. A codon optimised gag/pol construct was also used for 
the production of a stable cell for clinical vector production213. Stable cell line development 
is generally associated with the advantages of stable and scalable vector production. 
However, the viral titre of the aforementioned stable cell line was only of 106 transducing 
units/mL, while transient transfections can yield supernatant of up to 108 transducing 
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units/mL. Additionally the expression of certain therapeutic transgenes has been observed 
to negatively impact vector production by affecting cell metabolism and/or vector virion 
itself. To overcome this challenge Oxford Biomedica developed the Transgene Repression In 
vector Production (TRiP) system that blocks mRNA translation. Introduction of the TRiP 
system in a lentiviral vector coding for the Cyclo-oxygenase-2 enhanced titres by 600-fold214. 
2.2.9. Transduction efficiency-What are the challenges? 
 
Despite the tremendous potential of hematopoietic gene therapy, Hematopoietic Stem and 
Progenitor cells (HSPCs), the target cells of gene therapy applications, are poorly permissive, 
requiring multiple rounds of high vector doses and prolonged ex vivo culture to reach 
adequate transduction levels215 216. This poor permissiveness can be explained by the 
retroviral origin of LVs combined with the high viral particle load used in LV transduction 
compared to a natural LV infection. Viruses evolve to compete against their hosts which in 
turn develop sophisticated defensive mechanisms against them. Along with LV transduction 
resistance, HSPCs have also proved to be resistant to viral and bacterial infections217 218.  
Recent research has revealed the expression of mammalian antiviral factors known as 
restriction factors (RFs)219 220. Viral arsenals include several accessory proteins whose major 
role is to counteract RFs and avoid innate immune activation221. LV lack of accessory 
proteins make LV-mediated gene transfer inefficient, highlighting the importance of 
improved LV design to increase transduction efficiency.  
The size, sensitivity to inhibitors, particle complexity and instability of lentiviral vectors can 
further affect vector integrity and functionality after bioprocessing222. Low titres and 
maintenance of infectivity are the biggest challenges for upstream and downstream 
processing respectively. Retroviral particles typically have a half-life of 6-7 hours at 37°C. 
The reduction of LV infectivity at 37°C was shown to be associated with loss of reverse 
transcriptase activity223. Instability of Env due to dissociation of SU and TM contributes to 
particle instability; a problem which as explained in section 2.2.3, is now resolved with 
replacement of Env with VSVg. Additional challenges contributing to reduction of functional 
titres include the presence of reported cell culture media components that act as viral 
inhibitors224 225. Host cell-derived proteoglycans and glycosaminoglycans have also been 
reported as inhibitors of transduction226. 
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It has been estimated that early phase clinical trials for ex vivo therapy require 1011-1012 
functional particles227. Titres from transiently transfected HEK293T cells are typically close 
to 107 TU/mL228. It is generally assumed that the quality control consumes half the produced 
batch and that after downstream processing, only approximately 10% of the batch will be 
recovered. That leads to a requirement of harvesting of big volumes of viral supernatant 
which restricts gene therapy from taking off as a treatment for more common diseases.  
To address these current challenges facing the field of gene therapy, research groups 
working with LVs have focused their recent efforts on improving the current transduction 
protocols. Such efforts include ultracentrifugation and culturing conditions optimisation229 
and use of new transduction enhancers230 231. However, such approaches are cell specific 
and are likely to increase costs and processing. Additionally, transient pharmacologic 
immune system modulation achieved by certain transduction enhancers231 may not be a 
genetically safe approach. Therefore, here, I suggest the improvement of LV infectious titres 
by modifying the basic backbone of the 3rd generation transfer vector currently used in 
clinical applications, through generating new packaging signal RNAs with improved 

















2.3. Aims of the project  
 
LV titres are a limiting factor for the wide use of lentiviral vectors in clinical applications. 
Many stages of the HIV-1 life cycle could be limiting vector titres, with packaging being a 
potential limiting factor candidate. As mentione above, the LDI-BMH model suggests 
competition between the processes of packaging and translation7, which could be 
eliminated via rationally designing mutations in the transfer vector construct to increase 
packaging. 
 
To increase LV infectious titre through generating packaging signal RNAs with                                       
more efficient dimerisation and encapsidation properties. 
 
This project focused on improving the efficiency of lentiviral vector dimerisation and 
packaging. The tight relationship between these two processes had been shown by Sakuragi 
et al., and has already been discussed109. I designed dimerisation promoting mutations by 
targeting the polyA, U5-AUG and SL1 structural motifs in an attempt to evaluate their 
impact on vector infectivity and packaging efficiency. As an improvement to previous work I 
worked with the full-length gRNA encoded by the transfer vector construct and with a 690 
nt long in vitro transcribed RNA fragment, instead of focusing solely on the 5’UTR. 
Furthermore, unlike previous studies, I assessed the dimerisation ratio and the 
encapsidation efficiency of gRNA produced in the cell rather than in a in vitro context. I then 
investigated whether the improvement of these two processes could also increase the 
transduction efficiency of these modified vectors. Identification and validation of mutations 
that increase LV packaging and infectious titre have the potential to impact the design of LV 







3. Materials and Methods 
3.1. Lentivirus production by transient transfection 
 
293T cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% 
fetal bovine serum (GIBCO) at 37 oC.  For transfection 5 x 106 cells were seeded under sterile 
conditions in 10 mL medium in a 10 cm2 dish. The medium was changed 18 h after seeding 
and transfected 2-3 h later. For each transfection plate, 25 μg DNA (25 μg total, composition 
of vector mix is detailed in each experiment) were added to the first tube with 250 mM 
CaCl2 in a 500 μL final volume. Air was bubbled through 500 μL of 1M, pH 7.0 Hepes 
Buffered Solution (HBS) while adding the CaCl2-DNA solution drop-wise. The solution was 
incubated at room temperature for 30 min. The solution was mixed by pipetting up and 
down and immediately added dropwise, evenly across the entire plate, followed by swirling 
to ensure even distribution. Cells were incubated at 37°C overnight. Medium was replaced 
with 8 mL fresh medium 16 h post transfection. Virus-like particles were harvested 40 h post 
transfection, 1 mL aliquots of supernatant were filtered through a 0.2 μm filter, aliquoted 
into cryovials, and stored at -80°C. Transfection efficiency was assessed by flow cytometry.  
3.2. Vector titration with flow cytometry 
 
293T cells were seeded at 3 x 105 per well of a 6-well plate in a final volume of 2 mL. Viral 
supernatants were thawed and used to infect cells 18 h post-seeding at 10-1, 10-2 and 10-3 
dilutions in a final volume of 500 μL containing 8 μg/mL polybrene. Plates were returned to 
a 37°C CO2 incubator for 2 h, followed by the addition of 1 mL medium to each well. The 
vector can be titrated 48 h post transduction by flow cytometry. 250 μL of TrypLETM Express 
(1x) were added to cells, which were incubated with the dissociation reagent at 37°C for 5 min. 
50 μl of the TrypLETM Express treated cells were resuspended in 500 μL of PBS to perform flow 
cytometric analysis to determine the percentage of eGFP positive cells. The transduction 
efficiency of each produced lentiviral vector was calculated by multiplying the number of seeded 
cells by the percentage of eGFP positive cells and by the vector dilution factor. This value was 
then divided by the volume of lentiviral vector used for HEK293T cell transduction. Values used 
for titration were between 4% - 25% eGFP positive cells. Flow cytometry analysis was 
performed using the BD AccuriTM C6 Plus system (excitation at 488 nm, filter at 491 nm and 
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emission at 530 nm, filter at 533±30 nm)232. Non transduced HEK293T cells were used to 
draw a live gate on a SSC vs FSC plot. Such plots were used to distinguish cell populations 
based on their forward and side scatter properties that gave an estimation of the cell size 
and granularity cells respectively. eGFP was detected in FL1 by using the standard C6 filter 
configuration (FL1 = 530/30 BP)232. Hence, a count vs FL1 histogram was used to study the 
distribution of fluorescence intensities of transduced cells and calculate the number of eGFP 
positive cells. The FL1-X axis represented fluorescence intensity and the Y axis showed the 
cell count. The non transduced HEK293T sample was also used to set an FL1 threshold bar to 
differentiate eGFP expressing HEK293T cells to non-eGFP expressing HEK293T cells. The live 
gate and the FL1 bar were then applied to all samples to positively select populations for 
further examination. 10.000 events were collected for each sample of interest.  
3.3. Design and cloning of mutants  
3.3.1. Mutagenesis primer design 
 
Primers to create mutations in pCCL-eGFP were designed using the Agilent QuikChange 
Primer Design Program available online233.  
               
Primer ID Primer Sequence (5´-3´) 
uc2m Fw1 gagtgcttcaagtagtgcgcgcccgtctgttgtgtga 
uc2m Rv1 tcacacaacagacgggcgcgcactacttgaagcactc 
uc2m Fw2 ctagaaggagagagacgggcgcgagagtgtcagtattaagcgg 





NCSL4s Fw cttcaagtagtgtgtgcctgtttgttgtgtgactctggta 
NCSL4s Rv taccagagtcacacaacaaacaggcacacactacttgaag 
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NCSL4s Fw tgggtgcgagagcgccagtattaagcggg 
NCSL4s Rv cccgcttaatactggcgctctcgcaccca 
S1 Fw gagtgcttcaagtagtgtgcacccatctgttgtgtgactctggt 
S1 Rv accagagtcacacaacagatgggtgcacactacttgaagcactc 
LU5AUG Fw1 ctagcggaggctagaaggagagagacgggcacaagagcgtcagtat 





polyAs Fw cgtactcaccagtcgcctggactcgcctcttgccgtgc 
polyAs Rv gcacggcaagaggcgagtccaggcgactggtgagtacg 
J9Gag+ Rv1 ccgagtcctgcgccgagagagctcc 
J9Gag+ Fw1 ggagctctctcggcgcaggactcgg 
J9Gag+ Rv2 ctcaccagtcggcgcccctcgcc 
J9Gag+ Fw2 ggcgaggggcgccgactggtgag 
SIVS1 Fw tcggcttgctgaagtgagcacggcaagaggc 
SIVS1 Rv gcctcttgccgtgctcacttcagcaagccga 
polyAw Rv cagacgggcacacactgcttaagcactcaagg 
polyAw Fw ccttgagtgcttaagcagtgtgtgcccgtctg 
ΔP1 Del Fw cggcgactggtgagtacgccggctagaaggagagagatgggtg 
ΔP1 Del Rv ccatctctctccttctagccggcgtactcaccagtcgccg 
Table 4. List of primers used for SDM. 
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Mutations could not be directly introduced into the U5 regions of the WT pCCL-eGFP 
plasmid as this region is present both in the 5’ and 3’LTRs. Thus a subcloning strategy was 
designed to isolate the 5’LTR via PCR and subsequently clone this fragment into the Blunt-
TOPO vector (Invitrogen). Nucleotides 280-3100 (pCCL-eGFP plasmid map provided by 
Conrad Vink, GSK) were amplified using Fw Subcloning Primer 5´-
TACGGTAAACTGCCCACTTG-3´ and Rv Subcloning Primer 5´-TAGGTCAGGGTGGTCACGAG-
3´, including the 5’LTR and flanking sequences. PCR reactions contained 0.5 U AccuprimeTM 
Pfx Supermix (22 U/mL of Thermococcus species KOD thermostable Polymerase, which 
leaves blunt ends, complexed with anti-KOD antibodies, 66 mM Tris-SO4 (pH 8.4), 30.8 mM 
(NH4)2SO4, 11 mM KCl, 1.1 mM MgSO4, 330 μM dNTPs, AccuPrime™ proteins, and stabilisers, 
250 nM of each primer and 50 ng of the plasmid template in a final volume of 25 μL. The 
thermal cycling conditions were: 95°C for 5 min, 35 cycles of: 95°C for 15 sec, temperature 
gradient 60-65°C for 30 sec, 68°C for 3 min and a final extension step at 68°C for 7 min. 
Following this, 1 μL of the PCR product, 1 μL of the TOPO-Blunt vector (Invitrogen) and 3 μL 
of water were incubated at 24°C for 30-40 min and 2 μL of the resulting products were used 
to transform Stbl3 E.coli competent cells. Cells were incubated on ice for 30 min, and heat-
shocked for 45 sec at 42oC. 250 μL of pre-warmed S.O.C Medium (2% tryptone, 0.5% yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) were 
added to each vial and cells were placed in a shaking incubator at 37°C for 1 h at 225 rpm, 
before the whole transformation suspension was spread on a selective plate and incubated 
overnight at 37°C. Insert-containing clones were identified by diagnostic digest with EcoRI. 
Mutagenesis was performed using the Site-Directed-Mutagenesis (SDM) XLII Agilent kit. 
Reactions contained 2.5 U  Pfu, 200 μM each primer, 200 μΜ dNTP mix, 1x Buffer (50 mM 
Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate and 100 μg/mL BSA) 
and 50 ng of plasmid in a total volume of 50 μL. Cycling conditions were: 95°C for 1 min, 35 
cycles of: 95°C for 50 sec, 60°C for 50 sec, 68°C for 5 min 30 sec and a final extension step at 
68°C for 7 min. The SDM products were analysed by gel electrophoresis to ensure the 
presence of the correct PCR product size which was then treated with 10 U of DpnI to 
remove the parental methylated plasmid template and used to transform XL10-Gold® 
Ultracompetent Cells. Colonies were screened by diagnostic digest and mutations verified 
by Sanger sequencing.  
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3.3.3. Transfer of mutant inserts into pCCL  
 
Transfer vector pCCL backbone (1μg) and mutated TOPO-vectors (1.5 μg) were digested 
with 20 U NdeI and 20 U MfeI-HF enzymes in a 20 μL reaction in 1x CutSmart Buffer (50 mM 
Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate and 100 μg/mL BSA ) at 
37°C for 2 h. Digestion products separated on a 1% agarose gel and bands of interest were 
excised and DNA extracted using a Gel extraction Kit (Qiagen). Ligation reactions contained 
50 ng of each mutant insert and backbone and 5 U T4 expressLink ligase (Invitrogen) in a 
final volume of 20 μL and were incubated at room temperature for 2h 30min. Stbl3 E. Coli 
cells were transformed with 2 μL ligation reaction and cultures were amplified and screened 
as above.  
3.4. Intracellular RNA purification  
 
RNA from transfected cells was extracted using the Qiagen RNeasy kit.  Cells were washed 
twice with 3 mL of sterile PBS and lysed in 1 mL RLT buffer at RT for 20 min with occasionally 
swirling. Lysates were homogenised by vortexing; 350 μL of each cell lysate sample were 
mixed with 1 volume of chilled 70% ethanol in a new Eppendorf tube and transferred to an 
RNeasy Mini Spin column, followed by centrifugation at 16,000 x g for 1 min.  Columns were 
washed once with Buffer RW1 (700 μL), twice with Buffer RPE (500 μL) and eluted in 40 μL 
of RNase-free water.   
3.5. Extracellular RNA purification  
 
Vector supernatant (8 mL) was centrifuged for 10 min at 3000 x g and 1 mL of it was added 
to 400 μL 8.4% Opti-Prep in sterile PBS and centrifuged at 22000 x g for 2 h at 4°C. Pellets 
were resuspended in 100 μL PBS and incubated in 200 μL protease K extraction buffer (50 
mM Tris-HCl pH 7.5, 100 mM Nacl, 10 mM EDTA, 1% SDS, 100 μg/mL Protease K (Ambion) 
and 100 μg/mL yeast tRNA (Sigma-Aldrich) at 37⁰C for 30 min. An equal volume of acidic 
phenol-chloroform (5:1) was added and the mixture was centrifuged for 2 min at 1600 x g. 
The upper layer was mixed with an equal volume of chloroform-isoamyl alcohol (24:1) and 
was centrifuged for 2 min at 16000 x g. The upper layer was mixed with 1/10 volume of 3M 
sodium acetate (pH 5.2) and 2.5 volumes of 100% ethanol. The precipitate was incubated at 
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-80°C for 1 h and then centrifuged at 16000 x g at 4°C for 20 min. The pellet was washed 
with 200 μL ice-cold 70% ethanol followed by centrifugation at 16000 x g at 4⁰C for 20 min. 
The pellet was resuspended in 10 μL nuclease-free water and stored at -80⁰C. 
3.6. RT-qPCR assays 
3.6.1. WPRE RT-qPCR  
3.6.1.1. DNase digestion  
 
Extracted RNA (800 ng) was digested with 9 U Turbo DNase in a total volume of 40 μL at 
37⁰C for at least 2 h. The volume was brought to 110 μL with RNase-free water and an equal 
volume of acidic phenol-chloroform was added. The mixture was vigorously vortexed and 
centrifuged at 16,000 x g for 2 min. Supernatant was carefully removed to a new Eppendorf 
tube. An equal volume of chloroform-isoamyl alcohol was added and the mixture was 
vortexed and centrifuged again. The supernatant was carefully removed to a new Eppendorf 
tube and mixed with 1/10 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of 100% 
ethanol. The mix was incubated at -80⁰C for 1 h and then centrifuged at 16,000 x g at 4⁰C 
for 20 min. The supernatant was decanted, and the pellet was washed with 200 μL 70% 
ethanol and centrifuged at 16,000 x g at 4⁰C for 20 min. The pellet was air-dried, 
resuspended in 10 μL nuclease-free water and stored at -80⁰C.  
3.6.1.2. Reverse Transcription  
 
RNA samples isolated from the previous step were normalized to 100 ng per sample and 
used for cDNA synthesis using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). Reactions contained 1x Buffer, 1x RT Random Primers, 40 mM dNTPs, 50 U 
Multiscribe Reverse Transcriptase and 20 U RNase Inhibitor in 20 μL final volume. Reactions 
lacking RT were included as controls. Thermal cycler conditions were: 25⁰C for 10 min, 37⁰C 




3.6.1.3. Real Time qualitative PCR (qPCR) 
  
The cDNA products were quantified by qPCR using primers targeting the WPRE element (Fw 
5´-CCGTTGTCAGGCAACGTG-3´ Rv 5´-AGCTGACAGGTGGTGGCAAT-3´, and probe 5’-FAM-
TGCTGACGCAACCCCCACTGGT-BHQ1-3’234. After optimisation the final reaction conditions 
were 100 nM probe, 400 nM each primer, 1x Fast Advanced buffer (Applied Biosystems) and 
10 ng cDNA in 10 μL reaction volume. Cycling conditions were 95⁰C for 5 min and 40 cycles 
of 95⁰C for 15 sec, 60⁰C for 15 sec and 72⁰C for 15 sec. The cellular levels of β-actin cDNA 
were measured using the SYBR Green technology and 40 nM of the following primers: Fw 
5´-GAGCGGTTCCGCTGCCCTGAGGCACTC-3´, Rv 5´- GGGCAGTGATCTCCTTCTGCA 
TCCTG-3´. The reaction conditions were 40 nM each primer, 1x SYBR Green Fast Advanced 
buffer (Applied Biosystems) and 10 ng cDNA in 10 μL reaction volume. Cycling conditions 
were 50⁰C for 2 min, 95⁰C for 20 sec and 40 cycles of 95⁰C for 1 sec and 60⁰C for 20 sec. 
3.6.2. Competitive RT-qPCR BglG and MSL assay 
3.6.2.1. Cloning of the unique sequences BglG and MSL into the pCCL backbone 
 
Oligos containing the sequences of BglG: 5’-GGATTGTTACTGCATTCGCAGGCAAAACC-
3’ and MS2: 5’-GCATGAGGATCACCCATGT-3’ flanked between the PvuI recognition 
sites were designed and then used in an annealing reaction that contained 100 μΜ Fw Oligo, 
100 μΜ Rv Oligo, and 1x ExpressLinkTM T4 Buffer (Invitrogen) in a 100 μL final volume 
reaction that was held at 90°C for 10 min. Reagents were allowed to cool down to RT. 
Meanwhile 1 μg of the pCCL backbone was digested with 20 U of FastDigest PvuI (Thermo 
Fisher Scientific) and dephosphorylated with 1 U of FastAP Thermosensitive Alkaline 
Phosphatase (Thermo Fisher Scientific) in a 20 μL reaction in 1x Fast Digest Buffer (Thermo 
Fisher Scientific) at 37°C for 1 h. Digestion products were separated on a 1% agarose gel and 
the bands of interest were excised and DNA extracted using the Gel extraction Kit (Qiagen). 
Ligation reactions contained 35 ng of annealed oligos, 100 ng backbone and 5 U of T4 
expressLink ligase (Invitrogen) in a final volume of 20 μL and were incubated at room 
temperature for 2h 30min. Stbl3 E. Coli cells were transformed with a 2 μL ligation reaction 
and cultures amplified and screened as above.  
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3.6.2.2. RNA preparation 
 
WT and Mutant transfer vectors were then used for co-transfections as described above. 
Intracellular and Extracellular RNAs were isolated as described in sections 3.4. and 3.5. 
Removal of contaminant plasmid DNA was achieved using the Turbo DNA-freeTM kit 
(Invitrogen) in a reaction containing 8 U of Turbo DNaseTM Enzyme, 1x Turbo DNAseTM 
Buffer and the total amount of RNA isolated. Reaction was left at 37⁰C for 2 h. 0.2 volumes 
of the inactivation reagent were added and samples were incubated at RT for 5 min. Clean 
RNA was recovered after centrifugation at 10,000 x g for 2 min. 
3.6.2.3. RT-qPCR 
 
The reverse transcription step was performed as above. The cDNA products were then 
quantified by qPCR using a common set of primers Fw 5´-GAATTCTGCAGTCGACGGTA-3´, 
Rv 5´-TCCAGAGGTTGATTGCGA-3´ and Probes targeting either the unique sequence of the 
BglG 5’-FAM-TCGATCGGGATTGTTACTG-BHQ1-3’ or the MS2 sequence 5’-HEX-CATGGGT 
GATCCTCATGCCGAT-BHQ2-3’. After optimisation the final reaction conditions were 750 
nM BglG probe or 250 MS2 probe, 550 nM  each primer, 1x Fast Advanced buffer (Applied 
Biosystems) and 3 μL cDNA in a 10 μL reaction volume. Cycling conditions were 95⁰C for 5 
min and 40 cycles of 95⁰C for 15 sec, 60⁰C for 15 sec and 72⁰C for 15 sec.  
3.7. Production of a DIG-labelled RNA probe for Northern Blotting 
 
A 744 nucleotide PCR fragment including the eGFP ORF and the start of the WPRE sequence 
was amplified by PCR using primers Fw 5´-GCTCCCTCGTTGACCGAATC-3´ and Rv 5´-TAA 
TACGACTCACTATAGGGTCGTCCATGCCGAGAGTGATC-3´. PCR reaction contained pCCL-
eGFP template (100ng), 1x Phusion HF Buffer, 12.5 μM each primer, 10 mM dNTPs, 3% 
DMSO and 1 U HF Phusion DNA Polymerase (NEB). The thermal cycling conditions were: 
98°C for 30 sec, 35 cycles of: 98°C for 10 sec, temperature gradient 58°C for 30 sec, 72°C for 
1 min and a final extension step at 72°C for 10 min.The PCR fragment was electrophoresed 
on a 1% agarose gel, visualised by UV and extracted using the Qiagen gel extraction kit 
according to the accompanying protocol. In vitro transcription was carried out using the 
MEGAScript T7 transcription kit (Ambion).  Reactions contained extracted PCR product (1 
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μg), 1x transcription buffer, 10 mM each ATP, CTP and GTP, 6 mM UTP, 7 mM DIG-UTP, and 
2 ul of T7 Polymerase enzyme mix in a final volume of 20 μL. The product was treated with 6 
U Turbo DNase for 1h at 37⁰C. RNA was visualised on a 1% Ethidium Bromide stained 
agarose gel alongside Low Range (LR) and High Range (HR) RNA ladders (Thermo Fisher 
Scientific). DNA template and the 1 kb Invitrogen ladder. The RNA probe was purified by 
lithium chloride precipitation, resuspended in RNase-free water and stored at -80oC.  
3.8. Northern Blotting  
 
Vector encapsidated RNA samples extracted from 1 mL of culture supernatant were purified 
as in section 3.5. and were analysed on ethidium bromide-stained 1% agarose gels in Tris-
borate-EDTA (TBE) (Thermo Fisher Scientific) and electrophoresed at 60 V for at least 4 h. 
Samples were transferred from the gel to a Hybond N+ nylon membrane (GE healthcare) by 
capillary transfer for 2 h in UltraPure™ 20x SSC (Thermo Fisher Scientific). The membrane 
was briefly washed in 0.5x TBE, and crosslinked by baking at 80⁰C for 30 min. The 
membrane was then transferred to a 50 mL Falcon containing 4 mL pre-warmed UltraHybTM 
(Ambion) and rotated at 68⁰C for 30 min. RNA probe (75 ng) was hybridised to the 
membrane in 1 mL of pre-warmed UltraHyb for 18 h at 68⁰C. The membrane was washed 2 
x 5 min in low stringency wash buffer (75 μM NaCl, 8 μM Sodium Citrate and 0.1% SDS) at 
room temperature, and then 2 x 15 min in high stringency wash buffer (50 μM NaCl, 400 μM 
Sodium Citrate and 0.1% SDS) at 68⁰C. Bound probe was visualised using the DIG 
luminescent detection kit (Roche). Briefly, the membrane was washed for 5 min in 50 mL 1x 
washing solution and then blocked for 1 h in 50 mL blocking solution. The anti-DIG-AP 
fragments antibody was diluted 1:20,000 in 20 mL blocking solution and incubated with the 
membrane for 1 h. The membrane was washed twice for 15 min in 50 mL 1x washing 
solution and then incubated for 5 min in 20 mL detection buffer. RNA was visualised with 
the addition of 500 μL CDP-Star and detected with photographic film.   
3.9. In-Gel SHAPE 
3.9.1. In Vitro production of RNA 
 
A 690 nucleotide PCR fragment including the sequences between TAR and the partial gag 
was amplified by PCR using primers Fw 5´-TAATACGACTCACTATAG 
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GGTCTCTCTGGTTAGACCAGATCTG-3´, Rv 5´- CTTGCTGTGCGGTGGTCT-3´. Fw primer 
contains the T7 Polymerase promoter sequences to be used downstream for in vitro 
transcription. PCR reaction contained pCCL-eGFP template (100 ng), 1x Phusion HF Buffer, 
12.5 μM each primer, 10 mM dNTPs, 3% DMSO and 1 U HF Phusion DNA Polymerase (NEB). 
The thermal cycling conditions were: 98°C for 30 sec, 35 cycles of: 98°C for 10 sec, 64°C for 
30 sec, 72°C for 1 min and a final extension step at 72°C for 10 min. The PCR fragment was 
electrophoresed on a 1% agarose gel, visualised by UV and extracted using the NEB 
MonarchR extraction kit according to the accompanying protocol. The PCR product was 
eluted in a 15 μL final volume. In vitro transcription was carried out using the MEGAScript T7 
transcription kit (Ambion). Reactions contained extracted PCR product (14 μL), 1x 
Transcription buffer, 10 mM each ATP, TTP, CTP and GTP, and 4 μL of T7 Polymerase enzyme 
mix in a final volume of 40 μL. The product was treated with 6 U Turbo DNase for 1h at 37°C. 
The RNA product was purified by lithium chloride precipitation, resuspended in RNase-free 
water and stored at -80°C.  
3.9.2. In-gel chemical acylation of RNAs 
 
45 μg of RNA were resuspended in 160 μL of Renaturation Buffer (10 mM Tris pH 8, 100 mM 
KCL and 0.1 mM EDTA) heated at 85°C for 5 min and slow-cooled to room temperature. 40 
μL of 5x Refolding Dimerisation Buffer were added to adjust the buffer to 40 mM Tris pH 8, 
5 mM magnesium chloride (MgCl2), 130 mM KCl and 50mM sodium cacodylate pH 7.5. The 
mixture was incubated at 37°C for 30 min. 60 μL of Orange G native loading dye (1 x TBM 
(89 mM Tris Base, 89 mM Boric acid and 0.1 mM MgCl2), 5% (w/v glycerol, 0.1% (w/v) 
orange G dye) were added and 20 μL of the treated RNA were loaded in each lane of a 20 
cm x 18.5-cm 4% (w/v) Acrylamide/Bis 19:1 non denaturing gel prepared with 1x TBM. Gel 
electrophoresis was set at 90 V for 1h and 100 V for 4 additional hours. One fragment 
corresponding to the LR RNA ladder (Thermo Fisher Scientific) and one RNA sample were 
excised and stained for 10 min with 1.3 µM ethidium bromide in 1× TBM and visualized 
under UV to detect the position of the dimeric and monomeric RNA. The ethidium bromide-
stained gel fragments were aligned to the remaining of the unstained gel. The gel parts 
corresponding to the dimeric and monomeric RNA were excised using a scalpel. Both the 
dimeric and monomeric gel pieces were divided into two equal parts, with one fragment 
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incubated in 1× TBM containing 10% (v/v) dimethyl sulphoxide, and the other one in 1x TBM 
containing 10% (v/v) dimethyl sulphoxide and 10 mM N-methylisatoic anhydride. The 4 gel 
pieces were placed at RT for 1 h and were then washed three times in 1× TAE (40 mM Tris-
acetate and 1 mM EDTA pH 8.3). The cleaned gel pieces were then minced and the RNA was 
electroeluted using the BIO-RAD model 422 Electro-Eluter at 40mA for 1h 30min. RNA was 
precipitated with 300 mM sodium acetate and 2.5 volume of ethanol and recovered by 
centrifugation, washed with 70% ethanol and resuspended in 10 µl of water. RNA 
concentration was determined by spectrophotometry.  
3.9.3. Reverse Transcription and Structural analysis 
 
1000 ng of each RNA sample were resuspended in 12 µl of 2.1 mM Tris pH 8.0, 42 µM EDTA. 
5 nmol of 6FAMTM-labelled primers described in section 3.9.1  (Applied Biosystems) were 
added to the dimeric and monomeric NMIA-treated samples and 5 nmol of VIC®-labelled 
primer (Applied Biosystems) were added to the dimeric and monomeric Negative control 
samples. Primers were annealed to the RNA at 85°C for 1 min, 60°C for 5 min and 35°C for 5 
min. 8 μL of the Reverse transcription mix (100 U of Superscript III reverse transcriptase 
(RT), 1.5× SSIII RT buffer, 12.5 mM dithiothreitol (DTT), 5M Betaine, 1.25 mM Deoxycytidine 
triphosphate (dCTP), deoxyadenosine triphosphate (dATP), deoxyuridine triphosphate 
(dUTP) and 7-deaza-deoxyguanosine triphosphate (dGTP)) were added to each sample and 
were incubated at 55°C for 50 min. RNA was degraded with 200 mM NaoH at 95°C for 5 min 
and ice cooling for 5 min. The samples were then treated with 200 mM HCl and were 
precipitated as described above. The cDNA produced was combined with two sequencing 
ladders. Sequencing ladders were produced using the Thermo Sequenase Cycle Sequencing 
Kit (Applied Biosystems) and primers of the same sequence as before, but which were now 
labelled with NEDTM and PET® (Applied Biosystems). Each cycle sequencing reaction 
contained 300 ng of DNA template, 1.3 nmol NEDTM- or PET®-labelled primer, sequencing 
buffer, ddNTP of choice and enzyme as per manufacturer’s instructions. The thermal cycling 
conditions were: 95°C for 2 min, 40 cycles of: 95°C for 30 sec, 50°C for 30 sec, 72°C for 1 min 
and a final extension step at 72°C for 10 min. Sequencing ladders were precipitated with 300 
mM sodium acetate and 2.5 volume of ethanol and recovered by centrifugation, washed 
with 70% ethanol and resuspended in 30 µl of water. RNA samples were mixed with the 
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sequencing ladders in a 1:1:1 concentration ratio and were submitted for sequencing. 
SHAPEFinder software55 was used to align the peaks to the nucleotides of the sequence of 
interest. The 4 labelled primers were used for a control experiment to ensure mobility shift 
normalisation by running a sequencing reaction using each primer with the same ddNTP, 
ddATP. Reactivity was then calculated by subtracting the negative control peaks to the 
NMIA treated peaks.  Single level nucleotide structural modelling was performed using the 
RNAstructure software235 where RNA secondary structure is predicted using SHAPE data and 
free energy constraints. Structures were drawn using XRNA236. 
3.10. Western Blotting of viral supernatants 
  
Vector supernatant (8 mL) was centrifuged for 10 min at 3000 x g to remove cell debris. 
Purifiried viral supernatant (1 mL) was subsequently centrifuged at 22,000 x g for 2.5 h at 
4⁰C. The pellet was resuspended in 20 μL of PBS and the proteins were denatured by 
heating to 95⁰C in 1x Laemmli sample loading buffer (Sigma-Aldrich). Samples (1 μL) were 
separated in a 0.75 mm 15% SDS-PAGE gel, at 100 V for 4 h. Proteins were transferred to a 
nitrocellulose membrane by electroblotting at 100 V for 90 min in 1x transfer buffer (25 mM 
Tris, 192 mM glycine, 20% methanol (v/v) and 0.1% SDS, before blocking in 5% (w/v) 
skimmed milk powder in PBS for 30 min. The primary antibody ARP313 (NIBSC) for p24 was 
diluted 1:20,000 in 5 mL 5% milk in PBS. The membrane was incubated with the antibody 
overnight at 4⁰C, followed by 3 x 10 min washes with PBST (0.1% Tween in PBS). The 
membrane was incubated with secondary antibody (horse anti-mouse HRP, Abcam) at 
1:2,000 for 2 h. The membrane was washed as previously and bound secondary antibody 
was visualised by using 1 mL ECLTM prime Western blotting detection reagent (GE 
healthcare) and by exposing to photographic film.  Films were scanned and bands quantified 
using ImageJ237. 
3.11. Cell lysate preparation and Western Blotting  
 
Supernatant was removed 48 h post transfection and cells were harvested by adding 1mL 
ice cold PBS directly into half of the surface of a 10 cm2 plate. Harvested cells were 
transferred to a 1.5 mL microcentrifuge tube and were centrifuged at 6,000 x g for 5 min. 
Pellets were washed once in ice-cold PBS, re-centrifuged at 6,000 x g for 5 min and stored at 
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-80°C for later analysis. Cells were lysed in 250 μL RIPA Lysis and Extraction Buffer (Thermo 
Fisher Scientific) containing 1x HALT protease inhibitor cocktail (Thermo Fisher Scientific) by 
rocking on ice for 15 min. Lysates were clarified by centrifugation at 6,000 x g for 5 min at 
4oC. Protein quantification was performed using the BCA Protein assay kit (Pierce) according 
to the manufacturer’s instructions. Extracted cell lysates were heated in 1x Laemmli sample 
loading buffer (Sigma-Aldrich) at 95°C for 10 min. 20 μg protein per sample were analysed 
by SDS-PAGE as described above. GAPDH, used as a loading control, was dected with the 
use of anti-GAPDH (1:10,000 Abcam) and donkey anti-rabbit antibody (1:2,000 Abcam). 
3.12. ELISA p24 assay  
 
High protein binding 96 well plates were coated overnight with 25 μL per well of 10 μg/mL 
anti-HIV-1-p24 D7320 coating antibody. Plates were blocked for 1 h with 5% bovine serum 
albumin in 1x Tris-Buffered Saline (TBS) (100 μL per well). Samples were diluted in 1x TBS 
0.05% Empigen (Sigma-Aldrich) and a serial dilution of standard was prepared using the HIV-
1-p24 antigen AG6054 (Aalto Bio Reagents). Blocking solution was removed by washing 
plates four times in 1x TBS on a plate washer, before the plate was loaded with 25 μL of 
sample and standard. Plates were incubated in a shaking mode for 90 min and washed as 
above. 9.25 μL of the mouse monoclonal anti-HIV-1 p24 BC 1071 (alkaline phosphatase 
conjugated, Aalto Bio Reagents) solution was added in each well and the plate was 
incubated for 1 h on a plate shaker. The plate was then washed manually four times with 
PBS containing 0.1% Tween-20. 25 μL Lumiphos Plus reagent (Lumigen) were added to each 
well and the plate was incubated in the dark for 30 min. Luminescence levels were 
measured with the Glomax luminometer and p24 levels interpolated from the linear portion 








3.13. ELLA p24 assay  
 
ELLA is the branded name for next generation automated ELISA developed by 
proteinsimple238. The objective of this analytical method was the measurement of the 
intracellular and extracellular HIV-1 p24 levels to measure Gag expression and Gag budding 
using the ELLA automated microfluidic GNRs (Glass Nano Reactors) based cartridge system. 
ELLA is a fully automated ELISA that quantifies p24 protein in triplicate for each sample well 
and all results are determined from the factory-calibrated internal standard curve.  
Samples were thawed at RT for 30 min and 500x dilutions were performed using the 
provided 0.5% Triton X Lysis buffer. Meanwhile, the ELLA Instrument was allowed to 
perform the verification test before testing samples. 1 mL of the Wash Buffer was loaded in 
each of the designated wells and 50 μL of the diluted samples were loaded on the ELLA 
cartridge. The run lasted 90 min and the software automatically generated the final p24 













4. Rational design and biochemical 
characterisation of transfer vector mutants  
Despite the tremendous potential of gene therapy the main target cells are poorly 
permissive, requiring multiple rounds of high vector doses and prolonged ex vivo culture to 
reach adequate transduction levels215 216. Here, I aimed to address this challenge by focusing 
on improving the lentiviral vector efficiency. 
The HIV-1 gRNA can act as a template for translation but can also be packaged without 
having to be translated first121 122. Comparison studies of gRNA sorting mechanisms revealed 
that unlike MuLV gRNA, HIV-1 gRNA also has the potential to first be translated and then 
packaged121. As mentioned in section 2.1.11, the gRNA of HIV-1 is known to act as a switch 
between the monomeric conformation that is associated with translation and the dimeric 
conformation linked with packaging. While dimerisation positively regulates packaging108 
109, translation of the genome is in opposition to its encapsidation. Based on this 
observation I aimed to create transfer vector mutants that were more likely to adopt the 
dimeric conformation and therefore be packaged.  I targeted regions in the 5’UTR that play 
important roles in the process of dimerisation including the DSL, the U5-AUG duplex and the 
polyA stem loop.  
The effects of these mutations were assessed by measuring infectious titres with flow 
cytometry and physical titres with ELISA p24 and ELLA p24. Furthermore, Western Blotting 
and ELLA p24 were performed to investigate any potential effects of these 5’UTR mutations 
on in trans-Gag processing and budding. 
 
4.1. Verification of integrity of 3rd generation lentiviral plasmids 
 
pSYNGP packaging plasmid, pVSVg envelope plasmid, pRev and pCCL-eGFP transfer vector 
plasmid, obtained from GlaxoSmithKline, were used to transform One Shot Stbl3TM 
chemically competent E.coli cells. Test digestions were performed to verify the integrity of 
the isolated plasmids.  The expected band sizes for the EcoRI digestion of pSYNGP were 4.3 
kb, 4.1 kb and 401 bp, of pVSVg 4.1 kb and 1.6 kb and of pRev 3.6 kb and 311 bp. Expected 
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fragment sizes of the pCCL-eGFP plasmid’s digestion with HindIII were 3.3 kb, 2 kb, 584 bp, 
556 bp, 499 bp and 313 bp. Uncleaved controls of the plasmids were also loaded to verify 
the correct plasmid size. Figure 10 shows the plasmid maps with their restriction sites and 
expected band sizes, while Figure 11 confirms the correct identity of all plasmids comprising 
the 3rd generation lentiviral vector system.   
 
 




[A] pSYNGP plasmid map with its EcoRI restriction sites. EcoRI digestion of pSYNGP produces 
three bands of 4.3 kb, 4.1 kb and 401 bp. [B] pVSVg incubation with EcoRI is expected to 
create 2 fragments of 4.1 kb and 1.6 kb length. [C] pRev plasmid map accompanied with its 
EcoRI restriction sites. The size of the expected bands are 3.6 kb and 311 bp. [D] Plasmid 
map of the pCCL-eGFP transfer vector and its HindIII digestion sites. Expected fragment sizes 
of the pCCL-eGFP digestion with HindIII are 3.3 kb, 2 kb, 584 bp, 556 bp, 499 bp and 313 bp. 








1% agarose gel electrophoresed in TBE and stained with SYBR Safe. pSYNGP (lane 2), pVSVg 
(lane 4) and pRev (lane 6) were digested with EcoRI and pCCL-eGFP (lane 8) with HindIII. 
Lanes 3, 5, 7 and 9 represent undigested pSYNGP, pVSVg, pRev and pCCL-eGFP respectively. 
The fragment size of digested plasmids was estimated via the use of HyperLadder 1Kb 
(Bioline) (lanes 1 and 10). 
4.2 Transfection optimisation 
 
In order to study the packaging efficiency of the various transfer vector constructs, HEK293T 
cells were co-transfected with the plasmids described in section 4.1. Initially, a transfection 
protocol for lentiviral vector production was established, as described in the following 





Figure 11. Agarose gel electrophoresis of 3rd generation lentiviral plasmids. 
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4.2.1. Calculation of DNA mass 
 
Dull et al.,164 described a 3rd generation lentiviral vector system that consists of 4 plasmids 
including a packaging construct, a Rev expressing construct, an Envelope construct and a 
eGFP containing transfer vector construct. The number of template copies was calculated 
using the plasmid DNA mass and length based on the assumption that the average weight of 
a base pair (bp) is 650 Daltons. The formula used was: number of copies = (amount * 
6.022x1023) / (length * 1x109 * 650)239. The copy number required for each plasmid was 
calculated in table 5, using the aforementioned equation and the details provided from the 
Dull et al., paper. Maintaining the molar ratio 1:1:1:3 that came out of Dull’s research, table 








Table 5. Calculation of plasmid copy number for transfections. 
 
The amounts of plasmid used per 10cm dish come from the research scale vector 
production protocol established at GlaxoSmithKline which was shared via personal 















 p3Rev 2.5 5118 4.53E+11 
 
p3VSVg 3.5 7364 4.40E+11 
 
p3GP 5 9406 4.92E+11 
 













pRev 4100 4.5.E+11 2.0 
pVSVg 5800 4.4.E+11 2.8 
pSYNGP 8900 4.9.E+11 4.7 
pCCL eGFP 8000 1.5.E+12 13.2 
 
Table 6. Calculation of plasmid DNA mass for transfections. 
pRev was ordreded from Addgene240, pSYNGP and a newly synthesised pCCL eGFP transfer 
vector were obtained from GlaxoSmithKline, while pVSVg was part of the plasmid repertoire 
of the Lever group. The plasmids presented here were the ones consistently used in this 
thesis. The plasmid mass ratio used for high efficiency transfections was 1:1:1:3. 
4.2.2. Calculation of transfection and transduction efficiencies 
 
293T cells were transfected with the transfer vector and packaging plasmids to produce 
lentiviral vectors. 12 h post transfection cells were viewed under light and fluorescent 
microscopy. 
 
Figure 12. Measurement of Transfection efficiency with fluorescent microscopy. 
 [A] The cell monolayer viewed by light microscopy with a 10X magnification. [B] Image 
taken by fluorescence microscopy with a 20X magnification in order to estimate the 
transfection efficiency of the plasmid combination used. 
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Using table 6 as a guide, a 1:1:1:2 and a 1:1:1:3 mass ratio of the four plasmids was used for 
transfections. Additional combinations of plasmid mass ratios were tried, including the 
plasmid concentrations from the Dull et al., 1998 paper and the concentrations used at the 
GSK research scale vector production protocol (Dr Vink, personal communication). 
Furthermore, two different CaCl2 molarities were tried with all the aforementioned plasmid 
combinations. A final 125 mM of CaCl2 gave higher transfection efficiencies compared to 
150 mM CaCl2, and was thus chosen for the final protocol. The harvested supernatant was 
diluted 103 times and was used for 293T cells transductions. Vector titre was calculated as 
the seeded number of cells transduced x %eGFP+ cells x dilution factor / volume. The 1:1:1:3 
plasmid ratio generated the highest titre vectors of 2.4x107 TU/mL presented in Figure 13.E. 
                    
Figure 13. Measurement of transduction efficiency. 
 
Flow cytometry performed on cells harvested 42 h post transfection; the transfection and 
transduction efficiencies were calculated using the eGFP reporter gene included in the 
transfer vector. All cellular populations were lysed in TrypLE and harvested in PBS. [A] Non 
transfected 293T cells were used to create a histogram showing their distribution using the 
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FL1 parameter. [B] Flow cytometry graph of cells described in Figure 13.B, with a 
transfection efficiency of 99.2%. [C,D] Non transduced 293T cells showing gate associated 
with live cells (C) and [D] threshold to distinguish the transduced from the non-transduced 
cells. [E]. Flow cytometry graph showing the percentage of cells successfully transduced with 
the use of one in a thousand diluted viral supernatant. Flow cytometry set up, including 
gating of live cells and FL1 bar allocation, was performed as explained in section 3.2. 
4.3. Design and cloning of U5-AUG mutants 
 
The rationale behind the construct design was the introduction of mutations that would 
either strengthen or weaken the U5-AUG base pairing. As discussed in the introduction 
chapter, it has been shown that a stabilised U5-AUG interaction is associated with increased 
dimerisation, which is associated with efficient packaging. The structures of the monomeric 
and dimeric RNAs are proposed to differ significantly. In gel probing of RNA conformers has 
revealed a dimerisation structural switch in the HIV-1 leader8. 
Initially the design of the mutant transfer vectors was based on computer assisted structural 
prediction with mFold241. mFold structures were based on calculations of minimal free 
energy. Apart from the structural stability of the RNA, other parameters had to be taken 
into consideration including the pseudo-knot structure. SHAPE data as well as NMR studies61 
suggest the formation of a pseudo-knot via the base-pairing between DIS and U5, which 
cannot be predicted with mFold. A pseudoknot is a secondary structure in which half of one 
stem is intercalated between the two halves of another stem. Because of the overlapping 
nature of the base pairing, mFold is unable to predict the pseudoknot, but will instead 
predict the more stable of the two stems. Taking these two criteria into consideration, the 
following 3 mutants were designed in order to test whether increased stability of the U5-




        
 
Figure 14. Design of mutants with either strengthened or impaired U5-AUG base pairing. 
 [A] The U5-AUG duplex is an important structural motif of dimeric RNA. It is formed via the 
base pairing of 4 U-Gs, 2 U-As and 5 G-Cs. Adapted from:7 [B] The U5s mutant was created 
by introducing mutations in the U5 region that strengthened the U5-AUG base pairing. 4 U-G 
non-canonical pairs were converted into two A-U and two C-G pairs, increasing the number 
of hydrogen bonds by 6. UC4d mutant included the conversion of four U-G pairs to C-G pairs, 
increasing the number of hydrogen bonds by 8, and thus the stability of the U5-AUG base 
pairing. Also, this mutant included a mutation that destabilised SL-4 by the introduction of a 
mutation that converted a G-C pair to U-C. NC4s included the substitution of two A-U pairs 
by A-G that disrupted canonical base pairing in the U5-AUG and the introduction of a G-C 
base pair that strengthened SL4.  
 Figure 15. mFold predicted secondary structures of WT and mutants. 
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The first 800 bp of the WT and mutated pCCL-eGFP constructs, that include the HIV-1 leader 
sequences, were inputted into mFold using the default parameters of the RNA Folding form 
in order to predict their secondary structures based on minimum free energy. mFold 
indicates that the global structure of the main packaging signal region of the HIV-1 leader 
(SL1-3), shown in the red circles, was predicted to be maintained intact upon introduction of 
these mutations (Figure 15). [UC4d]: 2 U to Gs and 2 C to Gs conversions, expected to lead to 
U5-AUG duplex stabilisation and polyA formation. One of these mutations was designed to 
destroy the start codon of gag; furthermore this mutant included a destabilising mutation in 
the SL-4 loop. [U5s]: U to G, 2 C to G and 2 A to U conversions aimed to lead to U5-AUG 
duplex stabilisation but destruction of the structure containing the polyA signal. [NC4s]: 


















[A] PCR amplification of a DNA fragment spanning the CMV and RRE sequences [B] Blunt 
TOPO subcloning of the amplified DNA fragment shown in A, that includes the NdeI and MfeI 
restriction sites [C] Site directed mutagenesis reactions to incorporate mutations of interest 
only in the 5’LTR introduced in the Blunt-TOPO vector [D] Digestion of mutated TOPO vector 
and WT pCCL-eGFP vector with NdeI and MfeI-HF and ligation of the mutated 5’LTR digested 
fragment with the pCCL-eGFP backbone to produce rationally designed mutated lentiviral 
vectors.  [E] Plasmid map of pCCL-eGFP vector depicting the NdeI and MfeI restriction sites. 
 
Results from this cloning strategy are illustrated in Figure 17.  The pCCL-eGFP vector was 
used as a template for PCR using a gradient temperature and various high fidelity 
polymerases. Generation of the correct size products was confirmed by electrophoresing 5 
μl of each PCR product on a 1% agarose gel (shown in Figure 17.A). In particular; lanes 1-7 
represent the AccuprimeTM Pfx PCR products using a gradient temperature from 60-65oC. 
Bands 4 and 5 were excised and purified for use in downstream reactions. Lane 8 includes 
the Q5 Polymerase PCR product. The rest of the lanes, which are blank, represent the 
unsuccessful 60-64 oC gradient PCRs with the use of the Truestart Hot Start PolymeraseR. 
Both the gel extracted and non- gel extracted PCR products amplified with AccuprimeTM Pfx 
and Q5 high fidelityR polymerases were used for blunt-end TOPO-subcloning. 8 colonies 
were selected and their extracted DNA was used for test digestion with BamHI-hf and NdeI 
(shown in Figure 17.B). The expected sizes of a successful TOPO-subcloning reaction are 
3265, 2568 and 512 bp, which were visualised in lanes 2 to 5 and 9 to 12. 
Upon confirmation of the successful TOPO-cloning reaction, purified DNA from colony 4 
(Figure 17.B lane 5) was selected and used as a template for site directed mutagenesis 
(SDM) reactions. The 3 SDM products were used for bacterial transformation. Sequentially 
the extracted and purified plasmid DNA was digested with NdeI and BamHI-hf to identify 
plasmids that contained the correct insert (shown in Figure 17.C). Depending on the 
direction in which the inserts were ligated the outcome of the test digestion would be 
different. If the insert ligated in the forward direction, flanked between NdeI and BamHI-hf, 
then the products would be of sizes: 3695, 2568 and 81 bp, whereas if the insert was ligated 
81 
 
in the reverse direction, flanked between BamHI-hf  and NdeI, then the produced fragments 
would be of the sizes: 3520, 2566 and 256 bp. 
Generation of the UC4d and NC4s mutants required another round of SDM. Incorporation of 
the mutations of interest was confirmed by sequencing. Upon confirmation of appropriate 
mutation introduction, the transfer vector pCCL-eGFP backbone and the mutated TOPO-
vectors were digested with NdeI and MfeI-HF. The digestion products were separated and 
the bands of interest were excised and purified to be used in the final step that included the 
ligation of the TOPO-insert in the pCCL-eGFP backbone. HindIII test digestions were 
performed to verify the completion of cloning (shown in Figure 17.D). All 3 successfully 
cloned mutants gave rise to the expected size fragments which were 3.3 kb, 2 kb, 584 bp, 
556 bp, 499 bp and 313 bp long. The discrepancy between the expected number of bands 
and the number of bands on Figure 17.D was due to the inability to differentiate a 584 bp 
band from a 556 bp band on a 1% agarose gel. 
 
Figure 17. Agarose gel analysis of intermediates during the cloning process. 
[A] 1% agarose gel showing PCR products from a temperature gradient PCR of pCCL-eGFP 
using primers Fw-Subcloning and Rv-Subcloning. Lanes 1-7 show PCR product formed using 
Accuprime-Pfx mix at 60oC (lane 1), 61oC (lane 2), 61.9oC (lane 3), 63oC (lane 4), 64oC (lane 
5), 64.6oC (lane 6), and 64.8oC (lane 7). Lane 8 shows product formed with Q5 high fidelity 
Polymerase at 64oC. [B] Plasmids purified from 8 clones (lanes 2 to 5 and 9 to 12) and 
digested with BamHI-hf and NdeI. [C] NdeI and BamHI-hf digestion of clones following site 
directed mutagenesis to produce UC4d (lanes 1-5, NC4s (lanes 7-11), U5s (lanes 13-17). [D] 
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HindIII digested plasmids purified from clones resulting from a second round of site-directed 
mutagenesis for UC4d (lane 1) and NC4s (lane 2). Products of U5s digestion with HindIII are 
presented in lane 3. 
4.4. Cloning of S1 (Abbink et al., 2003) and LU5-AUG (Lu et al., 2011) 
constructs 
 
Abbink et al., and Lu et al., described the presence and importance of the U5-AUG duplex 
and its role in promoting a structure that favours dimerisation (Figure 18). These two papers 
included structural and biochemical characterisation of the U5-AUG duplex from the in vitro 
transcribed RNA of the HIV-1 leader sequence. The S1 and LU5AUG mutations, described in 
the aforementioned papers (Figure 18.A and 18.C), were introduced into the pCCL-eGFP 
transfer vector construct as controls to test their behaviour in a in virio context. 
           
Figure 18. Design and in vitro dimerisation propensity of S1 and LU5AUG mutants. 
 
[A] Rational design of S1 mutant. [B] Dimerisation propensity of S1 mutant against WT in 
the presence and absence of formamide. Taken from Abbink et al.[C] Rational design and 
free energy details of LU5AUG mutant. Mutated nucleotides are shown in red. The left part 
of this figure shows that SL4 can no longer form, while the right figure shows the newer, 
stronger U5-AUG interaction.  [D] Time dependent dimerisation assay of LU5AUG mutant. 
Taken from Lu et al. 
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The dimerisation properties of the transfer vector RNA expressed in a cellular context were 
compared to those of the in vitro transcribed RNA of the HIV-1 leader sequence. These 
mutants were cloned to study the effect of sequence size and environmental conditions on 
dimerisation and hence packaging. The rationale behind the creation of these U5-AUG 
mutants from the literature in the context of the pCCL-eGFP transfer vector system was to 
confirm the results described in these studies and use these and other similar mutations to 
improve packaging efficiency of lentiviral vectors, or identify potential parameters that 
could be affecting the dimerisation properties of the HIV-1 gRNA in an in virio context.  
The intermediate steps of the creation of S1 and LU5AUG transfer vector mutants are 
presented in Figure 19. The cloning strategy followed was exactly as presented in section 
4.3. 
                                     
Figure 19. Stages of cloning for S1 and LU5AUG transfer vector mutants. 
 
[A] 1% agarose gel showing PCR products from the site SDM reactions for S1 and LU5AUG 
mutants [B] EcoRI digestion of clones to investigate the results of TOPO-subcloning. 
Confirmation of S1 and LU5AUG insertion in the Blunt-TOPO® vector [C] WT pCCL-eGFP 
backbone and S1 and LU5AUG plasmids purified and digested with MfeI-hf and NdeI to be 
used for downstream isolation, extraction and ligation. [D] HindIII digested plasmids purified 
from final clones for both U5-AUG mutants.  
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4.5. Rational design and cloning of dimerisation mutants  
 
The idea behind this third round of construct design was the introduction of mutations in 
other regions of the HIV-1 leader that have been documented to affect dimerisation. Recent 
findings suggest that destabilisation of the polyA motif increases the ratio of monomeric to 
dimeric RNA127. Based on these findings I was interested in investigating whether 
stabilisation of the lower part of the polyA stem loop could lead to increased dimerisation. 
That led to the creation of two polyA transfer vector mutants: polyAsw and polyAs. J9+Gag 
was designed based on a study conducted by Van Bel et al., which showed that DIS 
extension could increase in vitro dimerisation242.Lastly, the potential of an alternative 
dimerisation palindrome sequence was investigated by creating mutant SIVS1 that 















Figure 20. Depiction of dimerisation mutant design targeting the polyA, U5-AUG and SL-1 
structural motifs. Adapted from source:8. 
 
 
A                                                          
 





[A] Indication of all targeted regions of the HIV-1 leader for generation of dimerisation 
promoting transfer vector mutants. [polyAs]: polyA stabilisation by conversion of the non 
canonical A-C pair, which leads to the formation of an RNA bulge in the lower part of the 
polyA stem, to an A-U Watson-Crick base pair. [J9+Gag]: Introduction of two point 
mutations resulted in two extra G-C pairs in the lower part of SL-1 achieving extension of the 
dimerisation stem loop, while maintaining the reported Gag binding sites46. [PolyAsw]: A 
single point mutation that converts a G-U pair to a G-C pair was designed to stabilise the 
lower polyA stem loop. [SIVS1]: A mutant transfer vector that contained the dimerisation 
palindrome sequence of SIV-1 GUGCAC. [B] Closer look at the targeted nucleotides of the 
polyA and SL1 stem loops. Arrows indicate the exact position of the introduced point 
mutations. In further detail, mutated nucleotides for the generation of polyAw, polyAs and 
J9+Gag are presented in pink, dark blue and orange respectively. 
 
Results from this cloning strategy are illustrated in Figure 21.  The intermediate TOPO-LTR 
plasmid generated in 4.3. was used as a template for SDM reactions. The 4 SDM products 
were used for bacterial transformation; sequentially the extracted and purified plasmid DNA 
was digested with EcoRI to identify plasmids that contain the correct size insert (shown in 
Figure 21.C). EcoRI digestion of the TOPO vector containing a modified insert would produce 
fragments of the sizes: 3500bp (TOPO vector) and 2800bp (insert). Both intermediate TOPO 
vector plasmids containing the modified inserts and the pCCL-eGFP plasmid were digested 
with NdeI and MfeI-hf and the produced fragments were visualised under the ultraviolet in a 
1% agarose gel. The fragments of interest were excised and extracted. The final step 
included the ligation of the TOPO-insert in the pCCL-eGFP backbone. HindIII test digestions 
were performed to verify the completion of cloning (shown in Figure 21.F). All 4 successfully 
cloned mutants gave rise to the expected size fragments which were 3.3 kb, 2 kb, 584 bp, 
556 bp, 499 bp and 313 bp long. As previously noted, the discrepancy between the expected 
number of bands and the number of bands on Figure 21.F was due to the inability to 
differentiate a 584 bp band to a 556 bp band on a 1% agarose gel. 
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Figure 21. Agarose gel analysis of intermediates during the cloning process of the 
dimerisation mutants. 
 [A], [B] 1% agarose gel showing PCR products from the site directed mutagenesis reaction 
for all dimerisation mutants [C] EcoRI digestion of clones for confirmation of mutagenic 
insert of polyAsw (lanes 1-6), J9+Gag (lanes 7-12), polyAs (lanes 13-18) and SIVS1 (lanes 19-
23). [D] Plasmids purified and digested with MfeI-hf and NdeI. [E] Bands of interest 
extracted. [F] HindIII digested plasmids purified from final clones.  
 
4.6. Measurement of viral titres via Flow cytometry  
 
The ability of the rationally designed transfer vectors to successfully transduce cells and 
express the eGFP transgene they carry was investigated with flow cytometry. 293T cells 
were transduced with serial dilutions of vector supernatant in order to assess the 
transduction efficiency of each transfer vector construct. In an attempt to understand the 
relationship between packaging efficiency and transduction efficiency, analysis of functional 
titres for a plethora of transfer vector mutants was performed. All transfer vector constructs 
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express eGFP under the control of the hPGK promoter that can be used as a marker of 
successful transductions. 72 h post transduction, cells were harvested and injected into the 
flow cytometer instrument to measure the successfully transduced eGFP expressing cells. 
Infectious titres were measured as transduction units per mL of viral supernatant (TU/mL). 
Transduction units were defined as the number of functional viral particles in the 
supernatant that were capable of transducing a cell and successfully expressing the 
transgene.  
                                                                                       
 
Figure 22. Comparison of infectious titres between WT and U5s viral vectors. 
[A] Determination of infectious titres from 3 independent transfection replicates for WT and 
U5s from the same round of transfection experiments. Infectious titres measured in 
transduction units per mL (TU/mL). [B] Graphs presenting infectious titres measured in 
TU/mL from 4 independent transfection replicates for WT and 3 independent transfection 
replicates for U5s mutant. These independent replicates were derived from a second round 
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Figure 23. Combined comparison of infectious titres between WT and U5s viral vectors. 
Columns showing the combined average transduction efficiency from 7 independent 
transfection replicates for WT and 6 independent transfection replicates for U5s. Column 1 
represents the average TU/mL for WT, and column 2 represents the average TU/mL for U5s. 
Error bars represent standard deviations. The T-test performed showed no statistical 
significance. 
HEK293T cells were transfected with the respective transfer vector and packaging constructs 
and viral supernatant was harvested 40 h later. Serial dilutions of harvested lentiviral 
supernatant were used to transduce HEK293T cells and the functional titres of WT and 
mutant lentiviral vectors were measured by multiplying the number of successfully 
transduced cells with the number of cells seeded and the viral dilution used, divided by the 















                       
 
Figure 24. Comparison of infectious titres between WT, U5s viral vectors and the S1 and 
LU5AUG U5-AUG mutants. 
Infectious titres of S1 and LU5AUG mutants were determined following the same 
methodology as described for WT and U5s above. Columns showing the average 
transduction efficiency from independent transfection replicates for each construct from 5 
different experiments. Average WT is the average of 20 transfection experiments, while U5s 
average value is derived from 6 independent transfections, S11 from 14 and LU5AUG from 6. 
Column 1 represents the average transduction units per mL (TU/mL) for WT, column 2 
represents the average TU/mL for U5s, column 3 represents the average TU/mL for S1 and 
column 4 represents the average TU/mL for LU5AUG. Error bars represent standard 
deviations and p values represent comparisons with WT. 
 
U5s, S1 and LU5AUG mutants were designed to increase the U5-AUG base pairing that is 
associated with a conformation documented to dimerise more efficiently7 61. PolyAs and 
PolyAsw were designed to have a stabilised lower polyA stem while both J9+Gag and SIVS1 
contained a modified SL1. All of these mutations aimed to promote adoption of a 
dimerisation efficient conformation. Flow cytometry was performed to investigate the 
ability of such constructs to successfully transduce cells. Functional analyses were 
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packaging efficiency, but also on their infectivity. Interestingly, a wide range of transduction 
efficiencies was observed with mutants like S1 and PolyAsw having functional titres 




Figure 25. Comparison of infectious titres between WT and the dimerisation vector 
mutants designed: PolyAs, J9+Gag, PolyAsw and SIVS1. 
Transfections and transductions were performed as previously described. Columns showing 
the average transduction efficiency from 7 independent transfection replicates for each 
construct. Column 1 represents the average transduction units per mL (TU/mL) for WT, 
column 2 represents the average TU/mL for PolyAs, column 3 represents the average TU/mL 
for J9+ Gag, column 4 represents the average TU/mL for PolyAsw and column 5 represents 
the average TU/mL for SIVS1. Error bars represent standard deviations and p values 
represent comparisons with WT. 
4.7. Measurement of virion production 
 
ELISA p24 was performed to measure Capsid-p24 protein concentration and thus Gag 
protein expression, which is associated with physical vector titre. WT, U5s and UC4d 
constructs generated similar amounts of p24 as seen in Figure 26.A, although U5s 

















































constructs and the transfer vector of interest. Viral supernatant was harvested 40 h post 
transfections and was used for measurement of physical titres. The standard deviation of 
NC4s results was high, but on average this construct produced the least amount of p24. 
Fluorescence microscopy analysis revealed that the WT plasmid was initially giving lower 
transfection efficiencies (data not shown). Another plasmid purification (Maxi-prep) was 
performed for WT and used for 3 independent transfections alongside the U5s plasmid. 
When transfection efficiencies were comparable (fluorescence microscopy, data not 
shown), supernatants produced with the use of these plasmids were harvested and treated 
for p24 measurement by ELISA. p24 expression for WT and U5s was very similar, with an 
average value of 189 ng/mL and 204 ng/ mL respectively.  Thus it can be concluded that WT 
and U5s constructs led to similar virion production, possibly because, unlike in WT HIV-1, 
Gag was provided in trans. 
 Graphs show the amount of p24 produced per mL and measured with ELISA. Error bars 
represent standard deviation. [A] Graph representing the average amount of p24 per mL for 
WT and the 3 designed mutants in viral supernatant from 3 transfection replicates. [B] A 
comparison of virion production between WT and U5s using supernatant generated from 
three independent rounds of transfections with the use of different plasmid purifications 
(maxi-preps). 
A                                                                                              B 





Figure 27. Measurement of virion production for the U5-AUG and dimerisation mutants. 
Graphs show the amount of p24 produced per mL and measured with ELLA p24 with error 
bars that represent standard deviation. [A] Graph representing the average amount of p24 
per mL for WT and the 3 U5-AUG mutants in viral supernatant from 21 transfection 
replicates per mutant. [B] A comparison of virion production between WT and the 4 
dimerisation mutants using supernatant generated from three independent rounds of 
transfections. 
Upon their translation, Gag and Gag/Pol multimerise alongside the gRNA. HIV-1 virus like 
particle (VLP) assembly can be achieved independently of the packaging of the gRNA, it is 
however facilitated by it243. Similarly to ELISA p24, ELLA p24 (GSK), an automated 
immunoassay, was performed to measure Capsid-p24 expression but in a more accurate 
way. The ELLA p24 run contained a pre-loaded on a cartridge p24 immunoassay with an 
internal calibration curve. The only non-automated part included the sample and buffer 
loading. Each sample ran through a microfluidic channel that contained 3 Glass Nano 
Reactors (GNRs) coated with a capture antibody. The final values were calculated based on 
the pre-loaded standard curve and the triplicate data generated per sample. Hence, ELLA 
performed the same p24 immunoassay with ELISA, but without the accompanying errors of 
traditional immunoassays.  
WT, U5s, S1 and LU5AUG produced physical titres analogous to their infectious titres, 
suggesting that mutations in the U5-AUG motif of the 5’UTR did not influence Gag 
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supernatant produced by polyAs, J9+Gag, polyAsw and SIVS1 mutants, revealed a similar 
pattern.  p24 expression and thus Gag expression and virion production for all dimerisation 
mutants was related to their respective ability to transduce cells successfully.  
4.8. Effect of mutations in 5’UTR on Gag processing and budding 
 
As shown in Figure 28, Gag expression levels were equivalent between the WT and mutated 
constructs. Interestingly, the p55/p24 antibody detected uncleaved p55 product in viral 
supernatants which suggests the presence of immature particles, or might be reflecting the 
presence of VLPs lacking gRNA in the supernatant. The conversion of p25 to p24 is one of 
the late stage processing events and a sensitive step in the whole process244. Westerns on 
cell lysates were performed in order to look into the p24/p25 ratio. The blots did not reveal 
any significant differences in the amount of total Gag products or in Gag processing. Both 
the Gag expression levels and the p24/p25 ratio appeared very similar for all constructs. 
          
Figure 28.  Investigation of Gag processing of first group of transfer vector mutants. 
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Anti-p55/p24 Western blots of purified virions and cell lysates were performed to quantify 
p24 expression and to also investigate any potential effect of mutations in the U5 region of 
gRNA in Gag processing in a trans system. [A] Western blots of purified virions. [B] Western 
blots of cell lysates. The same blot was stripped and re-used for GAPDH detection and 
sample normalisation. [C] Quantification of p24 on purified virions by ImageJ. [D] 
Quantification of p24/p25 ratio on cell lysates by ImageJ. 
                                    
Figure 29.  Gag processing study of U5-AUG mutants. 
[A] Western blots of cell lysates. This time the blot was not re-used for GAPDH detection, but 
sample normalisation was achieved by loading an equal amount of total protein as described 
in 3.11. [B] Western blots of purified virions.  
 
Anti-p55/p24 Western blots of cell lysates and purified virions were performed to compare 
p24 expression between Western Blots and ELLA and to also identify any changes in Gag 
processing caused by mutations in the U5-AUG motif. This was an important experiment to 
perform as ELLA, like ELISA, detects three dimensional structures, and the structures within 
Gag are known to change during particle maturation.   
Finally, ELLA p24 was also performed to measure intracellular Capsid-p24 expression levels 
to study any potential impact of the various 5’UTR mutations on intracellular Gag expression 
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and/or its ability to bud from the cell. 20 replicates per U5-AUG transfer vector construct 
from 4 independent rounds of transfections, and 7 repeats per dimerisation transfer vector 
mutant from 2 independent rounds of transfections were analysed in Figures 30.A and 30.B 
respectively. The extracellular to intracellular Gag amounts (p24 V/C) measured did not 
show any major differences between WT and the U5-AUG mutants while as suggested by 
the t-test statistical analysis, the calculated p24 V/C ratio was relatively higher for the 
dimerisation mutants polyAs, polyAw and SIVS1 compared to WT. 
 
                        
 
                        
Figure 30.  Effects of 5’UTR mutations on Gag budding. 
[A] Intracellular to extracellular p24 expression ratio for the U5-AUG mutants [B] 




















































4.9. Chapter conclusions 
 
Dimerisation promoting transfer vector mutants were designed by targeting regions in the 
5’UTR that play important roles in the process of dimerisation, including the DSL, the U5-
AUG duplex and the polyA stem loop. The mutants were firstly assessed for their infectious 
titres. Amongst all mutants, U5s and S1, designed to have strengthened U5-AUG base 
pairing, showed comparable, but slightly lower infectious titres to WT. However, the 
LU5AUG mutant that was also designed with a strengthened U5-AUG interaction, showed a 
14 fold infectious titre reduction. Interestingly, the dimerisation mutants showed a wide 
range of infectious titres, with mutants PolyAsw having infectious titres comparable to WT, 
while J9+Gag and PolyAs were characterised by a 50 fold decrease. This result could be 
reflecting the multifunctionality of the targeted areas. Mutations in the DSL, U5-AUG and 
polyA are likely to affect not only dimerisation and packaging, but also other important 
parts of the HIV-1 life cycle essential for the infectivity of the newly synthesised mutant viral 
particle. The amount of p24 Capsid in the viral supernatant of WT and mutants was 
measured next to assess the effect of the rationally designed mutations on physical titres. It 
was observed that physical titres follow the same trend as infectious titres. This observation 
might suggest that a certain amount of Gag was able to bud away independently of the 
presence of gRNA, in the form of VLPs, but that the presence of gRNA further facilitated Gag 
assembly and budding. Western Blots were performed to investigate whether the 5’ UTR 
mutations can affect the processing of Gag provided in trans. No change in the Gag 
processing pattern was observed between WT and mutants. Finally, intracellular Capsid-p24 
expression levels were measured to investigate any potential impact of the various 5’ UTR 
mutations on intracellular Gag expression and/or its ability to bud from the cell. The 
extracellular to intracellular Gag amounts (p24 V/C) measured did not show any differences 
between WT and the U5-AUG mutants while, with the exception of J9+Gag, the p24 V/C 
ratio was observed to be relatively higher for the dimerisation mutants compared to WT 
(p<0.5). 
This chapter discussed the biological characterisation of the transfer vector mutants. These 
mutants were rationally designed based on the premise that dimerisation promoting 
mutations should increase packaging and thus transduction efficiency. Vector titration 
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revealed the overall negative effect of these mutations on infectious titres. However, such 
assays could not provide information on RNA dimerisation or packaging efficiency. To assess 
this, the next chapter discusses assays performed to measure the total amounts of gRNA 
packaged in virions and its propensity to dimerise, but also the efficiency of the mutant 

















5. RNA dimerisation propensity  
Lentiviral vector particles contain two copies of the full length transfer vector RNA. HIV-1 
gRNA is known to act as a switch between the monomeric conformation that is associated 
with translation and the dimeric conformation linked with packaging8. The dimerisation and 
packaging properties of lentiviral vectors were targeted with the aim of improving their 
efficiency based on the hypothesis that WT HIV-1 regulates genome encapsidation tightly by 
recognising dimeric RNA12. Mutations introduced in the 5’UTR were assessed in the previous 
chapter for their effect on viral vector infectivity. In chapter 5, I investigated the effect of 
the same mutations on RNA dimerisation efficiency as well as any potential link between 
RNA dimerisation and viral vector infectivity. The propensity of RNA to dimerise was studied 
in virio with Northern Blotting and with in vitro dimerisation assays. Northern Blotting was 
chosen as the most appropriate technique due to its advantage of measuring both the 
quantity of total gRNA levels and the stability of its dimeric form. In vitro dimerisation assays 
were employed to further study the propensity of RNA to dimerise for mutants whose gRNA 
was not detectable with Northern Blotting due to low encapsidation levels.  
5.1. Probe generation 
 
The different kinetic properties of RNA and DNA were used to visualise the conversion of 
the PCR DNA to an RNA product via in vitro transcription, by running these two nucleic acid 
molecules alongside each other in a 1% agarose RNase-free gel. It can be seen that both PCR 
product 1 (lane 5) and PCR product 2 (PCR product band extracted from agarose gel, lane 6) 
used for in vitro transcription, generated probes of the right size and without any 
degradation (Figure 31). The RNA probe 2 (lane 3), which was produced from the gel-
extracted PCR template, was selected as the probe of choice for use in Northern Blotting to 




Figure 31. Production of an RNA probe that targets eGFP and WPRE sequences. 
1% agarose gel showing the 744 nt RNA probe (lane 2) transcribed from a gel extracted PCR 
product template (lane 6) and another RNA probe (lane 3) transcribed from a PCR product 
template that had not been gel extracted (lane 3).  
5.2. Non-denaturing (TBE) Northern Blots 
 
The expected size of the monomeric transcript of the transfer vector is 3.7 kb, thus the size 
of the genomic RNA in its dimeric form was expected to be 7.4 kb. RNA extracted from 1 mL 
of concentrated supernatant was loaded on a 0.8% agarose gel in TBE and was 
electrophoresed to allow different sizes of encapsidated gRNA to be separated. RNA was 
then transferred on a membrane on which was fixed with heat. The membrane was 
hybridised with the DIG-labelled probe from Figure 31 that spans the eGFP and WPRE 
region. RNA extracted from transfected cells (cRNA) was used as a control for the transfer 
step. WT and U5s RNAs electrophoresed in this blot were extracted from viral supernatants 
generated from either different transfection experiments, or independent replicates from 
the same round of transfection. RNA of the right sequence was labelled and visualised on X-
ray film. In all cases, based on visual inspection of band intensity shown in Figure 32, more 
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WT than U5s virion RNA was detected. NC4s RNA could not be detected in this blot, and 
UC4d RNA levels were lower than WT. A dimer/monomer RNA ratio could not be calculated 
due to the saturation of the dimer RNA band. 
 
 
Figure 32. Visualisation of virion RNA of WT and mutant samples with Northern Blotting. 
Native Northern Blot of purified transfer vector RNA probed with the 744 nt probe. 0.8% 
agarose gel was run in TBE for 4 h to allow separation of monomeric and dimeric RNAs. The 
membrane on which the separated RNAs were transferred to was incubated overnight with 
75 ng of a DIG-labelled RNA probe. Arrows indicate the bands corresponding to the full 
length dimeric and monomeric RNA for WT and mutants. Total levels of encapsidated gRNA 
were lower for all designed transfer vector mutants than for WT.  
 
The experiment was repeated and RNA extracted from WT and U5s supernatants from 
independent transfection experiments was electrophoresed in a native 0.8% agarose gel, 
Northern Blotted and used to calculate dimerisation efficiency. A t-test was performed to 
compare the dimerisation efficiency of WT and U5s, as Figure 33 indicated that U5s has a 
higher dimerisation efficiency. This observed trend was not found to be statistically 
significant (p=0.07). With the exception of WT2 and U5s2 repeats, the total amount of 







Figure 33. Visualisation of virion RNA of WT and mutant samples with Northern Blotting. 
 [A] Native Northern Blot of WT and U5s purified transfer vector RNAs probed with the 744 
nt probe targeting WPRE-eGFP. Arrows indicate bands corresponding to the full length 
genomic dimeric and monomeric RNA for WT and U5s replicates. [B] Calculation of 
Dimer/Monomer genomic RNA calculated via ImageJ. 
 
WT, S1 and LU5AUG virion RNA was extracted from two independent replicates from the 
same round of transfections and electrophoresed in a 0.8 % native agarose gel, then 
transferred to a positively charged AmershamTM HybondTM-N+ membrane (GE healthcare), 
and blotted using the 744 nt DIG-labelled probe. Visualisation of the RNA bands could not 
differentiate between dimeric and monomeric RNA, hence this blot was mainly used for a 
relative comparison of the total RNA levels. Band intensity was equivalent for WT and S1 
virions whereas no LU5AUG RNA could be detected in this blot.  












Native Northern Blot showing the total amount of RNA packaged and extracted from WT, S1 
and LU5AUG mutants. This Northern Blot was characterised by low resolution and it was 
thus used for a relative comparison of the total amounts of RNA packaged by each type of 
viral vector produced. 
WT and S1 virion RNA was extracted from three independent replicates from the same 
round of transfections and electrophoresed on a 0.8% native agarose gel, transferred and 
blotted as described above. S1 was chosen for further studies due to the higher viral yields 
produced by this mutant that would allow for its viral RNA to be detected with Northern 
Blotting,  but also due to its interesting functional phenotype. Northern Blotting (Figure 35) 
revealed that S1 RNA from virions appears to be characterised by a higher propensity to 
dimerise compared to WT. Dimeric and monomeric RNA band intensity analysis with ImageJ 
showed that S1(1) and S1(3) repeats have a 3 times higher dimerisation efficiency ratio 
(D/M) compared to the respective WT(1) and WT(3) repeats. However, the total levels of 
encapsidated RNA extracted from virions and detected here were lower for S1 than for WT. 
T-tests performed on both dimerisation efficiency (p=0.2) and packaging efficiency (p=0.08) 
did not reveal statistical significance, possibly due to the small number of repeats that could 
be assessed.  





Figure 35. Visualisation of virion RNA of WT and S1 with Northern Blotting. 
 [A] Native Northern Blot of WT and S1 purified transfer vector RNAs probed with the 744 nt 
probe targeting WPRE-eGFP sequences. The visualised bands correspond to the full length 
genomic dimeric and monomeric RNA for WT and S1 replicates. [B] Graph presenting a 
comparison between WT and S1 virion RNA dimerisation levels. Calculation of transfer vector 
dimerisation efficiency, defined as the ratio of dimeric to monomeric full length genomic 
RNA, was performed with ImageJ. [C] Graph showing the relative packaging efficiency of WT 
and S1 virions. Band intensity of both dimeric and monomeric RNA bands was measured 
with ImageJ. The dimeric and monomeric RNA values generated by densitometry were 
added to calculate the total amount of RNA packaged in virions and were then used to 
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5.3. In Vitro Dimerisation RNA Studies 
 
5.3.1. In vitro synthesis of RNA for dimerisation studies 
 
690 nt RNA fragments that included the sequences of the HIV 5’ R, U5 and partial gag 
included in the transfer vector constructs were produced to 1) study the effect of the U5-
AUG and dimerisation mutations on the RNA structure and its propensity to dimerise in vitro 
and 2) investigate the effect of partial gag sequences on the stability of the packaging 
conformation. PCR products spanning the aforementioned sequences were created using a 
Forward 5’ Primer that contained the T7-Pol Transcription start site (TSS). The 50 μl PCR 
reactions were loaded in a 1% agarose gel and the correct size products were excised and 
purified. Lack of cross contamination was ensured by loading a PCR negative control (NC), 
which was made of plasmid DNA template-free PCR mix, alongside the mutant plasmid 
containing reactions. The total amount of the gel extracted PCR products was then used as 
template for large scale in vitro transcription reactions (scaled up 4 times than the 
manufacturer’s suggested protocol). 2 μg of each RNA fragments were then visualised under 
the UV in a 1% ethidium bromide stained agarose gel to assess conversion of DNA to RNA 
























[A] PCR reactions were loaded in a 1% TBE agarose gel to visualise PCR products that should 
contain the T7 TSS for in vitro transcription of U5-AUG and dimerisation mutants. The correct 
size products were excised, purified and used as in vitro transcription templates. [B] 
Confirmation of synthesis of a 690 nt RNA fragment containing the cis-acting elements of 5’ 
R, U5 and partial gag, for a selection of U5-AUG and dimerisation mutants. In vitro 
transcribed products were mixed with 2x Ambion RNA loading dye and were electrophoresed 
in a 0.8% agarose gel in TBE to assess correct size, lack of degradation and potential 
existence of byproducts.  
 
 
Figure 36. Production of in vitro transcribed 690 nt RNA fragments of interest. 
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5.3.2. Optimisation of in vitro RNA dimerisation  
 
An in vitro RNA dimerisation protocol was optimised to study the dimerisation efficiency of 
WT and mutant RNAs, as well as the structural conformation of their respective dimers and 
monomers. As mentioned earlier and unlike previous studies that had focused only on the 
HIV-1 leader sequences, a longer 690nt RNA containing the HIV 5’ U5, R and partial gag was 
synthesised and studied. As shown by Sinck et al., in vitro RNA dimerisation is inhibited with 
increasing RNA size245, hence a new protocol had to be established to enable dimerisation of 
the longer RNA of interest. Similar to Sinck et al., a refolding buffer that contained sodium 
cacodylate and increased MgCl2 concentration was used to investigate whether sodium 
cacodylate addition and increased MgCl2 concentration could positively affect RNA 
dimerisation in vitro.  
Two independent rounds of in vitro transcription were performed using WT and U5s PCR gel 
extracted templates. Samples were heated at 95⁰C for 2 min, placed on ice for 2 min and 
then electrophoresed on a 1% agarose TBE gel with a native loading dye and visualised with 
EtBr staining and UV transillumination. As shown in Figure 37.A, under these renaturation 
conditions, both WT and U5s RNAs existed predominantly in the monomeric state. Figure 
37.B depicts WT RNA studied in a 4% polyacrylamide TBM gel, which is normally used for in-
gel SHAPE structural analysis experiments. WT RNA was mixed with 1x Renaturation buffer 
(10 mM Tris pH 8, 100 mM KCL and 0.1 mM EDTA) and heated for 5 min at 95⁰C. The sample 
was allowed to reach 28⁰C and was then mixed with 5x refolding buffer (40 mM Tris pH 8, 4 
mM MgCl2 and 130 mM KCl) for 30 min at 37⁰C. Gel electrophoresis took place for 4h 
allowing the dimeric and monomeric RNAs to separate. Similar to the 1% TBE agarose gel 
the WT RNA studied here was mainly in the monomeric conformation with only a very small 





Figure 37. In vitro dimerisation studies of WT and U5s RNAs visualised with the use of 
different types of gels. 
 [A] In vitro dimerisation study of WT and U5s RNAs visualised in a 1% agarose TBE gel. [B] In 
vitro dimerisation of WT RNA visualised in a 4% polyacrylamide TBM gel. 
With the aim of enabling dimerisation in this length of RNA, the effect of sodium cacodylate 
and increased MgCl2 concentration on enhancement of RNA efficiency was studied. The 5x 
Refolding buffer (Rb): 40 mM Tris pH 8, 4 mM MgCl2 and 130 mM KCl8 was compared 
against the 5x Dimerisation buffer (Db): 50mM sodium cacodylate pH 7.5, 40 mM Tris pH 8, 
5 mM MgCl2 and 130 mM KCl245. Confirming the results previously shown in Figure 37.A., 
both WT and U5s 690 nt long RNA fragments in Rb dimerised poorly (Figure 38 lanes 1 and 2 
respectively). Incubation of WT and U5s RNAs in Db caused a dramatic shift towards the 
dimeric conformation, with both RNAs mainly adopting the dimeric conformation (Figure 38 
lanes 3 and 4 respectively). Finally, addition of these reagents had an effect on the 

















WT RNA in Rb (lane 1), U5s RNA in Rb (lane 2), WT RNA in Db (lane 3) and U5s RNA in Db 
(lane 4) were visualised in a 1% agarose TBM gel containing 0.1 mM MgCl2
245. 
 
The RNA smear observed in Figure 38. was addressed by decreasing the MgCl2 
concentration in the TBM buffer. MgCl2 concentration was reduced to 0.03mM
8. 3 μg of U5s 
RNA were electrophoresed in a 4% non-denaturing polyacrylamide TBM gel. U5s was chosen 
over WT to assess the impact of MgCl2 concentration reduction on electrophoresis kinetics, 
as a higher level of smear and dimerisation efficiency was previously observed for this 
mutant. As shown in Figure 39 a good ratio of dimer to monomer RNA was achieved without 
the presence of any noted smear. Based on these observations Db buffer and 1x TBM buffer 
containing 0.03mM MgCl2 were chosen as optimised conditions for all further in vitro 
dimerisation assays and in-gel SHAPE experiments performed. This optimised protocol was 
also used for a quality control experiment using both the 356 nt long RNA fragment 
previously studied8 and the longer 690 nt fragment interrogated in this thesis (Figure 40).  








              
 
 
              
Figure 40. Side by side comparison of WT RNA of two different lengths in a 4% 
polyacrylamide TBM gel used for in-gel SHAPE experiments. 
356 nt long RNA fragment (8BP8) kinetics and dimerisation propensities were compared to 
the 690 nt long RNA fragment that contains the additional partial gag sequences. 
Figure 39. In vitro dimerisation of U5s RNA incubated in the optimised Db visualised in a 






5.3.3. In vitro dimerisation of WT and mutant RNA  
 
Previous studies from the literature have shown S1 to dimerise 60% better in vitro than WT. 
Hence, an in virio to in vitro study for S1 was performed above to study its dimerisation 
properties in our system (Figure 35).  In vitro studies of the 690 nt long RNA fragments 
presented in Figure 41 revealed a similar result with previously published data. S1 RNA 
synthesised in vitro had a higher dimerisation propensity compared to the same length WT 
in vitro synthesised RNA fragment.  
                                 
Figure 41. In vitro dimerisation assay assessing the dimerisation efficiency of WT and S1 
transcribed RNA fragments produced with the optimised protocol developed in 5.3.b. 
Arrows mark the 690 nt monomeric fragment and the 1380 nt dimeric fragment. Low Range 
Riboruler was the ladder of choice to confirm right size of RNA products. 
 
690 nt long RNAs were produced in vitro as described in 3.9.1. for WT, U5-AUG mutants S1 
and U5s, and the dimerisation mutants J9+Gag, polyAsw and polyAs. The produced RNAs 
were incubated under the same renaturing and refolding conditions, as previously described 
in 5.3.2, to directly compare the effect of the designed mutations on their in vitro RNA 
dimerisation efficiency. Both U5-AUG mutants, S1 and U5s, had a higher dimer to monomer 
RNA ratio than WT. Amongst them, S1 had the highest dimerisation efficiency, confirming 
the Nothern Blot data from virion RNA shown in Figure 35.A. The dimerisation mutants, 
J9+Gag, polyAsw and polyAs had a dramatic increase of their in vitro RNA dimerisation 
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efficiency, with only a small portion of the RNA adopting the monomeric conformation. 
Overall, the rationally designed mutations presented here, had a positive effect on the 













                         
Figure 42. Side by side comparison of in vitro RNA dimerisation efficiencies of WT to a 
range of U5-AUG and dimerisation mutants in 4% polyacrylamide non denaturing TBM 
gels. 
Low Range Riboruler, whose longest RNA fragment is 1000 nt was loaded in all gels to 







5.4. Chapter conclusions 
 
Rationally designed mutations introduced in the 5’UTR targeted the dimerisation and 
packaging properties of lentiviral vectors with the aim of improving their efficiency. The 
effect of these mutations on infectivity was investigated in chapter 4, while in this chapter I 
aimed to characterise the dimerisation efficiency of transfer vector mutants and attempt to 
investigate a potential link between transduction efficiency and RNA dimerisation efficiency. 
Northern Blotting revealed an increased RNA dimerisation propensity trend for S1 and U5s. 
However, it should be noted that this observed phenotypic difference between the S1 and 
U5s mutants and WT did not achieve statistical significance. In vitro dimerisation assays 
showed an overall positive effect of the introduced mutations on the propensity of RNA to 
dimerise in vitro. Therefore, these observations indicate that enhancing dimerisation does 
not automatically lead to improvement of vector infectivity. Northern Blotting was chosen 
as an appropriate technique to visualise the monomeric and dimeric RNA extracted from 
virions and measure the quantity of total gRNA levels packaged in virions. However, high 
yields and lack of degradation throughout the whole process were prerequisites for 
measurement of total gRNA levels. RT-qPCR was chosen as the best assay to overcome 
these technical hurdles and study in detail the extent on which the rationally designed 
mutations affect packaging per se. RT-qPCR was used to measure the levels of gRNA 
successfully encapsidated into virions in comparison to the gRNA found on the producer 
cells and thus address the next scientific question that is: ‘‘what is the relative packaging 









6. Measurement of relative packaging 
efficiency (RPE) by RT-qPCR 
In cells, positive strand RNA viruses like HIV-1, need to selectively recognise their full-length 
gRNA among similarly modified 5’-capped, 3’-polyadenylated abundant cellular RNAs to 
successfully assemble and release infectious viral particles70. Since RNA packaging is known 
to be linked with several aspects of retroviral replication, including RNA dimerisation12, it 
was rendered essential to determine the RNA packaging efficiency of the rationally designed 
transfer vector mutants. Northern Blot analysis, ribonuclease protection assay (RPA) and 
quantitative reverse transcriptase-coupled polymerase chain reaction as well as the most 
recent sequencing technologies are different approaches for assessing RNA packaging128. 
RT-qPCR was the method of choice to assess packaging efficiency due to its advantage of 
quantifying RNA expressed at very low levels. Additionally RT-qPCR is highly specific and 
much more sensitive than the methods mentioned above. In this chapter, packaging 
efficiency measured with RT-qPCR was employed to investigate whether the dimerisation 
enhancing mutations promoted packaging as hypothesised. As seen in chapter 4, all 
designed transfer vector mutants had lower infectious titres. However, this observation did 
not necessarily mean that the mutants were also of lower packaging efficiency, as the 
introduced mutations could have improved packaging but hindered a different step of the 
HIV-1 lifecycle. Lastly, this assay was employed to study the relationship between packaging 
and RNA dimerisation efficiencies.  
6.1. Measurement of the packaging efficiency of rationally designed U5-AUG 
mutants with a WPRE-targeting RT-qPCR assay 
 
Lizee et al., developed a qPCR assay that targets the WPRE element234, a sequence inserted 
in the backbone of lentiviral vectors due to its ability to enhance transgene expression201. 
This assay does not rely on reporter genes but targets a sequence unique to the lentiviral 
vectors which should thus secure assay specificity. Additionally, unlike most assays available 
in the literature that target sequences in the 5’UTR region of HIV-1246 247 248 249 250, the assay 
designed by Lizee et al., targets WPRE which is located in the 3’UTR. Assays targeting 
sequences in the 5’UTR would be inappropriate for this study because all dimerisation 
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enhancing mutations introduced in the transfer vectors (described in chapter 4) are located 
in the 5’UTR and could potentially interfere with assay efficiency. According to Lizee et al., 
their system allows the quantitation of lentiviral vector preparations at three levels: vector 
genomic RNA, integrated proviral DNA, and cellular lentiviral vector-mediated gene (mRNA) 
expression. For the purposes of this thesis the WPRE qPCR assay was employed to measure 
gRNA levels in both transfected cells and virions. Transfection efficiencies and cellular RNA 
extraction efficiencies were normalised by normalising to the expression levels of β-actin251.  
Based on the preliminary data shown in Figure 43, the U5s construct was characterised by a 
higher packaging efficiency compared to WT and all other mutants. Data were presented in 
Figure 43 as the average values of the replicates with error bars showing standard deviation. 
In specific, U5s mutant packaged RNA approximately 4 times more efficiently than WT, 
whereas the NC4s and the UC4d constructs were characterised by a 10 times and a 2 times 
lower packaging efficiency respectively.  
 
 
Figure 43. qPCR measuring relative packaging efficiency of mutant vectors against WT. 
RT-qPCR using the cDNA from 3 transfection replicates per construct was performed to 
calculate the relative packaging efficiency, which was defined as the ratio of the 
extracellular virion RNA to the normalized to β-actin intracellular RNA. RNA was extracted 
from both virions and cells. Bar graphs show the average packaging efficiency of each 
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RT-qPCR using the cDNA from 12 transfection replicates per construct showed that on 
average, the packaging efficiency of U5s was 3 times higher than that of WT (Figure 44.A). 
This result was statistically significant, with a p value of 0.006 using the Student’s t test. 
Similar transfection efficiency between all replicates was achieved via another round of 
plasmid extraction and purification. Figure 44.B, shows that the data were indicative of 
enhanced packaging, but that there was also observed variance. This variability was believed 
to be caused by several technical issues. Performed gRNA extraction was a multiple step 
process that employed yeast tRNA as a coprecipitant to aid recovery of gRNA,  but lacked an 
internal control necessary to assess gRNA recovery efficiency. Additionally, transfer vector 
plasmid traces have been challenging to be removed and could potentially interfere with RT-




RT-qPCR experiment comparing the relative packaging efficiency between 20 WT and 18 U5s 
independent replicates from separate experiments. [A] data presented as an average of all 
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Similarly, RT-qPCR was performed to assess the packaging efficiency of mutant NC4s 
compared to WT. Using the Student’s t test, the results were found to be statistically 
significant with a p value of 0.012. The NC4s mutant was designed so that the pseudoknot 
conformation will be favoured while the dimerisation one will be hindered. As expected the 
RNA encapsidation efficiency of this mutant was severely decreased compared to WT. A 
similar set of RT-qPCR experiments was set up to compare the packaging efficiency of 6 
UC4d replicates against 7 WT replicates. The UC4d mutant was found to be approximately 
half as efficient as WT in encapsidating RNA into the virion (Figure 45.B). The two sets of 












[A] Relative packaging efficiency of WT and NC4s mutant qPCR data showing relative 
packaging efficiency of 7 WT and 6 NC4s samples. Error bars represent standard deviation. 
[B] Relative packaging efficiency of UC4d mutant. qPCR data showing relative packaging 
efficiency of 7 WT and 6 UC4d samples. Error bars represent standard deviation. 
6.2. Design of a novel competitive qPCR assay to measure RPE  
 
The WPRE qPCR assay described above was characterised by large variability potentially due 
to lengthy processing of samples and lack of an internal control for the extracellular RNA.  
Although retroviruses, including HIV-1, are known to recruit host cell RNAs into virions, the 
A                                                                                            B 
Figure 45. Relative packaging efficiency of WT, NC4s and UC4d with the use of a WPRE-
targeting RT-qPCR assay. 
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spectrum of RNAs encapsidated, the amount of specific RNAs packaged and the mechanisms 
by which they are recruited remain largely unknown; hence the lack of a trustworthy 
internal control for virion gRNA. An alternative qPCR approach needed to be employed in 
order to conclusively assess the packaging efficiency ratio for each construct. To achieve 
this, I designed a competitive qPCR assay by introducing unique sequences in the WT and 
mutant transfer vectors to allow for simultaneous quantification of their gRNAs in a co-
transfection environment. The unique sequences of MS2 (ACATGAGGATCACCCATGT) and 
BglG (GGATTGTTACTGCATTCGCAGGCAAAACC) were introduced into the WT and mutant 
sequences and primer/probe pairs were designed using the Oligo 7.0, Molecular Biology 
Insights software252. The MS2 and BglG sequences were chosen because various studies 
have employed these stem loops without any noted effect on viral replication12 253. The 
unique MS2 and BglG sequences were introduced in a multiple cloning site (MCS) between 
the eGFP and WPRE elements. Cloning of these unique sequences in each of the mutant and 
WT constructs allowed for independent quantification of their gRNA levels in a co-
transfection context. The primer pair was designed to be common for both BglG and MS2 
constructs, while differently labelled probes were designed to target the unique MS2 and 
BglG sequences. This design was important because it could allow for simultaneous 
detection of WT and mutant transfer vector gRNA levels in a one-well reaction.  Each 
transfer vector construct was cloned twice, to include an MS2 and a BglG version so that the 
efficiency of each probe could be assessed in a reciprocal system where the results should 
be the same whichever way around the sequences were tested (MS2-WT and BglG-mutant 
or vice-versa).  The intention of these preliminary results was to assess the validity of the 
system; when the MS2 and BglG qPCR assays were optimised to equal efficiency, the MS2-
containing WT transfer vector and the BglG-containing mutant transfer vectors of interest 
were used in a competitive environment for further analysis. The experimental design was 
as follows: WT and mutant gRNA vectors were co-transfected into 293T cells and RT-qPCR 
targeting MS2 and BglG sequences was performed on each sample enabling a comparison of 
their encapsidation efficiencies to be performed in a controlled manner. The introduction 
and targeting of unique sequences in the WT and mutant transfer vectors aimed to resolve 
the observed variability (potentially due to different sample processing and lack of an 


































The BglG and MS2 assays were designed using the Oligo 7.0, Molecular Biology Insights 
software252. More specifically forward primer was 20 nt long, had a Tm of 55°C and was of 
50% GC context. The reverse primer was 18 nt long, had a Tm of 54.6°C and was of 50% GC 
context. The sequence fragment presented here included part of the eGFP and WPRE 
sequences, and the area of the MCS within which the unique sequences was inserted. The 
BglG and MS2 sequences were introduced following the same cloning strategy so that a 
common set of primers could be developed. This sequence fragment of interest is presented 
Figure 46. Design of a multiplex qPCR assay consisting of a common primer set and two 




both in its forward and reverse direction. The primer sequences are highlighted in yellow, the 
inserted BglG and MS2 sequences are highlighted in purple and transcribed in capital letters, 
and the designed probes spanning the unique BglG and MS2 sequences are underlined, 
italicised and in bold. The BglG probe was designed to be 23 nt long, had a Tm of 65.3°C and 
was of 48% GC context, while the MS2 probe was 22 nt long, had a Tm of 64.9°C and was of 
55% GC context. The assay sequences designed are: Fw 5’-GAATTCTGCAGTCGACGGTA-3’, 
Rv 5’-TCCAGA GGTTGATTGCGA-3’, PBglG 5’-[6’FAM]-TGCGAATGCAGTAACAATCCCGA-
[BHQ1]-3’,PMS2 5’-[HEX]-CATGGGTGATCCTCAT GCCGAT-[BHQ1]-3’.  
6.3. Cloning of transfer vectors containing the unique BglG and MS2 
sequences 
 
1 μg of WT pCCL-eGFP and 1 μg of U5s pCCL-eGFP backbones were incubated with 20 U of 
FastDigest PvuI and 1 U of FastAP Thermosensitive Alkaline Phosphatase in a 20 μL reaction 
in 1x Fast Digest Buffer at 37°C for 1 h, to achieve simultaneous dephophorylation and 
digestion. Digestion products were separated on a 1% agarose gel and bands of interest 
were excised and extracted (Figure 47). Meanwhile BglG and MS2 phosphorylated oligo 
sequences flanked between the PvuI recognition sites were used in an annealing reaction 
that contained 100 μΜ Fw Oligo, 100 μΜ Rv Oligo, and 1x ExpressLinkTM T4 Buffer in a 100 
μL final volume reaction that was held at 90⁰C for 10 min. The extracted bands of interest 
derived upon digestion of the transfer vectors with PvuI were treated similarly. Four ligation 
reactions of the following combinations were set up: WT pCCL-eGFP and BglG oligos, WT 
pCCL-eGFP and MS2 oligos, U5s pCCL-eGFP and BglG oligos and U5s pCCL-eGFP and MS2 
oligos. Each ligation reaction contained 35 ng of annealed oligos, 100 ng backbone and 5 U 
of ExpressLinkTM T4 DNA Ligase in a final volume of 20 μL.  1 μL of each ligation reaction 
containing a combination of backbone and oligos was used to transform Stbl3TM E.coli cells. 
Successful incorporation of the BglG and MS2 unique sequences in both transfer vectors 




   
 
 [A] PvuI digested WT and U5s pCCL-eGFP vector plasmids were loaded alongside control 
undigested (NC) WT and U5s pCCL-eGFP vector plasmids in a 1% agarose gel.  [B] PvuI 
digested WT and U5s pCCL-eGFP fragments were excised and purified. [C] pCCL-eGFP 
transfer vector plasmid map presented with the single PvuI restriction site located between 
eGFP and WPRE. PvuI cuts the pCCL-eGFP vector plasmid at nucleotide 3726 producing an 
8.5 kb long linear DNA fragment.  
6.4. Optimisation of a competitive qPCR assay to measure RPE 
 
According to the The MIQE Guidelines (Minimum Information for Publication of Quantitative 
Real-Time PCR Experiments) PCR efficiency is correlated with robust and precise qPCR 
assays254, and can be calculated based on the slope of the standard curve using the Thermo 
Fisher qPCR efficiency calculator255. The linear dynamic range should extend to 5 or 6 log10 
concentrations and must include the interval for the target nucleic acids being quantified. 
Correlation coefficients (R2 values) need to be calculated to ensure a strong linear 
relationship between two variable points of the standard curve and should be >0.99256. The 
limit of detection (LOD) is defined as the lowest concentration at which 95% of the positive 
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Figure 47. Cloning of transfer vectors containing the unique BglG and MS2 sequences. 
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as qPCR precision decreases with the copy number, and samples of Ct>35 will be considered 
negative256.   
TaqMan® Assays exploit the 5' nuclease chemistry of polymerases. Fluorogenic probes are 
used to detect specific PCR products as they accumulate during PCR. Such assays contain: a 
pair of unlabeled primers, a TaqMan probe commonly 5’ labelled with a FAM™ or VIC™ dye, 
a minor groove binder (MGB) and nonfluorescent quencher (NFQ) on the 3' end. The 
process begins with a temperature raise to denature the double-stranded cDNA. At this 
stage the signal from the 5’ fluorescent dye of the TaqMan probe is quenched by the 
presence of a NFQ on the 3’ end. The next stage involves decrease of temperature to enable 
primers and probes to anneal specifically to their target sequences. On the last step of 
extension, Taq DNA Polymerase synthesises new products with the use of unlabeled primers 
and the template whose expression is to be studied. When the polymerase reaches the 
annealed TaqMan probe, its endogenous 5' nuclease activity cleaves it resulting in 
separation of the dye from the quencher. Product amplification leads to more dye molecule 
release, resulting in an increase in fluorescence intensity proportional to the amount of 
amplicon synthesized257. 
Calibration of primer concentration was the first step towards optimisation of the new qPCR 
assay. The MS2 probe concentration was kept constant at 250 nM, while a gradient of 100 
nM-900 nM primer concentration combinations was used to create a matrix, presented 
below, to identify the optimal primer concentration. Optimal primer concentration was 
chosen based on the sensitivity which was assessed based on how early the sequence of 
interest was detected in the qPCR cycles, but also based on the specificity of primers which 




                 
Figure 48. Primer optimisation process for the competitive MS2/BSL RT-qPCR assay. 
 [A] Table presenting the matrix used to determine optimal primer concentration while using 
the HEX-labelled MS2 probe at a constant concentration of 250 nM. Numbers presented in 
this table represent [Forward primer concentration/Reverse primer concentration] measured 
in nM. [B] Reaction mixture for primer concentration optimisation. [C] Plate presenting the 
positions of the different primer concentration combinations. 5000000 copies of the pCCL-
eGFP-MS2 transfer vector were used as a template for each reaction (shown in black), while 
2 μl of water were used for the NC reactions (shown in blue). DNA samples were loaded in 
the black labelled wells, while water was loaded in the blue labelled ones. 
 
By independently varying the primer concentrations, one could identify the optimal primer 
set concentration to achieve the best qPCR assay performance. Based on observations from 
these experiments the [500/500] ratio was found to be the optimal primer concentration 
that achieved both a low Ct value and lack of product formation in the respective NC (data 
not shown). Using this primer set concentration; probe concentrations were then optimised. 
250 nM, 400 nM and 600 nM were the primer concentrations trialled for TaqMan assay 
optimisation. WT-pCCL-eGFP-MS2 and WT-pCCL-eGFP-BglG plasmids were used as standard 
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curve templates in independent monoplex reactions to interrogate the efficiency and 
linearity of the assays. A six log10 concentration standard curve between 5000000  and 500 
copies was created following the protocol published by Applied Biosystems258. As shown in 
Figure 49, all BglG probe concentrations showed variability between 500000 and 5000 copy 
numbers, without any of the probe concentrations achieving an acceptable level of linearity 
for BglG; all probe concentrations generated an R2 that was lower than 0.99. On the 
contrary, all MS2 probe concentrations had an R2> 0.99, with [250 nm] giving an R2=1! The 
PCR efficiency was ~98% for all MS2 reactions and 97-100% for the BglG reactions. 
 
A                                                                                      B 
Figure 49. Optimisation of BglG and MS2 probes’ concentration. 
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 [A] Assessment of BglG probe concentration was performed trying three different 
concentrations, including 250 nM, 400 nM and 600 nM. Primer concentration was 
maintained at [500/500] for all reactions. [B] The effect of MS2 probe concentration on qPCR 
efficiency and linearity was studied by setting reactions with variant MS2 probe 
concentration including 200 nM, 400 nM and 600 nM while maintaining primer 
concentration at 500 nM. 
 
The effect of the BglG and MS2 probes in a multiplex reaction was investigated next. A 
range of 5000000 to 500 copies of both WT-pCCL-eGFP-BglG and WT-pCCL-eGFP-MS2 
plasmids were used as standard curve templates in a multiplex reaction containing 250 nM 
MS2 probe, 600 nM BglG probe, 500 nM Forward primer, 500 nM Reverse primer and 5 μl 
of Fast Advanced TaqMan buffer to assess the linearity of the BglG and MS2 standard curves 
and the efficiency of the respective assays. The presence of pCCL-eGFP-MS2 template was 
shown to negatively affect the linearity of the BglG qPCR assay (Figure 50), with the R2 
dropping from 0.97 to 0.51. Additionally, the efficiency of the assay was also observed to 
decrease. Given the high efficiency of the MS2 assay, it was concluded that it was the BglG 




Figure 50. Investigation of the efficiency and linearity of the duplex BglG-MS2 qPCR assay. 
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Multiplex reaction set up with 600 nM BglG probe, 250 nM MS2 probe, 500 nM Forward 
primer and 500 Reverse primer for a range of 5000000 to 500 copies of both WT-pCCL-eGFP-
BglG and WT-pCCL-eGFP-MS2 plasmids. 
The Custom TaqManTM MGB Probe design service by Applied Biosystems259 was used to 
design a new FAM-labelled BglG probe. TCGATCGGGATTGTTACTG was the new probe 
sequence used to optimise a new BglG assay, using a concentration of 750 nM as directed 
by the manufacturer. Keeping the primer concentration at 500 nM as previously established, 
independent monoplex reactions for MS2 (250nM) and new AB BglG (750 nM) were 
repeated following the protocol presented in Figure 48.B. As shown in Figure 51, the new 
probe sequence had a significant positive effect on the assay’s linearity, with its R2 improved 
to be higher than 0.99. The linearity of the MS2 was maintained higher than 0.99 as shown 
previously. The PCR efficiency was lower than previously described for both assays, but was 
noted to be comparably reduced between BglG and MS2, hence it was assumed that this 
was due to a technical error. Nevertheless, overall the new AB BglG probe design had a 
positive effect on the assay and was used to further optimise the multiplex assay.  
 
  
Figure 51. Investigation of new BglG assay linearity and efficiency. 
 [A] Effect of the new BglG probe sequence on assay linearity and efficiency. Monoplex 
reaction set up with 750 nM new AB BglG probe, 500 nM Forward primer and 500 Reverse 
primer. 5000000 to 500 copies of WT-pCCL-eGFP-BglG plasmid were used as standard curve 
templates. [B] Repeat of the previously established MS2 monoplex assay conditions to 
ensure reproducibility and direct comparison to the new BglG assay efficiency. 
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Next, it was necessary to investigate the effect of primer concentration on the multiplex 
assay, as both BglG and MS2 assays were previously optimised in monoplex reactions. I 
compared the effect of 500 nM primer concentration, which is the optimal primer 
concentration established in the monoplex assays previously described, against 1000 nM 
primer concentration. The data was inconclusive as the linearity of the MS2 assay (red) 
increased with the increase of primer concentration whereas its efficiency decreased. On 
the contrary, the efficiency of the new AB BglG assay (blue) increased with the increase of 
the primer concentration, while the standard curve’s linearity was noted to decrease.  
 
 
Figure 52. Effect of primer concentration on the multiplex assay. 
 [A] Multiplex reaction set up with 750 nM new AB BglG probe, 250 nM MS2 probe, 500 nM 
Forward primer, 500 nM Reverse primer and 5 μl Fast Advanced Buffer. [B] Multiplex 
reaction set up with 750 nM new AB BglG probe, 250 nM MS2 probe, 1000 nM Forward 
primer, 1000 nM Reverse primer and 5 μl Fast Advanced Buffer. 
Given the lack of conclusive data, the experiment was repeated with an additional reaction 
of increased primer concentration to 1500 nM. The data presented in Figure 53 was 
inconsistent with the data presented in Figure 52. The increase of primer concentration to 
1500 nM affected both assays’ linearity positively but both assays’ efficiency negatively. A 
possible interpretation of this result could be that detection of MS2 and BglG containing 
sequences was stochastic in a multiplex environment .  
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Figure 53. Effect of primer concentration on the multiplex assay. 
 [A] Multiplex reaction set up with 750 nM new AB BglG probe, 250 nM MS2 probe, 500 nM 
Forward primer, 500 nM Reverse primer and 5 μl Fast Advanced Buffer. [B] Multiplex 
reaction set up with 750 nM new AB BglG probe, 250 nM MS2 probe, 1000 nM Forward 
primer, 1000 nM Reverse primer and 5 μl Fast Advanced Buffer. [C] Multiplex reaction set up 
with 750 nM new AB BglG probe, 250 nM MS2 probe, 1500 nM Forward primer, 1500 nM 
Reverse primer and 5 μl Fast Advanced Buffer. 
To address this challenge, a new set of experiments was designed maintaining the plasmid 
concentration of WT-pCCL-eGFP-BglG at a constant of 50000 copies in the presence of a 
log10 WT-pCCL-eGFP-MS2 standard curve and vice versa. The linearity of the assays was 
assessed with the calculated R2 and the ΔCt of each standard curve. This time the efficiency 
of each assay was investigated by the Ct consistency of the plasmid whose DNA mass was 
kept constant. The ΔCt of a 10x sample dilution was expected to be around 3.2. As shown in 
Figure 54, the ΔCt values of the MS2 standard curve in the presence of a constant amount of 
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50000 BglG copy number were between 4.1 and 7.9, which was of very poor efficiency. 
Respectively, the Ct difference of values of the BglG standard curve in the presence of a 
constant amount of 50000 MS2 copy number was between 3.8 and 5.7, which was also 
determined to be of poor efficiency. As expected, the Ct value of the BglG plasmid in the 
presence of 50000 copies was maintained at 24 between 5000000 and 500 MS2 copies. 
Similarly, the Ct value of the MS2 plasmid kept at 50000 copies was measured between 25.3 





Log10(CP) MS2 ΔCt BglG Log10(CP) MS2 BglG ΔCt 
6.69897 17.377204 4.1000261 - 6.69897 26.307735 16.372656 3.842514 
5.69897 21.47723 6.6052074 24.289837 5.69897 25.295114 20.21517 4.1127205 
4.69897 28.082438 7.8894901 24.295522 4.69897 26.572425 24.32789 4.5126457 
3.69897 35.971928 
 
24.012357 3.69897 26.632078 28.840536 5.7923031 
2.69897 - 
 
23.936703 2.69897 28.02824 34.632839 
  
Figure 54. Effect of contant and variable plasmid concentrations on MS2 and BglG assays. 
 [A] Effect of WT-pCCL-eGFP-BglG plasmid presence on a log10 WT-pCCL-eGFP-MS2 standard 
curve. [B] Effect of WT-pCCL-eGFP-MS2 plasmid presence on a log10 WT-pCCL-eGFP-MS2 
standard curve. Multiplex reactions presented in A and B were set up with 750 nM new AB 
BglG probe, 250 nM MS2 probe, 1000 nM Forward primer, 1000 nM Reverse primer. [C] Raw 
data of MS2 and BglG assays presented in graphs A and B to study the assays’ efficiency and 
linearity. 








































Log10 Copy Number) 
BSL 
MS2 




Given the data presented in Figure 54, I addressed the aforementioned challenges by 
comparing directly the linearity and efficiency of the multiplex assay and the two respective 
monoplex assays in the same plate.  
 
 
Figure 55. Comparison of monoplex and duplex reactions for MS2 and BglG assays. 
 [A] Graph showing a five log10 standard curve of the MS2 assay in a monoplex reaction 
containing 250 nM MS2 probe, 500 nM Forward primer and 500 nM Reverse primer. [B] 
Graph showing a five log10 standard curve of the MS2 assay in a multiplex BglG-MS2 
reaction containing 750 nM new AB BglG probe, 250 nM MS2 probe, 1000 nM Forward 
primer and 1000 nM Reverse primer. [C] Graph showing a five log10 standard curve of the 
BglG assay in a monoplex reaction containing 750 nM new AB BglG probe, 500 nM Forward 
primer and 500 nM Reverse primer. [D] Graph showing a five log10 standard curve of the 
BglG assay in a BglG-MS2 multiplex reaction containing 750 nM new AB BglG probe, 250 nM 
MS2 probe, 1000 nM Forward primer and 1000 nM Reverse primer.Reactions presented in B 
and D contain both MS2 and BglG plasmid templates, while A and C contain only MS2 and 
BglG plasmid template respectively. 
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The MS2 monoplex qPCR efficiency was calculated to be 99.77% with an amplification factor 
of 2 and an R2 of 0.999, while the equivalent MS2 multiplex qPCR efficiency dropped to 
89.23% with an amplification factor of 1.89 and an R2 of 0.998. Similarly, The BglG monoplex 
qPCR efficiency was 96.49% with an amplification factor of 1.96 and an R2 of 0.997, while the 
equivalent BglG multiplex qPCR efficiency was decreased to 78.35% with an amplification 
factor of 1.78 and an R2 of 0.992. Collectively, the data suggest that the equivalent 
monoplex assays were more efficient than the multiplex reaction. The multiplex assay was 
initially of preference as it would have been time and cost efficient but was not found as 
accurate as the monoplex assays. Therefore, the independent use of the optimised 
monoplex MS2 and BglG assays was chosen for accurate measurement of MS2- and BglG- 
sequence containing genetic material derived from the same co-transfection plate. The next 
section discusses the employment of these two monoplex assays (conditions described in 
Figure 55.A and 55.C) to measure MS2- and BglG- containing gRNA and the methodology 
followed to optimise the protocol for genetic material extraction and data analysis.  
6.5. Optimisation of a qPCR protocol for genetic material extraction and data 
analysis to measure RPE  
 
The main advantage offered by this new PCR approach was the ability to measure WT and 
mutant gRNA levels in the same sample, and thus an equal amount of WT and mutant 
plasmid DNA mass was used to co-transfect HEK293T (Figure 56). 6 μg WT pCCL-eGFP-MS2, 
6 μg mutant pCCL-eGFP-BglG, 2.5 μg pRev, 3.5 μg pVSVg and 5 μg pSYNGP were used to 
produce lentiviral vector following the protocol described in section 3.1. Intracellular and 
extracellular RNA was extracted from 1 mL cellular lysate and 1 mL of viral supernatant 
respectively, and used as template for reverse transcription. qPCR targeting the MS2 and 
BglG sequences was then performed to measure the relative packaging efficiency of WT to 




Figure 56. Representation of qPCR workflow to measure relative packaging efficiency. 
Relative packaging efficiency was defined as the ratio of extracellular to intracellular WT 
gRNA divided by the ratio of extracellular to intracellular mutant gRNA derived from the 
same co-transfection plate. This method overcame the necessity to normalise samples to a 
housekeeping gene as the genetic material from both WT and mutant vectors came from the 
same transfection environment and was already normalised to the transfection efficiency of 
each vector by dividing the encapsidated gRNA to the intracellularly expressed gRNA. 
The efficiency of the BglG and MS2 assays was previously studied in section 6.4 with the use 
of plasmid DNA. I then sought to investigate whether these assays were also equally 
efficient at detecting BglG- and MS2-containing cDNA produced from extracted gRNA. This 
was important to ensure unbiased and accurate measurement of WT and mutant gRNA 
packaging regardless of the sequence ‘’attached’’ to them. To study this, HEK293T cells were 
co-transfected with equal amounts of WT-pCCL-eGFP-BglG and WT-pCCL-eGFP-MS2 transfer 
vector plasmids. The WTMS2/WTBglG RPE should be of value 1, as both plasmids contained 




    
Figure 57. Measurement of WTMS2/WTBglG RPE. 
[A] Graph showing the measured WTMS2/WTBglG RPE values from 8 independent 
transfection replicates from two rounds of experiments. Average RPE was calculated to be 
1.13. [B] Plot of WTBglG Vector RNA/Cellular RNA to WTMS2 Vector RNA/Cellular RNA 
showing linear distribution of samples. 
Upon confirmation that WTMS2/WTBglG RPE indeed equalled to a value close to 1 when 
studied and analysed with the optimised qPCR monoplex assays (Figure 57), I proceeded to 
calculating the relative packaging efficiency of a known packaging deficient mutant to 
address the LOD of the assays. Lever et al., had created ΔP1, a mutant with a 19 bp deletion 
in the Ψ region, whose packaging efficiency was measured to be less than 2% of that of the 
WT virus by RNA dot blots. ΔP1-pCCL-eGFP transfer vector was created exploiting the ability 
of E.coli to recombine DNA with homologous ends. Primer ΔP1 Rv  
ccatctctctccttctagccggcgtactcaccagtcgccg was designed as the reverse 
complement of the sequence corresponding to 20 bases upstream of the plasmid DNA to be 
deleted, followed by 20 bases equal to the downstream sequence. Primer ΔP1 Fw 
cggcgactggtgagtacgccggctgaaggagagagatgggtg was designed in the same 
way but corresponding to the complementary strand. These primers were used in a 50 μl 
reaction in a final concentration of 0.2 μM also containing 10 ng WT-pCCL-eGFP-BglG, 2 U 
Pfu Polymerase, 1x Buffer with MgSO4 and 200 μM dNTP mix
260. The thermal cycling 
conditions were: 95°C for 2 min, 35 cycles of: 95°C for 1 min, 60°C for 30 sec, 68°C for 4 min 
and a final extension step at 68°C for 5 min. 10 μl of the reaction were treated with DpnI for 
1 h at 37°C to degrade any unwanted plasmid template. 1 ul of the DpnI treated PCR mix 
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instructions. Plasmid DNA was extracted from grown colonies with the use of the Qiagen 
mini-prep kit. Deletion of the 19 bp sequence was confirmed with sequencing (data not 
shown) and the ΔP1-pCCL-eGFP-BglG plasmid was used for co-transfections. Analysis of 
WTMS2/ΔP1BglG revealed that the relative packaging efficiency ratio of WT to ΔP1 was 64.4 
or alternatively that ΔP1 had 1.6% the packaging efficiency of WT. This result confirmed the 
previously published data on the packaging efficiency of ΔP1 (Figure 58). 
                                                      
Figure 58. Measurement of WTMS2/ΔP1BglG RPE. 
Graph showing the WTMS2/ΔP1BglG RPE as measured with the developed MS2 and BglG 
qPCR assays. ΔP1 RPE was measured to be 1.6% that of WT confirming previously published 
data on ΔP1. 
Transfections with packaging constructs and either WT-pCCL-eGFP-MS2 or WT-pCCL-eGFP-
BglG transfer vectors were performed to investigate any potential effects of the insertion of 
these unique sequences on transfection efficiency. The flow cytometry histograms showed 
no negative effect on transfection efficiency.  





























 [A] Gating of live HEK293T cell population. [B] Non transfected HEK293T cells used to create 
a histogram showing their distribution using the FL1 parameter. [C] Transfection efficiency of 
WT-pCCL-eGFP-Bglg transfer vector. [D] Transfection efficiency of WT-pCCL-eGFP-MS2 
transfer vector. Flow cytometry set up, including gating of live cells and FL1 bar allocation, 
were performed as explained in section 3.2. 
 
Upon completion of all these aforementioned control experiments WT-pCCL-eGFP-MS2 and 
mutant-pCCL-eGFP-BglG plasmids of interest were used for co-transfections following the 
protocol presented earlier in the beginning of this section.  
                               
Figure 60. Measurement of RPE of U5-AUG and dimerisation mutants of interest. 
 
A more accurate look at the raw data used to generate the graph of Figure 60 led to the 
observation that the Ct values from extracellular gRNA were relatively high, close to Ct 30, 
and did not always fit in the limits of the designed 5 log10 standard curve. A standard curve 
was set to determine the copy numbers of unknown samples by comparing them to a set of 
standard samples of known copy number. However, when the unknown samples fell outside 
of the known linear part of the standard curve limits, I could not be certain of the accuracy 
of the measured RPE. Therefore, efforts were focused on increasing the qPCR template load 
by enhancing cDNA synthesis with the addition of betaine, a reagent known to resolve 
secondary RNA structures by decreasing its melting temperature261, and/or increasing the 
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6 μg WT pCCL-eGFP-MS2, 6 μg WT pCCL-eGFP-BglG, 2.5 μg pRev, 3.5 μg pVSVg and 5 μg 
pSYNGP were used to produce lentiviral vector. This time, extracellular RNA was extracted 
from 2 mL of viral supernatant instead of 1 mL. The downstream process remained the 
same as described before. Viral Ct values were observed to shift from 28-30 to 25-28 as 
aimed and thus improving the reliability of the reading. However, measurement of 
WTMS2/WTBglG revealed an effect of the processed volume on RPE, which was now 




Figure 61. Assessment of WTMS2/WTBglG RPE with the use of a modified protocol. 
 [A] Graph showing a five log10 standard curve of the BglG assay in a monoplex reaction with 
R2>0.99. [B] Graph showing a five log10 standard curve of the MS2 assay in a monoplex 
reaction with R2>0.99. [C] Graph showing the measured WTMS2/WTBglG RPE values from 
20 independent transfection replicates. gRNA was extracted from 2 mL harvested viral 
supernatant. Average RPE was calculated to be 2.1.  
y = -3.7088x + 42.888 
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Based on this result, MS2 was concluded to be a more sensitive assay than BglG. To 
investigate further, HEK293T cells were co-transfected with the two following combinations 
of transfer vectors: 1) WTMS2 and U5sBglG, and 2) WTBglG and U5sMS2. 7 co-transfection 
replicates for each transfer vector combination were performed and analysed as described 
in the beginning of section 6.5. Measured WTMS2/U5sBglG RPE equalled 3.1 while the 
calculated U5sMS2/WTBglG RPE equalled 0.85. If the two assays were equally efficient, 
given that WTMS2/U5sBglG RPE was measured to be 3.1, the expected U5sMS2/WTBglG 
RPE should have been 0.3 (=1/3.1). Thus, the MS2 assay was found to be approximately 2 
times more sensitive than the BglG assay.  
 
                       
Figure 62. Measurement of WTMS2/U5sBglG and U5sMS2/WTBglG RPEs. 
Graph showing the calculated WTMS2/U5sBglG and U5sMS2/WTBglG RPEs. 
WTMS2/U5sBglG RPE was found to be 3.1 while U5sMS2/WTBglG RPE calculation equals 
with 0.85. Error bars show standard deviation. 
The next experiment was designed to assess the impact of both processed viral supernatant 
volume and betaine addition (0.5 M final concentration per reverse transcription reaction) 
on the measured RPE. The transfection protocol remained the same, but the downstream 
processing and the reverse transcription reaction were altered according to the following 
four combinations: 1) 1.4 mL viral supernatant + Betaine, 2) 2 mL viral supernatant + 

















of RPEs from 3 replicates per condition revealed that both increase of processed volume 
and betaine addition on the reverse transcription level had positive effects on the qPCR 
readout. The qPCR protocol was updated to accommodate these observations. Viral gRNA 
was extracted from 2 mL of viral supernatant and all reverse transcription reactions 
contained 0.5 M betaine in all following experiments. A final round of WT-pCCL-eGFP-MS2/ 
WT-pCCL-eGFP-BglG co-transfections was performed and all data were combined to assess 
the ratio of MS2/BglG assay sensitivity. gRNA extracted from viral supernatant and their 
respective transfected cells was analysed from 33 independent transfection replicates. The 
average MS2/BglG efficiency of the new protocol was 1.85 (Figure 63). This ratio was taken 
into account in all analysis presented below to compensate for the lower BglG assay 
efficiency. This adjustment enabled us to accurately measure the relative packaging 
efficiency of several biological mutants of interest while accounting for any technical biases.  
 
                                                  
Figure 63.  Measurement of WTMS2/WTBglG RPE with the use of an optimised protocol. 
Graph showing the measured WTMS2/WTBglG RPE values from 33 independent transfection 
replicates from three rounds of experiments. Average RPE reflecting the MS2/BglG assay 
sensitivity was calculated to be 1.85. 
Co-transfections of WT-pCCL-eGFP-MS2/U5s-pCCL-eGFP-BglG and U5s-pCCL-eGFP-MS2/ 
WT-pCCL-eGFP-BglG were performed to evaluate whether the qPCR protocol was optimal to 
accurately measure the biological significance of mutations on relative packaging efficiency 
without the interference of technical biases. As shown in Figure 64 the average 
WTMS2/U5sBglG RPE was 3.2 when taking into consideration the 1:1.85 MS2/BglG technical 





















WTMS2/U5sBglG RPE was measured to be 3.2, the expected U5sMS2/WTBglG RPE should 
be 0.3 (=1/3.2). The average U5sMS2/WTBglG was measured to be 0.34 when accounting 
for the aforementioned technical bias (Figure 64). These results validated the use of this 
novel qPCR assay to accurately measure relative packaging efficiency of lentiviral vectors in 
a competitive environment. This qPCR methodology was used in the following section to 
study the effect of rationally designed mutations on RPE. 
 
                             
 
Figure 64. Measurement of WTMS2/U5sBglG and U5sMS2/WTBglG RPEs with the use of 
an optimised protocol. 
Graph showing the calculated WTMS2/U5sBglG and U5sMS2/WTBglG RPEs. 
WTMS2/U5sBglG RPE was found to be 3.2 upon analysis of 7 independent transfections. The 
U5sMS2/WTBglG RPE calculation from 6 transfection replicates equals with 0.34, validating 
the methodology developed to accurately measure relative packaging efficiency. Error bars 






















6.6. Use of a novel qPCR protocol to measure relative packaging efficiency of 
lentiviral vectors in a competitive environment 
 
6 μg WT pCCL-eGFP-MS2, 6 μg mutant pCCL-eGFP-BglG, 2.5 μg pRev, 3.5 μg pVSVg and 5 μg 
pSYNGP were used for lentiviral vector production. Extracellular RNA was extracted from 2 
mL of viral supernatant while intracellular RNA was extracted from 900 μl transfected cell 
lysates. Extracted RNAs were treated with the Turbo DNA-freeTM kit to achieve plasmid carry 
over removal. Post digestion, gRNAs were used as templates for reverse transcription 
reactions containing 0.5 M Betaine, 1x Buffer, 1x RT Random Primers, 40 mM dNTPs, 50 U 
Multiscribe Reverse Transcriptase and 20 U RNase Inhibitor in 20 μL final volume. No RT NC 
reactions were also set up to ensure lack of plasmid carry over. qPCR reactions contained 
750 nM BglG probe or 250 MSL probe, 500 nM of each primer, 1x Fast Advanced buffer and 
3 μL cDNA in a 10 μL reaction volume. Data analysis was performed by adjusting the BglG 
readout 1.85 times to compensate for the assay’s sensitivity discrepancy compared to MS2.  
U5s, S1, J9+Gag and ΔP1 lentiviral vector mutants whose backbone was engineered to 
contain the unique BglG sequence, were chosen to be studied further based on their 
biochemical and dimerisation phenotypes. U5s mutant was previously studied extensively 
with the use of the WPRE qPCR assay. S1 mutant produced infectious titres equivalent to 
those of WT. Northern Blot and in vitro dimerisation analysis revealed that S1 had a higher 
propensity to dimerise than the WT construct. J9+Gag was characterised by a severe 
decrease in the production of infectious titres. Northern Blotting was not possible due to 
the poor encapsidation yield (data not shown), but in vitro dimerisation assays indicated an 
increased dimerisation propensity. ΔP1 is a packaging deficient mutant whose RPE was 
measured to assess the LOD of the developed assay. The transfection protocol, downstream 
processing and RT-qPCR conditions described in the beginning of this section were applied 
to study the relative packaging efficiency of U5s, S1, J9+Gag and ΔP1 lentiviral vector 
mutants and thus investigate the relationship between relative packaging efficiency, 





Average RPE from analysis of 14 replicates derived from the two independent rounds of 
transfections presented in Figure 65 was 2.4 for WTMS2/U5sBglG and 0.4 for 
U5sMS2/WTBglG. This result suggests once more the suitability of the developed qPCR 
methodogy for accurate and unbiased measurement of packaging efficiency of lentiviral 
vector mutants in relation to WT. 
                          
Figure 65. Relative packaging efficiency measurement of U5s mutant. 
Average WTMS2/U5sBglG and U5sMS2/WTBglG RPEs presented on a logarithmic scale. 
Error bars show standard deviation. 
ΔP1 was the next lentiviral vector mutant to be analysed. Quantification of the relative 
packaging efficiency of ΔP1 was important to define the assay’s limits of detection. From the 
13 independent transfections, only 7 were taken into consideration for further analysis. The 
other 6 replicates were excluded as their Ct values were as high as 37; too close to 
background control levels to be analysed; potentially due to the established low packaging 
efficiency of this mutant.  The average WTMS2/ΔP1BglG RPE of the analysed replicates was 
















                       
Figure 66. Relative packaging efficiency comparison between U5s and ΔP1 mutants. 
[A] Graph showing a six log10 standard curve of the BglG assay with an R
2>0.99, assay 
efficiency 92.04% and amplification factor of 1.92. [B] Graph showing a six log10 standard 
curve of the MS2 assay with an R2>0.99, assay efficiency 98.4% and amplification factor of 
1.98. [C] Chart confirming assay’s accuracy and LOD. Assay’s accuracy was confirmed by 
comparing the average RPE of WTMS2/U5sBglG and U5sMS2/WTBglG, while the LOD of the 
assay was defined by measuring the RPE of WTMS2/ΔP1BglG. Error bars show standard 
deviation. 
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Upon definition of the assay’s LOD, the assay was used to investigate whether the 50 fold 
decrease in the infectious titres of J9+Gag mutant was due to poor packaging. The RPE of 
WTMS2/J9+GagBglG was measured to study whether this dramatic infectivity reduction was 
indeed because of the effect of the designed J9+Gag mutations on the encapsidation 
process. The average WTMS2/J9+GagBglG RPE was found to be 11. However, viral 
production of this round was measured to be relatively low. Both MS2 the BglG Ct values 
were thus affected, resulting on BglG Ct values being close to or slightly outside the limits of 
the standard curve.  
  
                                                         
Figure 67. Relative packaging efficiency measurement of J9+Gag mutant. 
[A] Graph showing a six log10 standard curve of the BglG assay with an R
2>0.99, assay 
efficiency 95.52% and amplification factor of 1.96. [B] Graph showing a six log10 standard 
curve of the MS2 assay with an R2>0.99, assay efficiency 95.8% and amplification factor of 
1.96. [C] Average WTMS2/J9+Gag RPE analysis from 9 independent transfection replicates. 
Error bars show standard deviation. 
y = -3.4343x + 38.474 
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The S1 mutant was designed to have a strengthened U5-AUG base pair interaction and was 
shown to have increased dimerisation efficiency in vitro7. In vitro and in vivo experiments 
revealed an increased dimerisation efficiency of S1 lentiviral vector in our system (Figures 35 
and 41). The transduction efficiency of this mutant was found to be comparable to that of 
WT, but slightly lower. Interestingly, as shown in Figure 68, the relative packaging efficiency 
of S1 was also found to be comparable to that of WT, but slightly higher. 
 
                                       
 
Figure 68. Relative packaging efficiency measurement of S1 mutant. 
Graph presenting average RPE of WTMS2/S1BglG and average RPE of S1BglG/WTMS2. 
Average RPEs were calculated from 11 independent replicates from two different rounds of 
























6.7. Chapter conclusions 
 
The introduction of rationally designed mutations in the 5’UTR aimed to create vectors 
whose RNA was more likely to adopt the dimeric conformation and therefore be packaged. 
To evaluate this, an assay targeting the WPRE element of the 3rd generation lentiviral 
vectors, developed by Lizee et al., was initially used. The observed variability resulted in 
reassessment of the assay of choice and design of a novel assay to measure packaging 
efficiency accurately. Here, I presented a novel competitive qPCR assay designed such that it 
removes any technical bias by measuring WT and mutant RPE in a co-transfection 
environment. The unique MS2 and BglG sequences were introduced in the backbone of WT 
and mutant lentiviral vectors. In the final analysis, MS2 was associated with the WT 
backbone and BglG with each of the mutants chosen to be studied. The development of a 
competitive assay aimed to remove biases introduced by potential differences in 
transfection and/or gRNA extraction efficiencies.  Additionally, this novel assay is time and 
cost efficient as the chosen methodology analysis eliminates the need to normalise samples 
to an internal housekeeping gene. Initially, I had planned to develop a multiplex assay for 
measurement of relative packaging efficiency. However, both the efficiency and linearity of 
the MS2 and BglG assays were observed to decrease in multiplex reactions compared to 
individual monoplex reactions. The qPCR assay was optimised and then used to assess the 
relative packaging efficiency of U5s, S1, J9+Gag and ΔP1 lentiviral vector mutants (Figure 
69).  
The observed overall positive effect of the introduced mutations on RNA dimerisation 
efficiency did not correlate with RPE improvement. With the exception of S1, all other 
assessed mutants were characterised by a decrease in their packaging efficiency. 
Additionally, comparison between the RPE of mutants and their infectivity, releaved a 
negative effect of the dimerisation enhancing mutations on functional titres. In the case of 
U5s transfer vector, the reduction of RPE was proportional to its infectivity reduction. 
However, in the case of J9+Gag, the decrease in viral titres was disproportional to the 
reduction in RPE, and in the case of S1, vector infectivity was decreased despite the 
improvement of its packaging efficiency. This data reflects the multifunctionality of the 
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targeted regions and suggests that RNA flexibility might be more important than RNA 
dimerisation for vector infectivity. 
The assay was used to measure a broad range of relative packaging efficiencies of mutants. 
This range covered mutants comparably efficient to WT to mutants that encapsidated at 
approximately 1% of WT levels. I aimed to optimise HIV-1 derived lentiviral vectors through 
structure informed genome modifications and thus such modifications were introduced 
based on structural information rather than sequence importance. Even though the effect of 
these mutations on functionality, dimerisation and packaging efficiency was addressed, it 
still remained unclear how these rationally designed mutations affect RNA structure 
directly. In-gel SHAPE was performed to study the structures of lentiviral vector RNA 
mutants but also to explore the structure of WT psi in our vector RNAs, in particular 
studying the influence of regions adjacent to psi on dimerisation and packaging. The results 
of these studies are presented in the next chapter. 
                        
                       
Figure 69. Relative packaging efficiency measurement of U5s, ΔP1, J9+Gag and S1 
mutants. 
Graph presenting the average RPEs of all mutants studied with the use of the developed 
competitive qPCR assay. In comparison to WT, only 1.1% of the ΔP1 gRNA was successfully 
packaged. WT was measured to have a 2.4 and 11 times higher packaging efficiency than 
the U5s and J9+Gag mutants respectively. Lastly, S1 was the only mutant with a slightly 












7. RNA structural analysis with in-gel SHAPE 
Combined data from previous chapters showed that dimerisation enhancing mutations did 
not automatically lead to better packaging of vector RNA. These dimerisation enhancing 
mutations were created based on previous structural studies and our mFold structural 
predictions; however, the structures of the developed gRNA mutants have yet to be 
explored. The structure of the WT HIV-1 leader (figure 70.A) has been extensively studied 
with different techniques8 60 61 62, but the biological role of the downstream gag sequences 
remains unknown. Recent findings supported their importance on packaging, structure and 
function262 263. Efforts to remove gag sequences from the transfer vector backbone have 
been unproductive and gag deletion experiments revealed that in addition to the HIV-1 
leader sequences, a significant portion of gag was required in cis for efficient vector 
propagation264, and according to more recent evidence to mediate efficient RNA 
packaging262. The 3rd generation advanced lentiviral transfer vector genome was established 
to contain 355 bp of the 5’ gag gene (figure 70.B) based on the work of Naldini et al., 
despite its exact biological role being unknown173. 
 
Figure 70. Comparison of transfer vector and HIV-1 mRNAs. 
 [A] HIV-1 leader sequences and their respective structural motifs7. [B] gRNA sequences of a 
3rd generation HIV-1 derived lentiviral vector. [C] gRNA sequences of WT HIV-1 . 
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In-gel SHAPE was employed to study the effect of the introduced mutations on the 
monomeric and dimeric conformation as well as the influence of the 355 nt long gag region 
on the structure of psi on our vector system. SHAPE is a technique that can be used to 
identify RNA backbone flexibility, an indication of whether nucleotides are base-paired or 
not. In-gel SHAPE was specifically chosen due to the ability of the technique to determine 
the RNA secondary structure of individual conformers from a mixed RNA population and 
was shown to be an appropriate technique for examination of conformational switches or 
dimerisation processes8. In-gel SHAPE involved the separation of dimeric and monomeric 
structural population of HIV-1 RNA by non-denaturing gel electrophoresis followed by 
individual probing of the two different conformers within the gel matrix8. The following 
section discusses optimisation steps followed to develop an appropriate in-gel SHAPE 
methodology to study the 690 nt long RNAs of interest.  
7.1. In-gel SHAPE methodology 
690 nt long RNA fragments including the packaging signal and the adjacent gag sequences 
were prepared by in vitro transcription as described in 3.9.1. RNA was renatured, refolded in 
a buffer that was optimised to contain 50 mM sodium cacodylate and then fractionated by 
native gel electrophoresis to separate the monomeric and dimeric RNA. A portion of the gel 
was stained with ethidium bromide to visualise the level of bands that correspond to the 
690 nt long monomer and the 1380 nt long dimer. The remaining unstained monomeric and 
dimeric RNAs were excised and probed with NMIA before electroelution. Optimisation of 
the refolding conditions was discussed in 5.3.b and was performed to enhance dimerisation 
efficiency of this longer RNA fragment to the previously published 356 nt long HIV-1 leader 
RNA fragments. More specifically, in this chapter, the 356 nt long RNA fragments that 
contained the HIV-1 leader sequences and 21 nt of the gag region was defined as the 8BP 
length, named after a previously published primer set designed to study the HIV-1 leader 
region8, while the 690 nt long RNA fragment that contained the HIV-1 leader sequences and 
the 355 nt long partial gag region was called 8BP+gag. 
Improvement of in vitro RNA dimerisation efficiency was critical for isolation of adequate 
RNA amounts to be studied with in-gel SHAPE. Upon successful optimisation of these steps, 
the reverse transcription reaction had to be optimised next to proceed to data analysis. As 
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presented in Figure 71.A the reverse transcription protocol followed8 produced poor quality 
data; the signal quality for both cDNA and sequencing ladders was observed to decrease 
throughout the sequencing traces. It was hypothesised that the RNA secondary structure of 
the longer 690 nt RNA fragment could potentially be affecting the efficiency of reverse 
transcription. Increase of the RNA template reaction to 1000 ng and addition of 5 M (final 
concentration) betaine in the reverse transcription reaction were shown to improve the 
quality of data (Figure 71.B). The new reverse transcription conditions contained 1000 ng 
RNA template, 5 M Betaine, 100 U of Superscript III reverse transcriptase (RT), 1.5× SSIII RT 
buffer, 12.5 mM dithiothreitol (DTT), 1.25 mM deoxycytidine triphosphate (dCTP), 
deoxyadenosine triphosphate (dATP), deoxyuridine triphosphate (dUTP) and 7-deaza-
deoxyguanosine triphosphate (dGTP). 6FAMTM-labelled primers were used for the NMIA-






















 [A] WT RNA (8BP+gag) was used as a template for reverse transcription data analysis with 
sequencing. The blue trace represents the NMIA treated RNA under investigation while the 
green trace represents its untreated counterpart. Red and black traces represent sequencing 
ladders used to align each nucleotide to a reactivity peak. The numbers presented in the 
graph represent the scale along the sequencing capillary. Analysis of different parts of the 
chosen RNA fragments revealed a decrease in the quality of sequencing peaks throughout 
the sequence. [B] Use of the same RNA template in an optimised reverse transcription 
reaction including 1000 ng of RNA template and addition of 5 M betaine improved signal 
quality and allowed for data analysis. Conversion of fluorescence intensity to single level 
nucleotide reactivity is shown in the bottom graph. Nucleotide reactivity levels were 
assessed with the use of the NMIA reactivity ladder8.  
The products of the reverse transcription reactions were 5′-end-labeled cDNA fragments 
whose length and amount corresponded to the position and degree of modification for 
every nucleotide. The negative control reverse transcription reaction contained the RNA of 
interest that lacked NMIA treatment (-) as a template to assess RNA degradation and 
position-dependent processivity in parallel to the NMIA treated RNA (+) reactions. The 
resulting (+) and (-) cDNAs were then combined and resolved in a single capillary on a 
capillary electrophoresis sequencing instrument. The peaks were located, aligned, and 
quantified for every position in the (+) and (−) reagent channel using the SHAPEFinder 
software55. The difference in the fluorescence intensity between the (+) and (-) reactions 
was converted to chemical reactivity that was used to study backbone flexibility for each 
nucleotide. Two dideoxy sequencing reactions were set up with either NED or PET labelled 
primers and were used to map reactivity to the RNA sequence. 
Data were an average of 3–4 replicates at each nucleotide position. For the purposes of this 
chapter a replicate was defined as an independent repeat of the in-gel SHAPE process (as 
described above), including all steps from RNA renaturation to reverse transcription of the 
differently probed RNAs and analysis of their respective results. Differences in reactivity 
between 1) the monomer and dimer or 2) WT and mutant RNAs, were tested for statistical 
significance with the use of a paired t-test. The reactivity peaks for 10 nt at both ends of the 
structure were discounted as data for nucleotides closest to the reverse transcription primer 
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are more variable. The average NMIA reactivities at individual nucleotides were mapped 
using the RNAstructure software that predicts secondary structure based on the following 
prediction and analysis algorithms: calculating a partition function, predicting a maximum 
free energy (MFE) structure, finding structures with maximum expected accuracy, and 
pseudoknot prediction235.  Upon prediction of RNA structure, XRNA software was used for 
RNA structure illustration.  
The same conditions and methodology described in this section were employed to study the 
effect of gag sequences on psi by comparing the previously published shorther WT 8BP 
length RNA (356 nt)8 to the WT 8BP+gag length RNA (690 nt) for both monomeric and 
dimeric RNAs, as well as the effect of introduced mutations on the monomeric and dimeric 
conformations. The next section discusses the modelled structures of RNA fragments under 
investigation and regions of interesting NMIA reactivities. The single nucleotide level 
colouring in all structures presented in this chapter was according to the NMIA reactivity 
ladder presented in Figure 71.   
7.2. Structural analysis of the monomeric WT HIV-1 RNA 
A 356 nt long RNA fragment of the WT HIV-1 leader sequence was in vitro transcribed and 
the 356 nt size corresponding to the monomeric conformation was studied with in-gel 
SHAPE following the protocol described in section 7.1. Average SHAPE reactivity data from 
three replicates were analysed with the RNAstructure software and nucleotides were 
mapped on the predicted structure as presented in Figure 72. Data from the monomeric 
RNA mapped accurately onto the TAR structure with high reactivity observed in the 




Figure 72. Structure Illustration of a 356 nt long monomeric RNA fragment corresponding 
to the HIV-1 leader. 
In-gel SHAPE was performed as described in section 7.1 and the data from monomeric HIV-1 
RNA were mapped onto the proposed structure. Predicted structure includes TAR, PBS and 
SL2-SL4 stem loops. Numbering is noted every 50 nucleotides.   
 
Similar to Kenyon et al., the lower part of the TAR stem was characterised by intermediate 
reactivity, suggesting a potential involvement of the TAR base in regulating the monomer-
dimer structural switch8. Unlike the proposed monomeric structures from Kenyon et al., and 
Lu et al., there was no formed polyA stem loop, but interaction of the 79-104 nucleotides of 
the polyA sequences with nucleotides 248-270 of the SL1 sequences. A similarly described 
model known as LDI was described by Abbink et al7. Similarly to the structure presented in 
Figure 72, the LDI proposed structure contained a long distance base-pairing interaction that 
occluded the DIS region.  
Highly reactive nucleotides 73-78 of the polyA formed a loop with the highly reactive 
nucleotides 271-274 of the SL1. While in the monomeric HIV-1 leader RNA structure 
proposed by Kenyon et al., and Lu et al., the SL1 was observed to form a pseudoknot with 
the 5’ of the U5-AUG motif, which was formed in their proposed structure of the dimeric 
RNA8 61, in the monomeric structure predicted from work performed in this thesis, the 3’ 
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stem of SL1 was shown to interact with sequences in the polyA. Interaction between the 
polyA and SL1 sequences suggests a mechanism for both polyA suppression and SL1 
occlusion in the 5’UTR of the monomeric RNA to prevent RNA polyadenylation and RNA 
dimerisation. Sequences downstream of the polyA that have been reported to form the U5-
AUG motif in the dimeric structure of Kenyon et al., and Lu et al., were observed to 
participate in the formation of two loops with sequences downstream of the PBS and 
sequences that would belong to the 5’ stem of SL1. NMIA reactivities for the PBS stem-loops 
mapped accurately onto previously published structures8 61. An exception was the formation 
of an additional stem loop of nucleotides 199-213, which were also reported to be highly 
reactive in the monomeric structure by Kenyon et al. Reactivities mapped accurately onto 
SL2 and SL3. The existence and function of SL4 has been the topic of debate7 8 60 265 266,but 
our predicted model supported its formation in the monomeric RNA structure. The 
nucleotides around the gag start codon have also been documented to form an extended 
hairpin structure in the LDI conformation, preventing their engagement in a long distance 
interaction with the U5 sequences known to take place in the WT HIV-1 8BP dimeric RNA7.  
 
Similarly, a 690 nt long monomeric RNA fragment, including the WT HIV-1 leader sequence 
and the partial gag sequences, was produced and studied with in-gel SHAPE following the 
protocol described in section 7.1. As shown in Figure 73, addition of gag to the RNA 
sequence had no observed effect on the structure of the HIV-1 leader, with sequences from 
TAR to SL4 adopting the same structural conformation as in Figure 72, suggesting that gag 
sequences do not play a role in regulating structural motif formation of the monomeric RNA 
conformation. No direct interaction was observed between the sequences of the WT HIV-1 
leader and gag. High reactivity was noted throughout the gag sequences resulting in the 
formation of only five short stem loops and one more extended one, while the majority of 





Figure 73. Structure Illustration of a 690 nt long monomeric RNA fragment including 
sequences of the HIV-1 leader and partial gag of the 3rd generation HIV-1 derived 
lentiviral transfer vector. 
Four rounds of in-gel SHAPE were performed as described in section 7.1 and average values 
from monomeric HIV-1 RNA were mapped onto the proposed structure with the use of RNA 
structure and XRNA software. No direct interaction between the gag sequences and the HIV-
1 leader was observed. Predicted structure of the HIV-1 leader sequences included the same 
stem loops depicted in Figure 72 and five short stem loops and one extended stem loop 
formed by the gag sequences. Shape reactivity values could not be retrieved for 637-690 nt, 




7.3. Structural analysis of the dimeric HIV-1 leader 
 
The 712 nt long RNA fragment corresponding to the dimeric conformation adopted by the 
dimerisation of the 356 nt WT HIV-1 leader was excised and analysed following the same 
process as for the monomeric RNA described above. Each type of monomeric RNA studied in 
section 7.2 and dimeric RNA studied in this section were excised from the same three 
rounds of in-gel SHAPE to ensure comparability. Similarly, the RNAstructure software was 
used to predict structures based on the calculated average reactivity values of each 
nucleotide and free energy constraints. In order to model the structure using RNAstructure, 
the dimeric RNA was modelled as a single strand containing a duplicated RNA sequence 
separated by 30 uracil residues that were forced to be single-stranded. The DIS palindrome 
was forced to be single-stranded as otherwise the initial models generated did not pair DIS 
with DIS and were hence unlikely to be physiologically relevant. Overall the dimeric 
structure presented in Figure 74 was similar to previously proposed structural models. 
Examination of the dimeric RNA structure revealed a TAR stem loop with low reactivity 
throughout the stem and moderate reactivity of the GGGA nucleotides that comprised the 
loop. High reactivity was observed in two nucleotides located in a bulge in the bottom of the 
TAR stem, consistent with previous studies that have identified high reactivity in the closing 
parts of helices as a common structural trait267. Unlike in the monomeric structure, the 
formation of the polyA stem loop was observed. Nucleotides 58-104 formed the polyA stem 
loop which, similarly to TAR, was characterised by low reactivity throughout the stem and 
moderate to high reactivity in the nucleotides of the loop. High reactivity nucleotides 91 and 
96 formed two bulges in the middle of the polyA stem while the two Us in the bottom of the 
stem were found to be reactive in U-A pairs. Similarly to previously proposed models by Lu 
et al., and Kenyon et al., the dimeric structure of the 356 nucleotide long HIV-1 leader was 
indeed characterised by the formation of the U5-AUG motif. There are a number of 
limitations of the model due to the way in which it was modelled, using one RNA sequence 
duplicated, rather than two that interacted:  In the proposed dimeric structure of the HIV-1 
leader presented in Figure 74, the U5-AUG motif was formed between nucleotides 106-115 
of the U5 of one RNA molecule with nucleotides 720-729 around the gag AUG start codon 
of the second RNA molecule, however this would be likely to be representative of the 
intramolecular interaction occuring. There was also a proposed interaction between the A/U 
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rich sequence between SL2 and SL3, which could be serving as an additional contact site. 
The DIS-DIS pairing was not shown in the model either, as due to modelling constraints the 
DIS palindrome had to be forced to be single-stranded. Despite PBS being the UTR region 
with the greatest structural heterogeneity268, similar NMIA reactivities were observed in the 
PBS region of our model with these presented in the model by Kenyon et al. Low reactivity 
of the semi-palindromic sequence 181-GUGGCGC-187 both in the dimer and the monomer 
of our system did not suggest a role of this sequence as a potential second dimerisation 
contact like previous studies have suggested8. However, the prediction of these nucleotides 
to engage in base pairing could be explained by modelling limitations that could be masking 
their in vivo biological relevance.  
           
Figure 74. Structure Illustration of a dimeric WT HIV-1 leader RNA fragment. 
Average NMIA reactivity values from three rounds of in-gel SHAPE experiments were used 
for prediction of the dimeric structure of the WT HIV-1 leader RNA. NMIA reactivities 
mapped accurately on the structure predicted by Lu et al., and Kenyon et al., and included 




Nucleotides 229–233 from RNA molecule 1 paired with nucleotides 329–333 from RNA 
molecule 2 to form a 5-bp helix. Nucleotides 229–233 were unreactive in the dimeric 
structure, with NMIA values less than 0.3, whereas these nucleotides appeared to be highly 
reactive in the monomeric structure and participated in the formation of a loop. Dimer 
destabilisation during probing could be accountable for this phenomenon as any loose 
dimer could be converted to a monomer and thus locally affect average NMIA reactivity. 
Previously performed 3D analysis of the region had suggested a possible interaction with 
the neighbouring helix at nts 125–131 and 217–223269. Finally, SL1, SL2 and SL3, which 
comprise the major packaging signal, fitted the SHAPE data accurately.  
 
Figure 75. Structure Illustration of a 690 nt long dimeric RNA fragment including 
sequences of the HIV-1 leader and partial gag of the 3rd generation HIV-1 derived 
lentiviral transfer vector. 
Average NMIA reactivity values from four rounds of in-gel SHAPE experiments were used to 
study the effect of gag on the dimeric structure of the WT HIV-1 leader RNA. Direct 
interaction between sequences of the gag region and the polyA, U5 and PBS were observed 
as indicated by the arrows. Shape reactivity values could not be retrieved for 639-690 nt, 
hence -999 was used as a value for structural simulation. 
 
5’               
5’   
3    
3’               
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 A 1380 nt long RNA fragment corresponding to the dimeric conformation adopted by the 
WT HIV-1 leader followed by the partial gag region was excised and analysed as previously 
described from four rounds of in-gel SHAPE. This experiment was designed to investigate 
the effect of extended gag on the packaging conformation. Structural analysis was 
performed as described for the shorter dimer above, again using a duplicated RNA sequence 
separated by 30 single-stranded U residues, and forcing the DIS palindrome to be single-
stranded. Similar to the dimeric RNA fragment of the WT HIV-1 leader that lacked more 
extensive gag sequences (8BP-gag), examination of the dimeric RNA structure followed by 
the gag region (8BP+gag), revealed a TAR stem loop with low reactivity throughout the 
stem and moderate reactivity of the GGGA nucleotides that comprised the loop. However, 
unlike previously described for 8BP-gag, no reactivity was observed in the bottom of the 
TAR stem of 8BP+gag, suggesting that the presence of gag promoted a more rigid dimeric 
conformation. As presented in Figure 75, unlike the formation of the polyA stem loop noted 
in the 8BP-gag structure, sequences of the polyA (72-95nt) were observed to pair with 
nucleotides of the gag region (1340-1360 nt) in the 8BP+gag structure.           
 
Table 7. Sequence conservation analysis of the regions of polyA (72-95nt) and gag (1340-
1360 nt). 
Sequence conservation analysis of the regions of polyA (72-95 nt) and gag (1340-1360 nt) 
predicted their direct interaction based on NMIA reactivity values from four independent 
rounds of in-gel SHAPE structural analysis. Nucleotide preservation analysis was performed 
by comparing the available HIV-1 strain sequences from the Los Alamos database270. 
 
To investigate the likelihood of this interaction, sequence conservation analysis was 
performed for nucleotides 72-95 and 1340-1360 that took part in the suggested polyA-gag 
interaction, by comparing available HIV-1 strains from the Los Alamos database sequence 
compendium database 2018270. As expected, nucleotides of the cis-acting element of polyA 
polyA             
72-95 
T A A A G C T T G C C T T G A G T G ---- C T T 
99% 99% 98% 97% 97% 97% 97% 96% 96% 97% 98% 98% 98% 98% 98% 97% 98% 98% 
 
94% 99% 98% 
gag               
1360-
1340 
A T T T C G A A ---- G G A A C ---- C A C A G A A 
99% 100% 68% 80% 100% 100% 94% 100% 
 
100% 75% 100% 99% 97% 
 
100% 100% 96% 100% 100% 86% 73% 
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were highly conserved. Interestingly, half of the gag nucleotides taking part in this 
interaction were measured to be 100% conserved, higher than even the highly conserved 
sequences of the cis-acting element polyA (Table 7). Additionally, analysis of the base 
pairing with the RNAstructure software supported the likelihood of this interaction with a 
higher than 99% probability (Figure 7.8). 
 
The presence of the U5-AUG motif in the dimeric RNA of the WT HIV-1 leader (8BP-gag) has 
been supported by several groups7 8 60. However, there was no U5-AUG formation in the 
presence of the extended gag, but a direct interaction between U5 and gag nucleotides 
further at the 3’ end of the sequence under interrogation. As shown on table 8, structure 
preservation analysis based on sequencing variability supported the predicted U5-gag 
interaction. Nucleotide 112 of the U5 highly conserved region is a guanosine in the WT HXB2 
sequence and in 95% of HIV-1 strain sequences but an adenosine in the remaining 5% of 
HIV-1 strains. This sequence variability further supported the aforementioned U5-gag 
interaction, as the (U5) G-U (gag) pair of the WT HXB2 sequence would become a paired 
(U5) A-U (gag) with two hydrogen bonds. Notably, 13/19 nucleotides of the involved gag 
sequence were 100% conserved, whereas only 1/19 nucleotides of the involved U5 region, 
known to be a highly conserved region of the HIV-1 leader, were 100% conserved.  
Additionally, nucleotide 1156 is a uracile in the WT HXB2 sequence and in 81% of HIV-1 
strain sequences but a cytosine in the remaining of the 19% of HIV-1 strains. This sequence 
variability further supported structure conservation due to the conversion of the (U5) G-U 
(gag) non canonical pair to a now canonical (U5) G-C (gag) pair. The only exception was 
1157 nucleotide that was highly variable. As shown in Figure 76, the gag nucleotides 
predicted to interact with the U5 region were shown to be highly conserved compared to 
the rest of gag sequences not involved in direct engagement with sequences of the HIV-1 
leader. Lastly, the 90-99% base pair probability calculated by the RNAstructure software also 







U5             
103-
122 
T G T G T G C C C 
G-> 
A! T --- C T G T T G T G 
98% 99% 99% 99% 99% 99% 98% 98% 98% 95% 99% 
 
98% 99% 99% 99% 96% 96% 100% 96% 
gag               
1154-
1172 




C! A C 
99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 94% 100% 97% 96% 100% 
 
26% 81% 100% 100% 
 
Table 8. Sequence conservation of the regions of U5 (103-122 nt) and gag (1553-1172 nt). 
Sequence conservation of the regions of U5 (103-122 nt) and gag (1553-1172 nt) predicted 
base pairing of these nucleotides instead of engagement of the U5 nucleotides in the 
previously reported U5-AUG motif. NMIA reactivity values were retrieved from four 
independent rounds of in-gel SHAPE structural analysis. Nucleotide preservation analysis was 
performed by comparing the available HIV-1 strain sequences from the Los Alamos 
database270. 
           
 
Figure 76. Visual representation of gag region sequence variability. 
 HIV-1 strain sequences presented here were derived from the Los Alamos database270. gag 
nucleotides predicted to interact with the U5 region were placed in the red box. Comparison 
of the gag nucleotides contained in the red box with gag nucleotides on each side, showed 
high sequence conservation of the gag sequences under investigation, a phenomenon linked 
with structure preservation. 
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The formation of a 6 bp helix followed the U5-gag interaction which was in turn followed by 
the prediction of another HIV-1 leader-gag interaction. Nucleotides 142-147 within the PBS 
were predicted to pair with the nucleotides 1127-1132 in the gag region. Structural 
preservation analysis presented in table 9 was in relative favour of this interaction, although 
it needs to be noted that this was a 6 bp interaction only. Furthermore, the probability 
calculation by RNA structure estimated that the engagement of the (142-147 nt) PBS-gag 
(1127-1132 nt) was only around 60% (Figure 77). 
 
PBS             
150-155 
T C C C T C 
99% 99% 99% 99% 100% 100% 
gag               
1127-1132 
A G G G G G 
93% 99% 100% 85% 99% 100% 
 
Table 9. Sequence conservation of the regions of PBS (142-147 nt) and gag (1127-1132 nt). 
Potential PBS-gag interaction was predicted based on NMIA reactivity values from four 
independent rounds of in-gel SHAPE structural analysis. Nucleotide preservation analysis was 
performed by comparing the available HIV-1 strain sequences from the Los Alamos 
database270. 
 
Addition of gag sequences on the RNA level did not affect the structural motifs PBS and SL1-
SL3, which were formed as described above. However, a profound effect on the reactivity 
values of SL3, denoted as the ψ element, was noticed. In this predicted dimeric structure, 
SL3 was formed by nucleotides 289-338. Almost half (18/41) of the 41 nucleotides forming 
SL3 had a decrease in their measured reactivity value, five of them were characterised by an 
increase in their measured NMIA reactivity, while the remaining were not affected. This 
observation suggests that gag sequences stabilise the ψ element in the dimeric RNA to 
promote its packaging. Finally, addition of the downstream gag sequences promoted the 
creation of SL4, which did not appear in the dimeric WT 8BP structure due to the formation 
of the U5-AUG motif. 
The model derived from our data showed a direct interaction between sequences of the 
polyA, U5 and PBS, cis-acting elements of the HIV-1 leader, with sequences within the 
partial gag region of the dimeric 8BP+gag RNA, for the first time. In Figure 73, the majority 
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of gag nucleotides were part of extensive single stranded regions in the WT 8BP+gag 
monomeric structure, whereas in the WT 8BP+gag dimeric structure (Figure 75) gag was 
seen to engage in interactions with the aforementioned regions of the HIV-1 leader. This 
interesting finding in the gag base pairing engagement difference might be part of a 
structural switch mechanism between the monomeric and dimeric RNA. These HIV-1 leader-
gag interactions were closely visualised and presented in Figure 77 with the use of the 
RNAstructure software. Analysis of the full length 690 nt fragment was performed by 
probing the extracted RNA and performing reverse transcription with the use of primers 
that spanned the 8BP length (1-356 nt) and gag region independently.     
 
 










Figure 77. Visualisation of modelled HIV-1 leader-gag interactions with the RNAstructure 
software. 
Close up visualisation of [A] polyA-gag, [B] U5-gag and [C] PBS-gag interactions with 
RNAstructure software. Colouring of nucleotides represents the likelihood of the interacting 
nucleotides to form a base pair, as calculated by the RNAstructure software. In specific: 
red>=99%, orange 99% to >=95%, yellow 95% to >=90%, dark green 90% to >=80%, light 
green 80% to >=70%, light blue 70% to >=60%, dark blue 60% to >=50% and pink <50% 
probability.  
The effect of gag sequences on the packaging conformation was studied by creating a 690 
nt long RNA fragment that contained the WT-HIV sequences and the partial gag region 
which was processed as described above.  
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The SHAPEFinder software used for secondary RNA prediction included alignment of 
reactivity peaks to the sequencing ladder traces on a single nucleotide level faced certain 
trace length limitations. The maximum number of nucleotides that could be analysed with 
this technology was ~350 nucleotides55, which is half the number of nucleotides of the gag 
including RNA fragment of interest. Hence, two sets of primers had to be designed and used 
for independent reverse transcription and sequencing reactions to cover the 8BP and gag 
sequences separately. This limitation combined with the aforementioned challenges due to 
the nature of the longer RNA fragment, made the process extremely laborious and time 
costly. Given the interesting findings on the effect of gag on the dimeric RNA packaging 
conformation, it was desirable to keep the gag region in the RNA sequences of the mutants 
but investigate if probing only for the 8BP 356 nt long region would still accurately predict 
any potential HIV-1 leader-gag interactions. The NMIA values of the dimeric 8BP+RNA were 
loaded on the RNAstructure software for nucleotides 1-356 of the HIV-1 leader, while the -
999 value, indicative of no data present, was loaded for nucleotides 357-690 belonging to 
the gag region. The generated predicted structure was identical to the one presented in 
Figure 75 in which NMIA values were used for all 690 nucleotides. This result suggests that 
use of the full length 690 nt RNA but probing only of the HIV-1 leader sequences was 
adequate to predict interactions between the 5’UTR sequences and gag with the same 
accuracy as with the inclusion of probing data for the 3’ half of the nucleotides. Based on 
this observation, S1 and J9+Gag transfer vector mutants were used as templates for in vitro 
transcription of 1-690 nucleotides containing the respective mutated HIV-1 leader 
sequences and the WT HXB2 gag sequence. However, probing was performed only for 
nucleotides 1-356. S1 and J9+Gag structures were generated by using the calculated NMIA 
values for nucleotides 1-356 and the simulating value -999 for nucleotides 357-690 of the 
gag region. The predicted structures for S1 and J9+Gag are discussed in the following 
sections. 
7.4. Structural analysis of the J9+Gag mutant 
 
A 690 nt long RNA fragment containing the J9+Gag mutants described in section 4.5 was in 
vitro transcribed and used for in-gel SHAPE analysis. 
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As shown in Figure 42, the J9+Gag mutant, designed to have an extended SL1 and 
characterised by a severe drop in functional titres, mainly adopted the dimeric 
conformation. Excision of adequate amounts of monomeric J9+Gag RNA has not been 
possible, hence only the dimeric RNA could be analysed for this mutant. Dimeric J9+Gag 
RNA was excised from three rounds of in-gel SHAPE. Average calculated NMIA reactivity 
values for nucleotides 1-356 were loaded on the RNAstructure software while using the -999 
simulating value for the remaining of nucleotides belonging to the gag region. Structural 
modelling was again conducted based upon a single RNA sequence that contained two 
monomer sequences separated by 30 Us,  and with the DIS forced to be single-stranded.  















Figure 78. Structure Illustration of a 690 nt long dimeric RNA fragment including 
sequences of the J9+Gag HIV-1 leader and partial gag of the 3rd generation HIV-1 derived 
lentiviral transfer vector with XRNA. 
Average NMIA reactivity values from three rounds of in-gel SHAPE experiments were used to 
study the secondary structure of the J9+Gag transfer vector mutant dimeric RNA. The 




TAR stem loop, polyA-gag and U5-gag interactions mapped accurately on the WT 8BP+gag 
dimeric structure presented in Figure 75. The PBS motif was characterised by great 
variability to the previously presented PBS structural motifs. Nucleotides 148-158 were of 
high reactivity in the WT 8BP+gag RNA construct and were predicted to be single stranded 
in Figure 75, whereas more than half of these nucleotides were of low reactivity in the 
J9+Gag 8BP+gag RNA fragment and were predicted to form an independent extended stem 
loop (Figure 78). Other differences in the PBS motif between WT and J9+Gag could be 
explained by notable differences in NMIA reactivity of nucleotides 165-172 and 183-187, 
with nucleotides of WT being mainly unreactive and of J9+Gag being moderately to highly 
reactive. Surprisingly, SL1 also mapped accurately to the previously described WT structures 
and was not extended as initially designed. SL2 was not formed at all, but was instead 
observed to interact with sequences of the PBS. Lastly, SL3 was observed to be extended 
and to contain the sequences around the Gag start codon, which were previously described 
to either interact with sequences of the U5 (WT 8BP) or to independently form SL4 (WT 
8BP+gag).  
The J9+Gag mutations were introduced based on available data from WT structures of the 
8BP length8. However, as shown in section 7.3, addition of gag sequences had a profound 
effect on the dimeric structure of the HIV-1 leader with three observed interactions 
between sequences of the HIV-1 leader and the gag region. These structural differences 
could not have been predicted before studying the effect of gag on the WT packaging 
conformation and were therefore not taken into consideration when the transfer vector 
mutants were first designed. The newly studied HIV-1 leader-gag interactions could explain 
the unexpected effect of the J9+Gag mutations on the predicted RNA structure as according 
to data from section 7.3, nucleotides of the HIV-1 leader are engaged in different structural 
motifs than previously thought. The profound disruption of the J9+Gag introduced 
mutations on the structural motifs of the packaging signal could explain the negative effect 
of these introduced mutations on packaging and transduction efficiencies. However, neither 
the structural modelling, which predicted shortening of SL1 and lengthening of SL3, nor the 
NMIA reactivity values and free energy calculations that indicated a decrease in J9+Gag 
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structural stability, could explain the increased propensity of this mutant to dimerise in 
vitro. 
7.5. Structural analysis of the S1 mutant 
 
S1 mutant, originally designed by Abbink et al. to have a strengthened U5-AUG base pair 
interaction7, was the only rationally designed mutant that was measured to have equivalent 
packaging and transduction efficiencies to WT. This mutant was furthermore characterised 
by an increased dimerisation propensity both in vitro and in vivo. Hence based on its 
interesting phenotype, S1 mutant was chosen for further investigation. Four independent 
rounds of in-gel SHAPE were performed and gag containing S1 dimeric and monomeric 
RNAs were excised, probed with 8BP primers and studied as described in earlier sections.  
                  
Figure 79. Structure Illustration of a 690 nt long monomeric RNA fragment including 
sequences of the introduced S1 mutations in the HIV-1 leader and partial gag of the 3rd 
generation HIV-1 derived lentiviral transfer vector with XRNA. 
Average NMIA reactivity values were retrieved from four rounds of in-gel SHAPE 
experiments. NMIA reactivities for nucleotides 1-356 and the -999 simulating value for 
nucleotides 357-690 were loaded on RNAstructure software. The predicted interactions were 
used as a template for structure illustration with XRNA. 
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Monomeric S1 8BP+gag RNA exhibited several structural similarities with the dimeric WT 
RNAs. As per usual NMIA reactivity data mapped accurately on previously described TAR 
structures. However, unlike the monomeric WT 8BP+gag RNA that was characterised by the 
formation of polyA, the monomeric S1 8BP+gag was characterised by a polyA-gag 
interaction, a common feature of the gag-containing dimeric RNAs. Downstream of the 
polyA-gag interaction, S1 8BP+gag RNA saw the formation of the U5-AUG structural motif, 
previously described in the WT 8BP dimeric RNA. Additionally, SL1 formation was observed 
in the S1 monomeric RNA, which was previously documented to be mainly formed in 
dimeric RNAs (with or without the presence of gag). Data mapped accurately onto the PBS, 
SL2 and SL3 structures of the monomeric S1 8BP+gag RNA.  
The formation of the U5-AUG and SL1 structural motifs observed in monomeric S1 8BP+gag 
RNA have so far mainly been described as characteristic features of the secondary 
structures of dimeric RNAs. The predicted structure suggests that the introduced S1 
mutations indeed strengthened the U5-AUG interaction and promoted characteristics of 




Figure 80. Structure Illustration of a 690 nt long dimeric RNA fragment including 
sequences of the introduced S1 mutations in the HIV-1 leader and partial gag of the 3rd 
generation HIV-1 derived lentiviral transfer vector with XRNA. 
Average NMIA reactivity values were retrieved from four rounds of in-gel SHAPE 
experiments. NMIA reactivities for nucleotides 1-356 and the -999 simulating value for 
nucleotides 357-690 were loaded on RNAstructure software. Predicted interactions between 
HIV-1 leader-gag are highlighted with an arrow. 
S1 dimeric 8BP+gag RNA NMIA reactivity data mapped accurately on the structure of TAR 
and on the polyA-gag interaction as predicted for the WT 8BP+gag dimeric RNA secondary 
structure.  However, unlike the U5-gag interaction observed in the WT 8BP+gag dimeric 
RNA, S1 dimeric 8BP+gag RNA was characterised by the formation of a U5-AUG structural 
motif. Notably, the S1 mutant was designed to have a strengthened U5-AUG interaction, 
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which as presented in Figures 79 and 80 was formed both in the monomeric and dimeric S1 
8BP+gag RNAs. PBS, SL1-SL3 fitted the WT 8BP+gag RNA SHAPE data accurately. Finally, SL4 
formation was not observed as the nucleotides around the gag start codon were engaged in 
the U5-AUG interaction. S1 and WT dimeric 8BP+gag RNAs were shown to have very similar 
secondary structures with the exception of the U5-gag interaction of WT being substituted 
with the formation of the U5-AUG structural motif in S1, a structural motif previously 


















7.6. Chapter conclusions 
In-gel SHAPE was performed to study the secondary RNA structures of transfer vector 
mutants and assess the effect of the partial gag sequences which are included in all transfer 
vector constructs on RNA structure and particularly on the packaging conformation of 
dimeric RNAs. Protocol optimisation had to be performed due to the inefficient in vitro 
dimerisation of longer RNAs. The structure of the WT HIV-1 leader, previously studied by 
several groups, was re-evaluated with the use of the newly optimised protocol. It was 
shown that it resembled the LDI-BMH model suggested by Abbink et al., including the 
formation of the U5-AUG structural motif, the target region of several of our rationally 
designed mutants, in WT 8BP-gag dimeric RNA but not in the WT 8BP-gag monomeric RNA. 
Addition of gag sequences had no effect on the monomeric WT RNA, but a profound effect 
on the conformation of the dimeric RNA. Direct interactions between the polyA, U5 and PBS 
elements of the HIV-1 leader with gag were observed and validated both with sequence 
conservation analysis and base pairing probability calculations. The U5-AUG motif observed 
in the dimeric WT 8BP-gag RNA was substituted by a U5-gag interaction. Furthermore, 
addition of gag sequences downstream of the HIV-1 leader was accompanied by a decrease 
in SHAPE reactivity in the packaging signal, suggesting that gag had a stabilising effect on 
the structure of psi. The existence and importance of the suggested interactions between 
U5, polyA, PBS and gag could be examined with the use of antisense oligonucleotides 
designed to block the interactions between the aforementioned regions of the HIV-1 leader 
and the involved gag sequences in vitro. Incubation of the 690 nt long RNA fragment with a 
series of different antisense oligonucleotides sequences and concentrations, followed by gel 
electrophoresis and visualisation could be used to assess the importance of the interactions 
under investigation271.  
The J9+Gag mutant, designed to have an extended SL1, mainly adopted the dimeric 
conformation hence investigation of the monomeric conformation was rendered 
impossible. Structural analysis with in-gel SHAPE, revealed extension of SL3 rather than SL1 
extension. Furthermore, J9+Gag 8BP+gag dimeric RNA structure was distrurbed compared 
to the predicted WT 8BP+gag structure, as it had a disformed PBS, that could potentially be 
negatively affecting the process of reverse transcription leading to the observed reduction 
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in infectious titres, and lacked SL2. The disturbance of structural motifs that comprise the 
packaging signal could explain the negative effect of the J9+Gag introduced mutations on 
packaging and infectivity. The last mutant whose structure was interrogated was S1, which 
was first designed by Abbink et al., to have strengthened U5-AUG base pairing. Interestingly, 
S1 monomer had many similarities with the dimeric RNAs, including the formation of SL1 
and the U5-AUG motif. Dimeric S1 8BP+gag RNA was rather similar to dimeric WT 8BP+gag 
RNA, apart from the substitution of the U5-gag interaction (WT) with U5-AUG motif 
formation (S1). The predicted structure revealed that S1 mutations successfully stabilised 
the U5-AUG interaction and promoted the dimeric conformation. Notably, even the 
monomeric S1 8BP+gag RNA contained structural motifs, like U5-AUG and SL1 formation, 
previously observed mainly in dimeric RNAs. Overall, the predicted S1 structures suggest 
that the formation of the U5-AUG motif was important for promoting dimerisation and 
enhancing packaging efficiency as hypothesised. However, the biological contribution of the 
U5-AUG interaction could not be concluded, as its structural importance was assessed with 
in-gel SHAPE analysis that was performed on static structures of 690 nt long in vitro 
transcribed RNAs. A different approach would be to investigate the existence of the 
observed interactions between regions of the HIV-1 leader and gag in vivo, exploiting 
techniques like the recently published COMRADES, that is designed to determine 
interactions and structures in vivo 272. Nevertheless, despite the aforementioned limitations, 
combined data would suggest that RNA flexibility to adopt U5-AUG, U5-gag, and, potentially 
other interactions in vivo could be one of the most critical parameters in performing the 
different functions needed to maintain packaging and transduction efficiencies. In 
particular, S1 data that implied the importance of the U5-AUG interaction for improved 









Work performed for this PhD thesis targeted the dimerisation and packaging properties of 
HIV-1 derived lentiviral vectors to improve lentiviral vector efficiency. HIV-1 gRNA is known 
to act as a switch between the monomeric conformation, associated with translation, and 
the dimeric conformation, linked with packaging. While dimerisation positively regulates 
packaging108 109, translation of the genome is in opposition to its encapsidation. Rationally 
designed transfer vector mutants that were more likely to adopt the dimeric conformation 
and therefore get packaged were created by targeting regions in the 5’UTR, including SL1 
extension, U5-AUG duplex and polyA stabilisation (Table 10). A variety of assays were 
designed to assess the effects of the introduced mutations on different parts of the vector 
life cycle. ELLA p24 was performed to measure physical titres while flow cytometry was 
performed to measure functional titres. Western Blotting and ELLA p24 were performed to 
investigate any potential effects of these 5’UTR mutations on in trans-Gag processing and 
budding. Northern Blotting and in vitro dimerisation were used to investigate the propensity 
of WT and mutant transfer vector RNA to dimerise in vivo and in vitro respectively, while 
prediction of the in vitro transcribed RNA secondary structure was achieved with in-gel 
SHAPE. Lastly, the effect of mutations on the packaging efficiency of mutant transfer vectors 
was calculated with a novel in-house designed competitive RT-qPCR assay. Table 10 lists the 























Table 10. List of rationally designed transfer vector mutants. 
 
The mutants were first assessed for their transduction efficiency. Amongst all mutants, U5s 
and S1, designed to have strengthened U5-AUG base pairing, showed comparable, but 
slightly lower infectious titres to WT. However, the LU5AUG mutant that was also designed 
with a strengthened U5-AUG interaction, showed a big reduction in transduction efficiency. 
The dimerisation mutants showed a wide range of infectious titres, with mutant PolyAsw 
having functional titres comparable to WT, while J9+Gag and PolyAs were characterised by a 
dramatic decrease. ELISA p24 was performed next, to assess the effect of the 
aforementioned mutations on physical titres and budding efficiency. Extracellular ELISA p24 
analysis revealed that physical titres followed the same trend as infectious titres, while 
intracellular ELISA p24 showed no differences between WT and the U5-AUG mutants but a 
relatively higher p24 V/C ratio for the remaining dimerisation mutants compared to WT. 
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Biochemical vector characterisation was completed with Western Blotting used to 
investigate whether the effect of 5’ UTR mutations impacted the processing of Gag provided 
in trans. Western Blotting visualisation showed no change in the Gag processing pattern of 
mutants compared to WT.  
It was concluded that the variety of observed effects on functional titres reflected the 
multifunctionality of the targeted areas. Mutations in the DSL, U5-AUG and polyA were 
likely to affect not only the dimerisation and packaging properties of HIV-1 derived lentiviral 
vectors, but also other important parts of the HIV-1 life cycle essential for the infectivity of 
the newly synthesised mutant viral particle. Vector titration revealed an overall negative 
effect of the rationally designed mutations on vector infectivity. These experiments were 
performed using the optimised transfection protocol presented in section 4.2. A different 
approach would be to perform these infectivity experiments under conditions in which 
availability of dimerised genomic RNA would be limiting for packaging. This could be 
achieved by performing a number of independent transfections with the use of the 
packaging plasmids and a series of reduced WT pCCL-eGFP transfer vector DNA mass.  The 
use of a ‘buffer plasmid’ is recommended to maintain the total amount of DNA at 25 μg to 
avoid negatively affecting transfection efficiency. Infectivity experiments could then be 
performed under the identified limiting conditions. The use of dimerisation promoting 
mutants under limiting conditions might enhance their biological effects on infectivity and 
improve our understanding of the mutant phenotypes. 
The performed biochemical assays could not provide any information on the impact of 
mutations on RNA dimerisation efficiency, which was the focus of this PhD thesis. To assess 
this, Northern Blotting was performed to measure the total amounts of encapsidated gRNA 
packaged and its propensity to dimerise. Northern Blotting revealed an increased RNA 
dimerisation propensity trend for S1 and U5s. Northern Blotting was initially chosen as the 
most appropriate technique due to its advantage of measuring both the quantity of total 
gRNA levels and the stability of its dimeric form. However, in vitro dimerisation assays had 
to be employed to further study the propensity of RNA to dimerise for mutants whose gRNA 
was not detectable with Northern Blotting due to low encapsidation levels. In vitro 
dimerisation assays showed an overall positive effect of the introduced mutations on the 
propensity of RNA to dimerise in vitro. Overall findings suggest that enhancing dimerisation 
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did not automatically lead to improvement of vector infectivity. In general, even though in 
vitro dimerisation information was significant for understanding the RNA biology of 
dimerisation, it was not possible to assess a potential link between gRNA dimerisation and 
vector infectivity from data that was not derived from in virio assays. The requirement for 
high yields and lack of degradation throughout the whole process challenged measurements 
of packaged gRNA levels for transfer vectors whose virion production and/or RNA stability 
could have been affected by the introduced mutations. RT-qPCR has the advantage of 
quantifying RNA expressed at very low levels and was therefore chosen as the best assay to 
overcome these technical hurdles and study in detail the extent to which the rationally 
designed mutations affected packaging per se. 
A novel competitive RT-qPCR assay was designed and employed over previously published 
qPCR assays, to investigate whether the dimerisation enhancing mutations promoted 
packaging as originally hypothesised and to study the relationship between packaging 
efficiency and RNA dimerisation propensity. The qPCR assay was optimised and then used to 
assess the relative packaging efficiency of U5s, S1, J9+Gag and ΔP1 lentiviral vector mutants. 
ΔP1 mutant, previously published to package less than 2% of WT gRNA, was used as a 
negative control to assess the LOD of our assay. WT/ΔP1 RPE was calculated to be 85, which 
meant that the packaging efficiency of ΔP1 was 1% to WT’s, confirming the previously 
published data. WT/U5s RPE ratio was measured to be 2.4, while the equivalent 
transduction efficiency ratio was calculated to be 1.7, suggesting that impact of introduced 
mutations on packaging directly affected the functional titres of the U5s vector. 
Interestingly, even though the J9+Gag mutations caused only an 11 times decrease in 
packaging efficiency, they caused a 50 fold decrease in transduction efficiency. This result 
implied that the J9+Gag mutations, in addition to packaging, must have also affected other 
parts of the HIV-1 vector life cycle; potentially reverse transcription. Finally, S1 was the only 
mutant that had a packaging efficiency equivalent of WT’s and more specifically slightly 
higher. This result was unexpected given the previously measured slightly lower functional 
titres of S1 in comparison to WT, and reinforced once again the multifunctionality of the 
targeted regions. Based on this observation, it was concluded that despite the packaging 
advantage of S1 transfer vector mutant, the introduced mutations must have negatively 
affected different to packaging processes of the HIV-1 vector life cycle. This topic is analysed 
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further in section 8.2.3. Overall, our in house designed and optimised competitive qPCR 
assay could be used to measure a broad range of relative packaging efficiencies of mutants 
accurately. This range covered mutants comparably efficient to WT to mutants that 
encapsidated at approximately 1% of WT levels. Nevertheless it might be advantageous to 
further assess this competitive assay with digital droplet PCR (dPCR). dPCR is performed by 
dividing the sample into separate reaction droplets, so that each reaction droplet would 
contain either only 1 or 0 target molecules providing this way an improved approach for 
sensitive absolute quantification273. Lastly, with further optimisation this assay could also be 
used for measuring vector copy number of transduced cells. 
I had aimed to optimise HIV-1 derived lentiviral vectors through structure informed genome 
modifications. In other words, mutations were designed and introduced based on structural 
information rather than sequence importance. It was therefore essential to finally study the 
direct impact of these rationally designed mutations on the RNA structure. In-gel SHAPE was 
performed to study the structures of lentiviral vector RNA mutants and to explore the 
influence of adjacent to psi sequences on its structure. Previous efforts to remove gag 
sequences from the transfer vector backbone have been unproductive and gag deletion 
experiments had revealed that in addition to the HIV-1 leader sequences, a significant 
portion of gag was required to mediate efficient RNA packaging262. Even though the 
structure of the WT HIV-1 leader had been extensively studied8 60 61 62, the biological role of 
the downstream gag sequences remained unknown. Addition of gag sequences had no 
effect on the monomeric WT RNA, but a profound effect on the packaging conformation of 
the dimeric RNA. Direct interactions between elements of the HIV-1 leader, including the 
polyA, U5 and PBS, with gag were documented here for the first time. Potential interactions 
of these aforementioned cis-acting elements and gag were further validated with sequence 
conservation analysis and base pairing probability calculations. The U5-AUG motif previously 
observed in the dimeric WT RNAs was substituted by a U5-gag interaction, while the 
formation of an independent polyA stem loop was substituted with a polyA-gag interaction 
in the WT 8BP+gag RNA fragment. Furthermore, addition of gag sequences downstream of 
the HIV-1 leader was accompanied by a decrease in reactivity in the packaging signal, 
suggesting that gag promotes a more compact and stable psi structure. Lastly, the gag 
sequences were mainly observed to be single stranded in the monomeric RNA, whereas the 
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regions of the gag sequences were predicted to form base pairs with sequences of the HIV-1 
leader, implying the potential participation of gag in regulating the role of HIV-1 gRNA to 
switch between alternative conformations that serve different functions. My data 
supported recent studies that had suggested a role of gag as a cis-acting element, important 
for RNA packaging, structure and function262 263. J9+Gag and S1 mutants were chosen for 
structural analysis based on their overall interesting phenotypes. Briefly, the J9+Gag mutant 
displayed a very disturbed RNA secondary structure with an extended SL3 instead of an 
extended SL1 as originally designed, a differently formed PBS and the absence of SL2. The 
effect of the introduced mutations on multiple structural motifs could be a potential 
explanation for the discrepancy between vector infectivity and the relative packaging 
efficiency of the J9+Gag transfer vector. Based on the predicted dimeric structure of J9+Gag, 
it was hypothesised that these mutations had a negative effect on packaging due to the 
disturbance of SL2 and SL3 that are part of the packaging signal and on transduction 
efficiency potentially because of an impact on reverse transcription due to PBS 
malformation. S1 was the last mutant whose RNA secondary structure was interrogated. 
The predicted S1 structure revealed that mutations successfully stabilised the U5-AUG 
interaction and promoted the dimeric conformation. Notably, even the monomeric S1 
8BP+gag RNA contained structural motifs, like U5-AUG and SL1 formation, previously mainly 
observed in dimeric RNAs. Overall, the predicted S1 structures suggest that the formation of 
the U5-AUG motif was important for promoting dimerisation and enhancing packaging 
efficiency as hypothesised. However, this observation was made by analysing a single static 
RNA structure. The ability of RNA flexibility to adopt U5-AUG, U5-gag, and, potentially other 
interactions in vivo, could be one of the most critical parameters for maintaining packaging 
and transduction efficiencies. In support of this argument is the observation that the 
increase in dimerisation and packaging efficiency of S1 did not translate to an increase of 
functional titres as expected. S1 and J9+Gag structural findings suggest that the ratio of 
monomeric to dimeric RNA and RNA’s flexibility to alternate between its two states and 
fates must be essential for vector infectivity. Lastly, the discovery of the polyA-gag 
interaction on the RNA level made the polyAs and polyAsw of great interest for structural 
analysis. However due to time constraints this has not been possible, but interrogation of 
the RNA structure of polyAs and polyAsw would be of great significance to further validate 
the polyA-gag interaction and to understand the significant infectivity difference between 
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these two polyA mutants that were designed with the same rationale before the finding of 
the polyA-gag interaction. Additionally, it might be beneficial to perform a new round of 
rationally designed dimerisation promoting mutants after taking into consideration these 
new interesting structural findings, including the interactions of the HIV-1 leader sequences 
with gag sequences. A potential strategy is further analysed in 8.2.1. 
To conclude, this thesis presented the design, generation, biochemical and structural 
characterisation of dimerisation promoting transfer vector mutants based on the hypothesis 
that WT HIV-1 regulates genome encapsidation tightly by recognising dimeric RNA12. These 
dimerisation enhancing transfer vector mutants, whose RNA should be more likely to adopt 
the dimeric conformation and therefore be packaged, were created based on previously 
published structural studies and our mFold structural predictions and were employed to 
investigate a relationship between dimerisation, packaging and transduction efficiencies. 
Biochemical characterisation showed that transduction and packaging efficiencies were 
highly influenced by the region where the mutations were introduced. Both Northern blots 
and in vitro dimerisation assays confirmed that the propensity of mutated vector RNA to 
dimerise had indeed increased in the mutants as hypothesised. However, relative packaging 
efficiency data, acquired with the use of a novel, competitive, in-house developed RT-qPCR 
assay, suggest that enhancing dimerisation does not automatically lead to better packaging 
of vector RNA and that the introduced mutations might be affecting multiple vector 
processes, reflecting the multifunctionality of targeted regions. Finally, I explored by in gel-
SHAPE the structure of psi in our transfer vector RNAs, in particular by studying the 
influence of regions adjacent to psi on dimerisation and packaging. This single nucleotide 
level structural analysis revealed that the presence of gag sequences stabilise the psi 
element of the dimeric RNA by direct interactions with the polyA, U5 and PBS of the HIV-1 
leader, suggesting their role in supporting a stable RNA conformation that can be packaged 
and offering a potential explanation for their requirement in the transfer vector plasmid for 
maintenance of infectious titres. Finally, structural analysis of mutants confirmed the 
importance of the U5-AUG duplex in the dimeric RNA conformation. These findings will give 
us better insights into the biology of lentiviral vectors and enable us to design more efficient 
vectors for the demanding future of gene therapy.  
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8.2. Future directions 
 
8.2.1. In vivo SELEX for the production and selection of best replicating variants 
 
This thesis employed the introduction of specific, rationally designed mutations, which 
target the dimerisation and packaging properties of lentiviral vectors. However this 
approach of rationally designed mutations can only allow for the production of a limited 
number of different transfer vectors. The in vivo SELEX (systematic evolution of ligands by 
exponential enrichment) approach involves the creation of HIV-1 lentiviral vector variants 
libraries in which targeted segments of interest are randomized for selection of the best 
replicating variants274. Thus, in vivo SELEX could serve as an alternative way to produce and 
select for mutated lentiviral constructs with enhanced genome encapsidation properties in a 
larger scale. Briefly, this process involves either the design of various oligos bearing random 
mutations in selected regions or error prone PCR performed in a template of interest 
including sequences that are known to be important for RNA encapsidation. Once the 
targeted segment is mutated, a mass-transformation would be performed at the level of the 
transfer vector. The produced transfer vector library would be assessed with sequencing to 
confirm both the variety of mutants and the lack of dominant mutants. Once the generation 
of the transfer vector library is achieved, the variety of mutated constructs would be used 
for co-transfections with the packaging plasmids for vector production. Generated vectors 
would be harvested and used for multiple rounds of transductions, giving the opportunity to 
the system to select and purify out the vectors carrying the sequences that lead to higher 
transduction efficiency. Multiple rounds of transduction aim to place the library under 
selective pressure in vivo. In vivo SELEX has previously been used in HIV-1 research to study 
the importance of the few well-conserved single-stranded sequences that connect the hairpins of 
















Figure 81. In vivo SELEX approach for the creation of HIV-1 derived lentiviral vector 
libraries to select the best replicating variants. Adapted from source276. 
 
Sequences of partial gag can serve as a potential region of interest, since this thesis has 
shown the direct interaction between gag and 5’UTR sequences. In our system all mutations 
introduced in the 5’UTR of HIV-1 have been associated with a negative effect on vector 
transduction efficiency. The 5’UTR is the most conserved part of the HIV-1 RNA genome277 
and is known to promote packaging, regulate transcriptional activation, splicing, primer 
binding during reverse transcription, and dimerisation70. On the contrary, partial gag 
sequences are relatively variable and could therefore be potentially targeted with a directed 
evolution experiment. 
The transfer vector of this lentiviral system is a 3rd generation Self Inactivating Vector (SIN), 
whose 5’ U3 is substituted with the CMV promoter and its 3’ U3 is partially deleted. Upon 
reverse transcription, the incorporated genome will be promoter-less. The carry-out of the 
described SELEX experiment, that requires active competition of the vectors, needs a mobile 
vector. To achieve this, an option would be to clone the WT-HIV-1 3’U3 back to the transfer 
vector construct and combine it with the use of a 2nd generation tat-gag/pol construct to 






8.2.2. Improvement of gRNA stability 
 
RNA is a single stranded molecule made of ribose sugars which contain a hydroxyl group at 
the 2’ position. These traits render this molecule chemically unstable and thus more prone 
to alkaline hydrolysis, making RNA an intrinsically  unstable molecule278. Auto-hydrolysis, 
self-cleavage of RNA that can occur spontaneously without the presence of an enzyme, is 
more likely to occur when the RNA is single-stranded and when the solution of the pH is 
basic. It could be hypothesised that during the various laboratory manipulations performed 
to process the vector samples, a certain proportion of RNA would get hydrolysised due to 
the slightly basic pH of the protease buffer, thus affecting the availability of intact extracted 
gRNA molecules to be assessed with techniques like Northen Blotting. Furthermore, HIV-1 is 
known to contain instability sequences (INS) in gag/pol279 and RRE280 that cause inefficient 
expression by impairining nucleocytoplasmic transport and stability that result to transcript 
degradation280. Hence, addition of a stability elelement could alleviate both any potential 
impact of vector processing on gRNA stability and the negative effect of INS on 
posttranscriptional regulation. Lastly, Nikolaitchik et al., speculated that larger inserts affect 
viral fitness due to inefficient expression and lower RNA stability rather than decreased 
packaging efficiency as initially hypothesised12. Therefore, introduction of a stability element 
could potentially reduce the fitness cost caused by a larger genome and hence improve the 
transduction efficiency of lentiviral vector expressing larger therapeutic transgenes. 
The aforementioned challenges caused by the nature of HIV-1 transfer vector gRNA could 
be overcome by engineering their basic backbone by introducing stability elements from 
other viruses. Palusa et al., described the identification of an RNA element in Rabies Virus 
that stabilises transcripts via interacting with the cellular poly(rC)-binding PCBP2 protein281. 
The authors had initially noticed the differential expression of the glycoprotein mRNA of the 
virus compared to the rest of the transcripts. This observation was followed by identification 
of a conserved region in the 3’UTR of the glycoprotein mRNA that was found to act as a 
stability element. Isolation and cloning of this region into reporter constructs revealed an 
approximate 2-fold stabilisation of the transcript compared to the control RNA281. 
Based on these encouraging findings, this Rabies’ stability element or an equivalent human 
analogue could be cloned into the basic backbone of the transfer vector. Ideally, the stability 
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element of choice should be cloned in various locations within the transfer vector, to 
investigate any potential positional effects. These engineered vector constructs can then be 
used for co-transfections with the packaging plasmids and their extracellular and 
intracellular RNAs can be extracted to evaluate the impact of the stability element in 
comparison to the control WT sequences of the current lentiviral vector system. 
8.2.3. Investigation of the effect of secondary gRNA structure on other parts of the HIV-1 
life cycle 
The secondary structure of viral RNAs is known to have an impact on the efficiency of 
reverse transcription282 and on immune response induction through the RIG-I pathway283. 
This thesis has addressed the effect of the 5’UTR mutations on dimerisation, packaging and 
transduction efficiency. However, it was observed that the relationship between these 
processes was not direct for all mutants. For example, despite S1 mutant being shown to 
have higher dimerisation and packaging efficiencies than WT, its transduction efficiency was 
measured to be lower than WT’s. This unorthodox result implicates the contribution of 
pathways different to the ones involved in dimerisation and packaging. Given that mutant 
transfer vector gRNAs of this thesis were shown to adopt secondary structures different to 
WT’s, it could be hypothesised that these differences in the secondary structure of RNA are 
accountable for this observed phenomenon due to their effects on reverse transcription 
efficiency and/or triggering of immune sensing. In vitro reverse trancription can be 
performed to assess the effect of different RNA templates on the efficiency of reverse 
transcriptase by measuring the incorporation of digoxigenin-labelled dUTP in newly 
synthesized DNA284. Cell based signalling assays can be employed to measure RIG-I 
activation by gRNAs of different structures285. Investigation of the effects of structure 
informed genome modifications on other parts of the life cycle will elucidate the importance 
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